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Introduction
The last few decades, the incidence and prevalence of end stage renal disease (ESRD) 
have been increasing steadily worldwide1, 2. In the Netherlands, the number of ESRD 
patients increased with about 10,000 patients over the last five years 3. These growing 
numbers likely reflect the ageing population and the increasing rates of lifestyle diseases 
like hypertension, diabetes mellitus type 2 and obesity, all known to be risk factors for 
the development and progression of chronic kidney disease (CKD) 4-7. Throughout the 
course of the renal disease, nutritional factors are relevant players in progression of 
kidney disease and its complications. This is partly due to the impairment of the renal 
capacity for excretion and metabolism of exogenous compounds that is consequent to 
renal function loss. Accordingly, increased susceptibility to the pathophysiological effects 
of exogenous compounds, including nutritional factors, is inherent to renal disease. 
The relationships between nutritional factors and renal disease and its complications, 
however, are complex, and only partly understood. Of note, these relationships are 
dynamic, evolving with the progression of kidney disease towards ESRD, and the 
different modes of renal replacement therapy. i.e dialysis and transplantation. 
The majority of ESRD patients commences dialysis treatment as renal replacement 
therapy. However, despite the life-extending qualities of dialysis, it still may be 
inadequate on the long run for addressing the critical problems of persistent fluid 
overload, hypertension, heart failure, infections and related complications in this patient 
group. Mortality risk in dialysis patients is still unacceptably high with an annual death 
rate of 16 per 100 patient-years at risk 8, which means that only half of all dialysis 
patients is still alive three years after the start of dialysis. A main factor contributing to 
the high morbidity and mortality rates is the high prevalence of malnutrition and protein 
energy wasting in these patients 9, 10, which is closely related to uremia as a state of 
chronic inflammation 11. However, inadequate intake is also involved. The requirements 
of protein in dialysis patients are high, while intake of protein and energy is usually low 
due to uremic toxicity, nausea, inflammation and psychosocial factors leading to loss of 
appetite 10. Additionally, dialysis patients are subject to stringent and demanding dietary 
prescriptions, such as restricted intake of whole-grains, fruits and vegetables to limit 
phosphorus and potassium intake and prevent hyperphosphatemia and hyperkalemia. 
These restrictions, albeit of vital importance for risk reduction of morbidity and mortality, 
can pave the way to nutrient deficiencies and add to the status of malnutrition, eventually 
leading to a deterioration of the nutritional and clinical condition of dialysis patients.
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For ESRD patients, renal transplantation is the preferred treatment as it ends the need 
for debilitating dialysis and improves both quality of life and life expectancy compared 
to patients on dialysis 8, 12, 13. In the Netherlands, the number of ESRD patients with a 
functioning renal graft has increased considerably over the last decades and currently 
constitutes a group exceeding 10,000 patients 3 (Figure 1).
Figure 1  Number of Patients on Renal Replacement Therapy in the Netherlands
While deceased donors have been the main source for transplantation for many 
years, living kidney donors have become increasingly important, also allowing pre-
emptive transplantation. The annual number of kidneys obtained from living donors 
has surpassed the annual number of deceased renal grafts in the Netherlands 14. 
However, this only in part explains the increasing prevalence of ESRD patients with a 
functioning graft. A more valid explanation for the increasing numbers is the impressive 
improvement of one-year graft and patient survival, mainly as a result of improvement of 
surgical procedures, prevention of acute rejection, treatment of opportunistic infections 
and introduction of stronger and more effective immunosuppressive agents 15-17. Over 
the last decades, an improved graft survival has been observed with a functioning graft 
for recipients of deceased and living kidney transplants at 90% and 95% respectively, 
compared to 40% in the 1970’s 18. Nevertheless, graft and also patient survival on the 
long run have not been concordant as can be seen in figure 2 where lines for graft 
survival over the different decennia run almost parallel. 
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Even after successful transplantation, morbidity and mortality rates are notably higher 
compared to the general population 19. Of all patients who survive the first year after 
transplantation, 50% of renal grafts originating from deceased or living donors are lost 
within 12 and 25 years after transplantation respectively 2. One of the main causes 
of graft loss is patient mortality with a functioning graft 20, 21. Cardiovascular disease, 
including hypertension, endothelial dysfunction and atherosclerosis, continues to be 
the leading cause of death after renal transplantation (Figure 3) and prevalence has 
been estimated to be five times higher than in the general population 22-24. Additionally, 
metabolic abnormalities and adverse effects of immunosuppressive medications 
significantly impact on the long-term morbidity and quality of life of renal transplant 
recipients. Previous studies observed a significant contribution of the chronic use of 
corticosteroids to post-transplant cardiovascular risk 25. Similar adverse effects are 
attributed to immunosuppressive drugs such as calcineurin inhibitors and m-TOR 
inhibitors 26, 27. As avoidance of immunosuppressive agents obviously is not feasible in 
patients with a renal graft, attention should be directed toward the search for other tools 
to help prevent post-transplant cardiovascular and metabolic diseases and to improve 
long-term graft and patient survival.
14  |  Chapter 1
Nutritional factors could provide new targets for intervention in renal transplant 
recipients. At present, the majority of renal transplant recipients visiting the University 
Medical Center Groningen underwent dialysis prior to transplantation. They previously 
were committed to aforementioned strict dietary limitations and have been exposed 
to the high risk of malnutrition and associated conditions for varying periods of time, 
usually amounting to several years. After transplantation, abrupt changes in nutritional 
needs are experienced as most of these restrictions do no longer apply after transplant 
surgery, in proportion to the restoration of renal function. Due to the newly obtained 
freedom to indulge in many different foods, combined with reversal of the uremic state 
and an increased feeling of hunger caused by immunosuppressive drugs such as 
corticosteroids, excessive weight gain is commonly seen after renal transplantation 28-30. 
Since overweight and obesity are well known risk factors for cardiovascular disease, in 
the general population 31 and particularly in patients already at risk like renal transplant 
recipients 32, 33, restriction of caloric intake should receive proper attention in clinical 
care. However, it undoubtedly is not merely food quantity that poses a threat to these 
patients. Cardiovascular as well as metabolic complications following transplantation, 
including hypertension, endothelial dysfunction, vascular calcification and low grade 
systemic acidosis, all conditions highly prevalent after renal transplantation, are likely to 
be influenced, at least in part, by the composition of the diet.
Over the last decades, various dietary factors and their effects on cardiovascular 
health have been studied in the general population. The ‘Interheart’ study in fifty-two 
countries revealed a positive correlation between cardiovascular risk and the Western 
diet, also after adjustment for body mass index 34 indicating that it indeed is not solely 
excessive body weight that is responsible for increased cardiovascular risk. One of the 
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most extensively studied nutritional risk factor for cardiovascular diseases is salt intake, 
not only in the general population 35, 36, but also in populations already at risk, such 
as patients with renal disease 37 and patients with established hypertension 38. High 
salt intake is increasingly recognized as an important determinant of cardiovascular 
and renal damage. However, its role in renal transplant recipients is not yet clear. 
Another dietary factor that has been focus of numerous studies is dietary protein and 
its potential effect on blood pressure 39-41. Evidence from a meta-analysis suggests a 
small beneficial influence of protein on blood pressure, especially for plant protein, in 
the general population 42. In renal patients however, the beneficial role of protein intake 
is disputed as dietary protein, or its equivalent of amino acid infusion, can affect renal 
hemodynamics and induces high intra-glomerular pressure, subsequently leading 
to kidney damage and hypertension 43, 44. For renal transplant recipients, it remains 
unknown what the optimal daily amount and optimal type of protein is. 
Considering the above, despite the numerous studies that have been performed on the 
contribution of nutritional factors to physical conditions in a wide range of subgroups 
of the general population, renal transplant recipients have only sparsely been subject 
to nutritional studies. From the considerations mentioned above, it may be clear that 
renal transplant recipients constitute a very specific patient group in whom the impact 
of nutritional factors cannot simply be considered similar to the general population 
or ‘common’ chronic kidney disease patients. Therefore, point-to-point extrapolation 
of findings from studies on the role of nutrition in cardiovascular health in other can 
not groundlessly be done. As a result of the absence of any evidence regarding the 
long-term dietary requirements of stable renal transplant recipients, solid guidelines 
on nutrition are lacking. Therefore, it remains unclear, for medical practitioners as well 
as for renal transplant recipients, what the optimal composition of the diet should be to 
improve long-term outcomes in renal transplant recipients.
Aims of the Thesis
The aim of this thesis is to document the nutritional intake in a large cohort consisting of 
stable renal transplant recipients who have a functioning graft for at least one year and to 
compare their dietary habits with those in a healthy reference group. Second, we aim to 
investigate the associations of several nutritional factors with cardiovascular, metabolic 
and renal risk profiles long-term after renal transplantation, allowing identification of 
appropriate targets for interventions to help prevent morbidity and mortality in renal 
transplant recipients.
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In chapter two we focus on dietary sodium intake which is an established risk factor 
for hypertension in the general population. We compare sodium intake, inferred from 
24-hour urine samples, between renal transplant recipient and healthy controls and 
investigate the association of dietary sodium intake with blood pressure in our renal 
transplant cohort, under conditions of routine clinical care. 
In chapter three we zoom in on protein intake, differentiating between total, animal and 
plant protein. We make use of a validated food frequency questionnaire and additionally 
measure urinary urea excretion, to assess dietary protein intake in our renal transplant 
recipients. Next, we analyze the association of protein intake with blood pressure and 
renal function, thereby differentiating between total, animal and plant protein. 
In chapter four we elaborate on the acidifying properties of dietary protein and its 
potential association with acid-base homeostasis and cardiovascular risk parameters 
in renal transplant recipients. We estimate dietary acid load, applying diet based 
algorithms, and assess metabolic acid load by analysis of urinary net acid excretion. 
Subsequently, we aim to identify dietary factors contributing to metabolic acid load that 
could provide tools for improving acid-base balance in renal transplant recipients. 
In chapter five we aim to shed some light on the association between sulfur metabolites 
and cardiovascular and metabolic parameters in renal transplant recipients. Conflicting 
hypotheses exist on the role of sulfur as it either might be harmful for acid-base 
homeostasis or, in contrast, be protective from a cardiovascular point of view through 
incorporation in the hydrogen sulfide metabolism. We assess intake of sulfur containing 
protein with a food frequency questionnaire and investigate its association with the two 
main urinary sulfur metabolites, sulfate and thiosulfate. Subsequently, we analyze the 
association of both sulfur metabolites with metabolic and cardiovascular parameters 
in our renal transplant recipients. In chapter six we investigate the association of 
endogenous synthesis of nitric oxide, a gaseous compound with a variety of protective 
properties, with various post-transplant cardiovascular risk parameters. We compare 
urinary NOx-excretion, reflecting systemic levels of nitric oxide, between renal transplant 
recipients and healthy controls. Next, we study whether potential differences in urinary 
NOx-excretion can be explained by differences in dietary habits. Third, we investigate 
whether levels of urinary NOx-excretion are associated with the cardiovascular risk 
profile in renal transplant recipients. 
In chapter seven we determine intake of vitamin K and its association with vascular 
vitamin K status, defined as elevated plasma uncarboxylated matrix glutamate protein 
in sixty renal transplant recipients. Furthermore, we aim to identify dietary factors that 
are associated with vitamin K status which might provide new targets for intervention to 
improve vitamin K status after transplantation. Dietary intake is assessed with three-day 
dietary diaries instead of food frequency questionnaires to enhance accuracy. 
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In chapter eight the results of all studies are summarized. Furthermore, the implications 
of the findings in this thesis and the future perspectives are discussed.
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Abstract
Background Hypertension is ubiquitous among renal transplant recipients (RTR) and a 
risk factor for graft failure and mortality. Sodium intake is a well established determinant 
of blood pressure (BP) in the general population. However, data in RTR are limited. 
International guidelines recommend a maximum daily sodium intake of 70mmol. We 
investigated sodium intake in RTR as compared to healthy controls, and its association 
with BP. 
Methods We included 660 RTR (age 53±13 yrs, 58% male) and 201 healthy controls 
(age 54±11 yrs, 46% male). Sodium intake was assessed from 24h urine. The morning 
after completion of urine collection, BP was measured according to a strict protocol. 
Results Urinary sodium excretion was 156±62 mmol/24h in RTR and 195±75 in controls 
(difference: P<0.001) and 95% of RTR had a UNaV above 70 mmol/24h. Systolic and 
diastolic BP were 136±18 and 82±11 mmHg respectively. Sodium intake was positively 
associated with SBP (β=0.042 mmHg per mmol/24h, P=0.002) and DBP (β=0.023 
mmHg per mmol/24h, P=0.007), independent of potential confounders.
Conclusion RTR had a lower sodium intake than healthy controls, yet intake still 
exceeded current guidelines. Reduction of sodium intake to recommended amounts 
could reduce SBP by 4-5 mmHg. Better control of sodium intake may help to prevent 
graft failure and mortality due to hypertension among RTR.
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Introduction
Renal transplantation is the preferred treatment for patients with end stage renal disease. 
Short term graft survival after clinical transplantation has improved progressively 
over the last decades. However, allograft and patient survival on the long run have 
not paralleled this improvement 1. Leading cause of long term morbidity and mortality 
among renal transplant recipients (RTR) is cardiovascular disease (CVD) and therefore 
attention should be paid to its prevention and treatment 2, 3. A major contributor to CVD is 
hypertension, which is very common after renal transplantation. Epidemiologic studies 
indicate that 50% to 90% of RTR either have hypertension (defined as BP higher than 
140/90 mmHg) or are on antihypertensive medications 4, 5. Prevention and treatment of 
hypertension should therefore receive proper attention. 
Numerous studies have been performed on identification of factors that are positively 
associated with hypertension. High salt intake is an established risk factor for 
hypertension in the general population 6-9, but also in populations with chronic kidney 
disease (CKD) 10, 11. Data on the association between sodium intake and BP in RTR, 
however, are sparse and inconclusive. The latter may be due to relatively small sample 
size of the studies 12-14 or a large time lag between collection of data on sodium intake 
and measurement of BP 15. 
The Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines 
on hypertension and antihypertensive agents in chronic kidney disease anticipate on a 
rising prevalence of hypertension among adults in the United States 16. Like the Dietary 
Approach to Stop Hypertension (DASH) guideline, they advocate moderate consumption 
of sodium with a maximum daily intake of about 100 mmol per day, equaling 5.8 grams 
of sodium chloride per day 17. Guidelines provided by the US Department of Health 
and Human Services (HHS) and the US department of Agriculture (USDA) promote an 
even more strict regimen of no more than 1,500 mg/d (~70 mmol/d) in individuals with 
hypertension, middle-aged and older adults 18, 19. One older study reported that sodium 
intake in RTR is higher rather than lower than in healthy controls and usually exceeds 
even the conservative limit of 100 mmol per day 14. 
The aim of our study, therefore, was to compare sodium intake in RTR with that in healthy 
controls and to investigate the association of dietary sodium intake with blood pressure 
in a large single center RTR cohort study under conditions of routine clinical care.
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Methods
Subjects
We invited all adult RTR with a functioning graft for at least one year who visited our 
outpatient clinic between 2008 and 2010. A group consisting of 660 out of 702 initially 
invited RTR signed written informed consent. As a healthy reference group, we included 
all 201 subjects evaluated for living kidney donation in our center during the same period. 
None had a history of kidney disease, diabetes or cardiovascular events. Hypertension, 
if present, was regulated with a maximum of one antihypertensive drug. All participants 
signed informed consent. The Institutional Review Board approved the study protocol 
(METc 2008/186) which was in adherence to the Declaration of Helsinki.
Data collection
Height, weight and waist circumference were measured at the day of the visit to the 
outpatient clinic. Body Mass Index (BMI) was calculated as weight divided by height 
squared (kg/m2) and Body Surface Area (BSA) was estimated applying the universally 
adopted formula of DuBois and DuBois 20. Information on medication use was derived 
from patient records and data on smoking behavior was inquired with a questionnaire. 
RTR were classified as current smokers, former smokers, or never smokers.
Blood was drawn after an 8-12h overnight fasting period in the morning after completion 
of the 24h urine collection. To assure adequate urine collection, both RTR and healthy 
controls were carefully instructed. Subjects were informed to discard their morning urine 
specimen, collect all subsequent urine through the next 24 hours and include the next 
morning’s first specimen of the day of their visit to the outpatient clinic. Renal function 
was assessed by 24h urinary creatinine clearance (ml/min) calculated as time-factored 
urinary creatinine concentration (mg/min) divided by plasma creatinine concentration 
(mg/mL). Daily salt intake was assessed on basis of 24h urinary sodium excretion 
(UNaV), since urinary sodium excretion largely equals sodium intake, when people are 
in steady-state 21, 22. Adequacy of 24h collection was assessed by comparing the actual 
24h creatinine-excretion rate (CER) with creatinine excretion as predicted by body 
dimensions, age and gender 23. In secondary analyses, urine samples deviating more 
than 30% from the predicted CER were excluded to investigate the association between 
UNaV and BP in RTR without possible noise due to inadequate urine collections.
Fasting BP (mmHg) was measured according to a standard protocol, which has been 
used in clinical studies from our department 24, 25 and in the large epidemiological 
PREVEND study (n = 8,592) 26-28. BP was measured with one and the same semi-
automatic device (Dinamap® 1846, Critikon, Tampa, USA) and all measurements were 
performed by the same investigator. To prevent white-coat effects, 29, participants were 
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left alone in a room in half-sitting position while BP and heart rate were measured every 
minute for fifteen minutes. The average of the last three values was taken as BP value 
in our study. The validity of this procedure is shown in Figure 1, depicting mean BP 
and heart rate over time. SBP and DBP of the averaged last three measurements were 
respectively 14 mmHg and 7 mmHg lower than the first measurement (both p<0.0001). 
BP reaches a plateau after about ten measurements, equivalent to ten minutes. The 
day-to-day coefficient of variation for BP evaluated in this way was 2.0% for SBP and 
4.3% for DBP. Mean arterial pressure (MAP) was calculated as twice the DBP plus SBP 
divided by three, approximating the average arterial pressure during a single cardiac 
cycle 30. Measurements were performed while patients were on their regular medication, 
including anti-hypertensive drugs at trough. All measurements were performed at the 
morning of the visit to the out-patient clinic.
Figure 1. Course of systolic blood pressure, diastolic blood pressure and heart rate during 15 
minutes of automated blood pressure measurements. A: Systolic blood pressure; B: Diastolic 
blood pressure; C: Heart rate. Values are given as mean with standard error.
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Analyses were performed using SPSS version 16.0 software (SPSS Inc., Chicago, IL). 
Normality was tested with the Kolmogorov-Smirnov test. Skewed data were normalized 
by logarithmic transformation in analyses. Parametric variables are expressed as 
mean±SD, whereas non-parametric variables are given as median [interquartile range]. 
Differences between RTR and healthy controls were tested with the t-test for independent 
samples, the Mann-Whitney U test or the chi-square test. To visualize associations of 
UNaV with BP in RTR, this study population was divided into gender- stratified tertiles of 
MAP. P-values for differences between these tertiles were obtained using the ANOVA, 
Kruskal-Wallis test or chi-square test. Linear trends of variables over the tertiles of 
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MAP were analyzed applying univariate linear regression analysis, to identify potential 
confounders of the association between sodium intake and BP. The association 
of sodium intake with MAP, SBP and DBP was investigated with multivariate linear 
regression analyses, with adjustments for age and gender (model 1), subsequently 
for waist circumference, renal function and smoking behavior (model 2) and plasma 
potassium concentration, urinary potassium excretion, proteinuria, HbA1c (continuous) 
and use of antihypertensives (ordinal) and calcineurine inhibitors (dichotomous) (model 
3). A two-sided P value less than 0.05 was considered to indicate statistical significance. 
Results
The characteristics of RTR and healthy controls are shown in table 1. The two groups 
were similar with respect to age, BMI and BSA. Men were overrepresented in the RTR-
group compared to the healthy controls. 
Sodium intake, as inferred from 24h urine sodium excretion, was significantly lower in 
the RTR group than in the healthy controls (156 ± 62 mmol/24h vs. 195 ± 75 mmol/24h, 
p<0.0001). Sodium intake in the RTR-group ranged from 19 to more than 300 mmol per 
day. Of all RTR, 85% had a sodium intake above 100 mmol per day and 95% had a 
sodium intake exceeding 70 mmol per day as recommended in international guidelines. 
One fifth of the patients had a sodium intake over 200 mmol per day.
As anticipated, creatinine clearance was significantly lower in RTR than in healthy 
subjects (65±26 vs. 123±37 ml/min; p<0.0001). Blood pressure was significantly higher 
in RTR than in controls (MAP 107±15 vs 95±17, p<0.001; SBP 136±18 vs. 125±15 
mmHg, p<0.0001; DBP 83±11 vs. 76±9; p<0.0001), despite significantly more use of 
anti-hypertensive drugs in RTR, as shown in table 2. The majority of RTR (91%) either 
had hypertension or was on antihypertensive medications. Seventy two (11%) RTR were 
not using any anti-hypertensive drugs, while 198 (30%) RTR used one, 231 (35%) two 
and 159 (24%) three or more different anti-hypertensive drugs. 
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Table 1 Patient characteristics of study participants at the day of their visit to the out-patient 
clinic
Characteristics Control Subjects (n = 201)
RTR
(n = 660) P
Demographics
Age (years) 53.5 ± 10.6 53.3 ± 12.6 0.9
Male gender, n (%) 92 (46) 377 (57) <0.01
Waist Circumference, men (cm) 94 ± 9 102 ± 13 <0.001
Waist Circumference, women (cm) 89 ± 10 95 ± 16 <0.001
BMI (kg/m2) 26.0 ± 3.5 26.6 ± 4.8 0.1
BSA (m2) 1.95 ± 0.20 1.94 ± 0.22 0.7
Smoking behavior
Never, n (%) 105 (52) 277 (42) 0.03
Current, n (%) 48 (24) 79 (12) <0.001
Ex-smoker, n (%) 48 (24) 304 (46) <0.001
Medication use
Patients on antihypertensives, n (%) 17 (8) 588 (89) <0.001
Amount of antihypertensives used (n) 0 [0-0] 2 [1-2] <0.001
Statins, n (%) 10 (5) 357 (54) <0.001
Antidiabetic Drugs, n (%) 0 (0) 106 (16) <0.001
Hemodynamic parameters
Heart Rate (bpm) 67 ± 10 68 ± 11 0.004
Systolic Blood Pressure (mmHg) 125 ± 15 136 ± 18 <0.001
Diastolic Blood Pressure (mmHg) 76 ± 9 83 ± 11 <0.001
Mean Arterial Pressure (mmHg) 95 ± 17 107 ± 15 <0.001
Renal Function
Serum Creatinine (umol/L) 72 [65-82] 125 [99-160] <0.001
Creatinine Clearance (ml/min) 123 ± 37 65 ± 26 <0.001
Albuminuria (mg/24h) 5.4 [3.1-9.2] 39.0 [9.6-193.9] <0.001
Urinary Protein Excretion (g/24h) 0 [0.0-0.2] 0.2 [0.0-0.4] <0.001
Serum Parameters
Glucose (mmol/L) 5.3 [5.0-5.6] 5.2 [4.8-6.0] 0.4
hsCRP (mg/L) 1.2 [0.6-2.4] 1.6 [0.7-4.6] <0.001
Cholesterol (mmol/L) 5.34 ± 1.05 5.12 ± 1.12 0.01
HbA1c (%) 5.7 ± 2.2 6.0 ± 0.9 0.003
Urinary Parameters
Sodium excretion (mmol/24h) 195 ± 75 156 ± 62 <0.001
Urea excretion (mmol/24h) 402 ± 119 387 ± 111 0.10
Chloride excretion (mmol/24h) 198 ± 72 146 ± 59 <0.001
Potassium excretion (mmol/24h) 92 ± 29 73 ± 24 <0.001
Calcium excretion (mmol/24h) 4.8 [3.4-6.7] 2.4 [1.1-3.9] <0.001
Creatinine excretion (mmol/24h) 13.1 ± 4.2 11.6 ±3.4 <0.001
28  |  Chapter 2
Table 2  Classes and number of medication used by the RTR




Beta blockers 416 (63)
Diuretics 271 (41)
Loop diuretics 136 (21)
Thiazide diuretics 106 (16)
Potassium-sparing diuretics 3 (<1)
Combination 27 (4)
Calcium entry blockers 152 (23)
Number of antihypertensive drugs
None 72(11)
1 class 198 (30)
2 different drugs 231 (35)
3 or more different drugs 159 (24)
Anti-diabetic drugs
Sulfonylurea  26 (4)
Biguanide  27 (4)
Insulin 65 (10)
Immunosuppressive drugs
Proliferation inhibitor 548 (83)
Calcineurine inhibitor 376 (57)
Prednisolone dose (mg/day) 10 [7.5-10.0]
In RTR, MAP was significantly higher in men than in women (108±14 mmHg vs 105±16 
mmHg, p=0.02). Therefore, further characteristics are presented according to gender 
stratified tertiles of MAP (table 3). With increasing BP, RTR were older and had higher 
BMI and BSA. Smoking behavior did not differ between tertiles. Regarding use of 
medication, more RTR were on antihypertensive medication in the highest tertile of MAP. 
Furthermore, use of anti diabetic drugs and calcineurin inhibitors gradually increased 
over the tertiles. Plasma creatinine and proteinuria differed significantly between tertiles 
(both p<0.001), however, creatinine clearance was similar. UNaV increased along with 
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increasing BP. In the highest tertile, mean UNaV excretion was 165 mmol, compared 
to 152 mmol in the lowest tertile (p<0.001). Figure 2 shows the mean BP values across 
gender stratified tertiles of UNaV. SBP, DBP and MAP were all significantly higher in the 
highest tertile compared to the lowest tertile of urinary sodium excretion (138 vs 134 
mmHg, p=0.01; 84 vs 81 mmHg, p=0.003 and 102 vs 98 mmHg; p=0.005 respectively). 
Urinary volume increased with increasing tertiles of urinary sodium excretion (2209±734 
mL, 2244±749 mL and 2660±847 mL respectively, p<0.001). The same was true for 
urinary sodium concentrations (48±19 mmol/L, 67±23 mmol/L and 91±33 mmol/L 
respectively, p<0.001).
Figure 2. Systolic blood pressure, diastolic blood pressure and mean arterial pressure of 
renal transplant recipients according to gender stratified tertiles of urinary sodium excretion. 
A: systolic blood pressure; B: diastolic blood pressure; C: mean arterial pressure. Values are 





































































Associations between UNaV and BP in RTR, analyzed as continuous variables, are 
shown in table 4. With adjustment for age and gender, βs for the association with MAP, 
SBP and DBP were 0.030 (p<0.001), 0.038 (p=0.001) and 0.026 (p<0.001) respectively. 
Additional adjustment for confounders as accounted for in the third model, revealed 
betas of 0.030 (p=0.002), 0.042 (p=0.002) and 0.023 (p=0.007) for the association of 
UNaV with MAP, SBP and DBP respectively. 
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Table 3  Patient characteristics according to gender-stratified tertiles of Mean Arterial 
Pressure (MAP; mmHg)




MAP (mmHg) 92 ± 8 106 ± 4 123 ± 10
Demographics
Gender (% male) 57% 57% 56% NS
Age (years) 52 ± 14 53 ± 13 55 ± 12 0.02
Waist Circumference men (cm) 100 ± 14 100 ± 13 104 ± 13 0.002
Waist Circumference women (cm) 94 ± 15 94 ± 15 96 ± 17 0.5
BMI (kg/m2) 26.1 ± 4.6 26.5 ± 5.1 27.0 ± 4.6 0.004
BSA (m2) 1.92 ± 0.22 1.94 ± 0.21 1.95 ± 0.23 0.001
Smoking behavior
Never (%) 43% 44% 39% 0.2
Current (%) 11% 12% 14% 0.3
Former (%) 46% 45% 47% 0.5
Time after transplantation (y) 5.9 [3.0-15.3] 5.7 [2.00-11.6] 5.2 [1.4-10.9] 0.02
Medication use
Antihypertensive drugs, n (%) 190 (87) 194 (87) 197 (90) 0.04
ACEi or AII antagonist, n (%) 105 (48) 94 (42) 110 (50) 0.5
β-blocker, n (%) 135 (62) 140 (63) 142 (65) 0.16
Diuretics, n (%) 76 (35) 87 (39) 105 (48) 0.02
Number of antihypertensives 2 [1-2] 2 [1-2] 2 [1-3] 0.13
Statins, n (%) 111 (51) 114 (51) 131 (60) 0.16
Antidiabetic drugs, n (%) 20 (9) 40 (18) 44 (20) 0.01
Proliferation inhibitor, n (%) 203 (93) 185 (83) 182 (83) 0.9
CNI, n (%) 107 (49) 127 (57) 140 (64) <0.001
Hemodynamic parameters
Heart rate (bpm) 69 ± 14 69 ± 11 68 ± 11 0.16
Systolic Blood Pressure (mmHg) 121 ± 13 135 ± 10 152 ± 14 <0.001
Diastolic Blood Pressure (mmHg) 73 ± 8 83 ± 6 92 ± 9 <0.001
Renal Function
Serum Creatinine (umol/L) 124 [98-155] 122 [97-153] 132 [102-175] <0.001
Creatinine Clearance (ml/min) 65 ± 24 68 ± 26 63 ± 27 0.18
Protein excretion (g/24h) 0.2 [0.0-0.3] 0.2 [0.0-0.3] 0.3 [0.0-0.6] 0.001
Proteinuria ≥ 0.5 g/24h (%) 21% 18% 32% <0.001
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Serum Parameters
Sodium (mmol/L) 140 ± 3 141 ± 3 141 ± 3 0.03
Potassium (mmol/L) 4.0 ± 0.5 3.9 ± 0.4 4.0 ± 0.5 0.32
Chloride (mmol/L) 105 ± 3 105 ± 3 106 ± 4 0.19
Urea (mmol/L) 9.4 [7.2-13.2] 9.0 [6.9-11.4] 10.4 [7.5-15.6] 0.001
Glucose (mmol/L) 5.2 [4.7-6.0] 5.3 [4.8-6.1] 5.3 [4.8-6.1] 0.4
hsCRP (mg/L) 1.8 [0.7-5.1] 1.6 [0.8-5.1] 1.6 [0.8-3.7] 0.15
Cholesterol (mmol/L) 5.0 ± 1.1 5.0 ± 1.1 5.3 ± 1.1 0.006
HbA1c (%) 5.7 [5.5-6.0] 5.8 [5.5-6.2] 5.9 [5.5-6.4] 0.02
Urinary Parameters
Urine volume (mL) 2437 ± 816 2445 ± 768 2435 ± 812 0.99
Sodium excretion (mmol/24h) 152 ± 63 153 ± 61 165 ± 60 <0.001
Chloride excretion (mmol/24h) 143 ± 60 144 ± 59 154 ± 57 <0.001
Urea excretion (mmol/24h) 388 ± 115 378 ± 106 393 ± 113 0.15
Creatinine excretion (mmol/24h) 11.5 ± 3.5 11.5 ± 3.3 11.6 ± 3.5 0.17
Potassium excretion (mmol/24h) 73 ± 24 72 ± 25 73 ± 24 0.37
Calcium excretion (mmol/24h) 1.98 [1.2-3.7] 2.6 [1.3-3.9] 2.5 [1.0-4.2] 0.9
Adequacy of urine collection
In secondary analyses, reliability and completeness of the 24h urine collections of RTR 
was evaluated by comparing 24h creatinine excretion with estimated creatinine excretion 
applying the equation recently proposed by Ix et al. Samples deviating more than 30% 
were excluded and analyses for the association between UNaV and BP were repeated. 
Based on all separate expected urinary creatinine clearances, 77% of all urine samples 
were considered to be collected properly. Consequently, the sample size of our study 
was reduced noticeably, leaving us with 502 samples. Nevertheless, associations of 
UNaV with MAP, SBP and DBP became slightly stronger, with βs of 0.033 (P<0.001), 
0.045 (p=0.001) and 0.026 (p=0.003) respectively (data not shown).
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Discussion
Hypertension is highly prevalent among RTR and contributes to cardiovascular disease 
and mortality in these patients 31, 32. In line, in our population the large majority of RTR had 
hypertension, defined as a BP higher than 140/90 mmHg or the use of antihypertensive 
medications. At variance with prior reports 12-15 we found that sodium intake in RTR 
was lower than in control subjects with similar body composition. Nevertheless, in 
95% of the patients sodium intake still exceeded the 70 mmol as recommended in 
current guidelines. In RTR a significant association between sodium intake and BP was 
observed, for both SBP and DBP, independent of potential confounders. As for RTR, it 
can be inferred that in our population, compliance with the maximally recommend daily 
intake of 70 mmol would have reduced mean SBP and DBP with approximately 5 mmHg 
and 3 mmHg respectively. 
This study is the first to demonstrate a positive association between sodium intake and 
BP in RTR. These data suggest that better control of sodium intake can lead to clinically 
relevant improvement of BP in RTR. 
The finding that RTR used less sodium than the controls (despite similar age and 
body composition), may be due to the fact that they were under medical supervision, 
including regular attention for general lifestyle advice. As for RTR, the large majority of 
patients has been under close dietary supervision during the period of end stage renal 
disease preceding renal transplantation. The lower potassium excretion suggests that 
the dietary habits of the RTR still partly reflect the dietary restrictions during dialysis. 
Nevertheless, mean daily sodium intake in RTR still exceeded current international 
guidelines, as was also found in several previous studies reporting mean 24h urinary 
sodium excretion rates of 178, 163, 224 and 165 mmol/24h respectively 33-36. This clearly 
leaves room for improvement.
Considering the achievement of sodium restriction goals, RTR performed comparably 
as patients with CKD, in whom sodium intake is generally more or less equal to the 
general population, as reviewed elsewhere 37, 38.
We acknowledge that this study has limitations. First, it is a cross-sectional, epidemiologic 
study. Therefore, no causal relationship can be proven. Subjects with a high sodium 
intake for instance, may have other dietary or lifestyle habits than subjects with a lower 
sodium intake which might influence BP. The observation that the association remains 
significant in the multivariate regression analysis indicated that it is independent of the 
tested potential confounders, including age, gender and medication that could alter 
sodium handling and BP. It is, however, possible that residual confounding remained 
even in multivariate analyses, because it is hard, if not impossible, to adjust for (the 
severity of) each confounder. Of the RTR, 41% used oral diuretics, which can acutely 
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influence urinary sodium excretion. However, it is not likely that interference occurs of the 
association between urinary sodium excretion and BP in RTR. Because these diuretics 
are chronic medication in RTR who are at least one year after transplantation, sodium 
balance will be in steady-state while on medication, with sodium excretion representing 
sodium intake. 
Furthermore, our study population consisted predominantly of Caucasian people, 
making extrapolation of our results to other ethnicities difficult. Nevertheless, the large 
size of the study population involved, and the performance of the measurements in 
a standardized manner renders our finding of a positive association between sodium 
intake and BP reliable and robust. Additionally, secondary analyses on the association of 
UNaV with BP after exclusion of inadequately collected 24h urine samples still showed 
a highly significant and even stronger positive association between sodium intake and 
BP, despite the reduction of sample size.
 
Our current study adds to the rationale for dietary sodium intervention in RTR. The Multiple 
Risk Factor Intervention Trial (MRFIT) showed that even small differences in population 
average BP relate importantly to CVD and all-cause mortality. It was estimated that a 4 
mmHg reduction of SBP was associated with meaningful benefit: lower ischemic heart 
disease and CVD death rates by 8-9% and lower all-cause mortality by 5.8% 39. The 
study by Cook et al demonstrated that dietary sodium intervention can indeed improve 
long term outcome 40. In line it has been proposed that in RTR even moderate BP 
lowering would already have favorable effects on cardiovascular disease and mortality 
4. Moreover, recent post-hoc analyses from the REIN 41 and the RENAAL/IDNT study 42, 
showed that a moderately lower sodium intake is associated with a substantially better 
long term renal and cardiovascular outcome in non-diabetic and diabetic renal patients 
respectively. To the best of our knowledge, no sodium intervention studies have been 
performed in RTR, which is remarkable, also considering the well-recognized beneficial 
effects of even a modest dietary sodium restriction to 90-100 mmol per day in patients 
with native kidney disease on blood pressure and proteinuria 37, 43. 
The feasibility of persistent reduction of dietary sodium has been questioned, especially 
when it comes to compliance with strict recommendations in current guidelines for high 
risk groups, including patients with chronic kidney disease. For these groups a sodium 
intake of no more than 1,500 mg (~70 mmol/d) is advocated 19, based on the DASH-
sodium trial, in which sodium intake was maintained at 65 mmol per day for 6 weeks 44. 
Intervention studies from our own group showed that reduction to approximately 100 
mmol day is feasible in a regular nephrology outpatient setting at least for the 6-week 
periods of the study 25, 45. The recent hard end point data suggest that even a modest 
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reduction in dietary sodium might already be highly beneficial in renal patients 41, 42, 
which increases the feasibility of obtaining health benefits by dietary sodium restriction. 
Our current data support the relevance of such an approach in RTR.
Previous epidemiological studies in RTR did not detect an association between sodium 
intake and BP. However, these studies were either small and therefore likely to be 
underpowered (9-11), or there was a large time lag between assessment of sodium 
intake and BP, without BP measurements being performed in a standard way (12). Taken 
together, these factors have likely hampered the power of those studies to detect an 
association between sodium intake and BP. 
Our cross-sectional data make it reasonable to postulate that BP in RTR is sodium 
sensitive. This could be related to renal function and/or proteinuria as both renal function 
impairment and proteinuria are associated with increased sodium sensitivity of BP in 
native kidneys 45, 46. Other factors could be the use of drugs interfering in the renin-
angiotensin-aldosterone system, that generally render BP sodium-sensitive 47 or the 
fact that many RTR are overweight, leading to increased sodium sensitivity of BP 48, 49. 
Another factor that could underlie our findings is the use of calcineurine inhibitors by the 
majority of RTR, which has been shown to be related to hypertension 50. Cyclosporine 
in particular activates the sympathetic nervous system, upregulates endothelin, inhibits 
nitric oxide and enhances sodium retention, all of which cause potent vasoconstriction 
and systemic hypertension 51-53. 
Like in the general population, the unfavorable effects of sodium intake on BP in RTR 
are most likely the consequence of expansion of the extra cellular volume (ECV) and 
the subsequent rise in cardiac output (CO), a phenomenon that has already been 
shown to be related to high salt intake in healthy subjects 54, 55. As result of increased 
vascular stiffness in RTR, especially in those who underwent pre-transplant dialysis 56, 
the concomitant compensatory decrease in peripheral vascular resistance fails to occur 
and hypertension is more likely to develop as compared to healthy subjects. 
Notwithstanding the above, the exact mechanisms of interaction of sodium with BP in 
RTR are incompletely known, mainly because of a lack of sodium intervention studies 
in RTR. 
Conclusion
Dietary sodium intake in RTR is below the level of healthy controls, but well above 
recommended targets. Our cross-sectional data show a positive association between 
sodium intake and BP in RTR. These data support the need for sodium intervention 
studies in RTR to improve blood pressure and cardiovascular and renal risk in this 
population.
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Abstract
Background Hypertension is highly prevalent among renal transplant recipients (RTR) 
and a risk factor for graft failure and cardiovascular events. Protein intake has been 
claimed to affect blood pressure (BP) in the general population and may affect renal 
function. We examined the association of dietary protein with BP and renal function in 
RTR.
Methods We included 625 RTR (53±13 yrs; 57% male). Protein intake was assessed with 
a food frequency questionnaire (FFQ), differentiating between animal and plant protein. 
BP was measured according to strict protocol. Creatinine clearance and albuminuria 
were measured as renal parameters.
Results Protein intake was 83±12 g/d of which 63% derived from animal sources. 
BP was 136±17 mmHg systolic and 83±11 mmHg diastolic. Creatinine clearance 
was 66±26 ml/min; albuminuria 41 [10-178] mg/24h. An inverse, though statistically 
insignificant, association was found between total protein intake and both SBP (β=-2.22 
mmHg per SD, p=0.07) and DBP (β=-0.48 mmHg per SD, p=0.5). Protein intake was 
not associated with creatinine clearance. Although albuminuria was slightly higher in 
the highest tertile of animal protein intake compared to the lowest tertile (66 mg/d vs 33 
mg/d resp., p=0.03), linear regression analyses did not reveal significant associations 
between dietary protein and albuminuria.
Conclusion Protein intake exceeded current recommendations. Nevertheless, within the 
range of protein intake in our RTR population, we found no evidence for an association 
of dietary protein with BP and renal function. Intervention studies focusing on different 
protein types are warranted to clarify their effect on BP and renal function in RTR.
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Introduction
High blood pressure (BP) is a serious health problem after renal transplantation 1-3. It 
is an important risk factor for graft failure, cardiovascular events and mortality in renal 
transplant recipients (RTR) 3, 4, and usually requires multiple anti-hypertensives to 
ensure adequate BP control. Remarkably, the mechanisms and treatment of high BP in 
RTR are poorly defined and management is largely derived from data in non-transplant 
populations. Better elucidation of the mechanisms underlying high BP in RTR is urgently 
needed, as emphasized recently 5. Data in non-transplant populations consistently 
demonstrate an important role of diet and lifestyle in BP. Well-established dietary factors 
that favorably affect BP in the general population are weight reduction, reduced salt 
intake, moderation of alcohol intake and increased potassium intake 6 and in non-
transplant renal patients dietary salt restriction 7, 8. In a first study on BP and dietary 
factors in RTR we recently reported a positive association between sodium intake and 
BP 9, suggesting that modification of dietary factors can beneficially influence BP in 
addition to pharmacological BP regimens. Currently, interest is growing in the influence 
of dietary patterns and macronutrient intake, including protein, on BP. Dietary protein 
has also been claimed to affect BP, but the large body of literature on dietary protein and 
BP in the general population 10-16 is not consistent. In renal patients, dietary protein can 
affect renal hemodynamics as well as renal protein loss, hence modifying the course 
of long term renal damage (7-10). By these mechanisms, dietary protein might also 
affect BP. Concern exists that high protein intake induces high intraglomerular pressure 
and concurrent hyperfiltration, eventually leading to kidney damage and subsequent 
hypertension 17, 18. Although data from intervention studies applying protein restriction in 
chronic kidney disease (CKD) were not entirely conclusive 19, 20, dietary recommendations 
for patients with CKD advocate a protein intake of 0.6–0.8 g/kg/d, to decrease renal 
workload and help delay progression of kidney failure 21.
Considering the vast body of studies on dietary protein in CKD, surprisingly little data 
is available on the impact of dietary protein in RTR. Data on dietary habits, and on 
associations of dietary protein with BP and renal function in RTR are virtually lacking, 
and consequently, the empirical basis for the few available dietary guidelines regarding 
protein intake for RTR is virtually absent 22, 23. Consequently, it remains unclear, for 
medical practitioners as well as for RTR, what the optimal level and favorable source of 
dietary protein is in this population 24.
In this study, therefore, we aimed to clarify the relation of protein with BP and renal function 
in stable RTR. To this purpose, we examined dietary habits, and analyzed whether the 
intakes of total protein and types of protein (plant and animal) were associated with BP 
and renal function, on cross-sectional analysis in a Dutch patient-based cohort of 625 
RTR with a functioning graft for at least one year. 
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Methods
Design and study population 
We conducted an observational study to perform cross-sectional analyses in a large, 
single center RTR cohort. We invited all RTR (≥ 18 years) with a functioning graft for at 
least one year who visited our outpatient clinic between November 2008 and March 
2011. RTR were all transplanted in our center, had sufficient knowledge of the Dutch 
language and had no history of drug or alcohol addiction, as reported in their patient 
files. RTR were on standard antihypertensive and immunosuppressive therapy. Of 817 
initially invited RTR, 707 (87%) signed written informed consent to participate in this 
study. We excluded all patients with missing dietary data, leaving 625 RTR eligible 
for analysis. This study was conducted according to the guidelines laid down in the 
Declaration of Helsinki and all procedures involving human subjects/patients were 
approved by the Institutional Review Board (METc 2008/186). The routine regimen 
included no specific dietary counselling, except for discouraging excess sodium intake 
and encouraging losing weight in overweight individuals. Patients with diabetes were 
counselled as appropriate to adapt their dietary habits to achieve normoglycaemia.
Assessment of protein intake
Dietary intake was assessed using a semi quantitative food frequency questionnaire 
(FFQ) that inquired about intake of 177 food items during the last month. For each 
item, the frequency was recorded in times per day, week, or month. The number of 
servings per frequency was expressed in natural units (for example, slice of bread or 
apple) or household measures (for example, cup or spoon). The questionnaire was self-
administered and filled out at home. At the day of the visit to the outpatient clinic, all 
FFQs were checked for completeness by a trained researcher and inconsistent answers 
were verified with the patients. Total energy and nutrient intake per day was calculated 
using a computerized Dutch Food Composition Table taking seasonal variation 
into account 25. Because RTR have only sparsely been subject to nutritional studies 
thus far, we checked consistency of our data on protein intake in our population by 
comparing the estimated protein intake with 24 hour urinary urea excretion. Therefore, 
all participants were carefully instructed to collect a 24 hour urine sample according to 
a strict protocol. Urinary urea excretion was considered as a marker reflecting dietary 
total protein intake and was used to calculate protein intake according to the method of 
Maroni and colleagues taking also proteinuria into account (protein intake (g/d) = (0.18 x 
urinary urea excretion in mmol per 24 hours) + 15 + urinary protein excretion in g per 24 
hours) 26, 27. In addition, excretion of several urinary components was measured to infer 
dietary intake of additional dietary nutrients like sodium and potassium.
Dietary Protein, Blood Pressure and Renal Function in Renal Transplant Recipients  |  45
3
Outcome measurements
All measurements were performed during a morning visit to the out-patient clinic. Fasting 
BP (mmHg) was measured according to a strict protocol. Participants were left alone in 
a room in half-sitting position while systolic BP, diastolic BP and mean arterial pressure 
(MAP) were measured with a semi-automatic device (Dinamap® 1846, Critikon, Tampa, 
FL, USA). Measurements were performed every minute for fifteen minutes and values of 
the last three measurements were averaged. 
Blood was drawn after an 8-12h overnight fasting period in the morning after completion 
of the 24h urine collection. Renal function was assessed by 24h urinary creatinine 
clearance (ml/min), calculated as time-factored urinary creatinine concentration (mg/
min) divided by plasma creatinine concentration (mg/mL). Serum creatinine levels 
were determined using a modified version of the Jaffé method (MEGA AU 510, Merck 
Diagnostica, Darmstadt, Germany). Plasma and urinary concentrations of electrolytes 
and urea were measured using routine clinical laboratory methods, as were serum 
cholesterol and HbA1c. Urinary albumin concentration was determined by nephelometry 
(Dade Behring Diagnostic, Marburg, Germany). Total urinary protein concentration was 
analyzed using the Biuret reaction (MEGA AU 510, Merck Diagnostica, Darmstadt, 
Germany). Proteinuria was defined as urinary protein excretion ≥ 0.5 g/24h. 
Collection of risk factor data
Information on patients’ health status, medical history and medication use was obtained 
from patient records. Questionnaires were used to obtain information on smoking 
behavior and alcohol intake. Participants were classified as current smokers, former 
smokers, or never smokers. Alcohol intake was assessed based on self-reported 
number of beverages consumed weekly, converted into grams of ethanol per day and 
divided into quartiles (no alcohol, 0-10 g/d, 10-30 g/d and >30 g/d). Body weight and 
height were measured with participants wearing indoor clothing without shoes. Body 
Mass Index (BMI) was calculated as weight divided by height squared (kg/m2). 
Statistical analyses
Data-analysis was performed using SPSS version 18.0 software (SPSS Inc., Chicago, 
IL, USA). Normality was tested with the Kolmogorov-Smirnov test and skewed data 
were normalized by logarithmic transformation (i.e. albuminuria and proteinuria). Protein 
intake (total, plant, animal) was adjusted for total energy intake according to the residual 
method which is based on an isoenergetic principle 28. Characteristics of the study 
population and data on dietary intake were calculated in tertiles of energy adjusted total 
protein intake. Data in text and tables are presented as mean ± standard deviation (SD), 
unless stated otherwise.
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We used multivariable linear regression models to obtain the regression coefficients 
for BP and renal parameters per SD of energy-adjusted protein intake (total, plant, 
animal) in RTR. Our basic model (model 1) included age (continuous) and gender. In the 
second model we further adjusted for BMI (continuous), SBP (continuous; only applied 
in analyses for the association between protein intake and renal function) smoking 
behavior (never/ever/current), alcohol consumption (no alcohol, 0-10 g/d, 10-30 g/d and 
>30 g/d), use of antihypertensive medication (number of drugs; continuous) and time 
since transplantation (years; continuous). In the final model we additionally adjusted for 
total energy intake (continuous; kCal/day), urinary sodium, potassium (all continuous; 
mmol/24h), intake of calcium, magnesium (continuous; mg/d) carbohydrates, saturated 
fatty acids and polyunsaturated fatty acids (all continuous; g/day). 
To allow for non-linear associations, general linear model analyses were used to 
investigate the associations of tertiles of energy-adjusted protein intake (total, plant, 
animal) with BP and renal function in RTR. Per tertile of energy adjusted protein intake, 
the estimated mean values of BP, creatinine clearance and albuminuria were calculated 
as well as the p-trend across tertiles. Multivariable analyses were repeated with 
aforementioned adjustments. Within all statistical analyses, a two-sided P value less 
than 0.05 was considered to indicate statistical significance.
Results
Population characteristics
The mean age of our study population was 53 ± 13 years and 57% was male. Mean BMI 
was 26.7 ± 4.8 kg/m2, with 59% of the patients being overweight. Mean BP was 136 ± 
17 mmHg systolic and 83 ± 11 mmHg diastolic and 91% of the cohort had hypertension 
(i.e. BP≥140/90 or use of antihypertensive medication). Of the 625 RTR, 72 (11%) were 
not using any anti-hypertensive drugs, while 198 (30%) used one antihypertensive 
drug, 231 (35%) used two and 159 (24%) used three or more different anti-hypertensive 
drugs. Calcineurin inhibitors (CNIs) were used in 57% of RTR, 2% of RTR used mTOR 
inhibitors and 83% of RTR was on proliferation inhibiting therapy. Median prednisolone 
dose was 10 [7.5-10.0] mg/day.
The diet contained 83 ± 12 g/d of energy-adjusted protein (corresponding to 15.5% 
of an individuals total energy intake (en%) or 1.1 ± 0.3 g/kg/d) of which 52 ± 13 g/d 
(9.9 en%) derived from animal origin and 31 ± 6 g/d (5.7 en%) from plant origin (mean 
animal-to-plant ratio approximately 2:1). The distribution of plant protein intake and 
animal protein intake per group of total protein intake (g/d) is shown in Figure 1. The 
percentage of protein intake declined from 57% in the lowest group to 28% in the highest 
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group. Animal-to-plant ratio in the lowest group of total protein intake was 0.75 versus 
2.5 in the highest group of total protein intake.
Figure 1 Distribution of plant protein intake and animal protein intake per group of total protein 
intake (g/d). The percentage of plant protein intake declined from 57% in the lowest group to 
28% in the highest group. Animal-to-plant ratio in the lowest group of total protein intake was 
0.75 versus 2.5 in the highest group of total protein intake.
Based on the Maroni formula, total protein intake was 85 ± 21 g/d (~1.1±0.3 g/kg/d), 
which did not significantly differ from the protein estimate derived from the FFQ (p=0.3). 
Mean intake of calories, calcium, magnesium and phosphorus were 2175 ± 637 kCal/d, 
1049 ± 378 mg/d, 331 ± 90 mg/d and 1521 ± 331 mg/d respectively. Mean urinary 
excretion of sodium and potassium was 157 ± 62 mmol/24h and 73 ± 24 mmol/24h 
respectively. Of the caloric intake, 36 en% derived from fat (saturated fat 13 en%; 
monounsaturated fat 12 en%; polyunsaturated fat 8 en%) and 46 en% came from 
carbohydrates. Mean intake of fiber was 22 ± 7 g/d.
Patient characteristics by tertiles of total energy-adjusted protein intake are shown in 
Table 1. RTR in the highest tertile of energy adjusted protein intake were likely to be older, 
to have a higher BMI and higher urinary urea excretion levels, whereas prevalence of 
males and smokers were lower with higher energy adjusted protein intake. With higher 
protein intake, RTR tended to increase intake of animal protein rather than that of plant 
protein, both in absolute (g/d) and relative (en%) amounts. 
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Table 1 Patient characteristics across tertiles of energy-adjusted total protein intake.






n = 208 p
Protein intake, g/d (en%) 71 ± 7 (13.1) 83 ± 3 (15.6) 96 ± 7 (17.8)
Demographics
Gender, % male 61 58 51 0.06
Age, y 50 ± 14 54 ± 12 56 ± 12 <0.001
Weight, kg 78 ± 16 79 ± 15 83 ± 17 0.01
Length, cm 174 ± 10 173 ± 10 173 ± 9 0.4
BMI, kg/m2 25.7 ± 4.6 26.3 ± 4.4 27.7 ± 5.0 <0.001
Current smokers, % 15 14 10 0.27
Time since transplantation, y 6.5 [3.1-12.4] 5.1 [1.6-12.5] 5.1 [1.3-11.9] 0.22
Dietary Intake
Energy intake, kCal/d 2255 ± 774 2085 ± 564 2185 ± 548 0.024
Animal protein, g/d (en%) 40 ± 9 (7.6) 52 ± 6 (9.9) 65 ± 10 (12.1) <0.001
Plant protein, g/d (en%) 31 ± 7 (5.6) 31 ± 5 (5.7) 31 ± 6 (5.7) 0.19
Fat, g/d 92 ± 44 84 ± 27 88 ± 29 0.052
Carbohydrate, g/d 269 ± 90 237 ± 71 242 ± 68 <0.001
Calcium intake, mg/d 865± 334 1001± 293 1279 ± 366 <0.001
Magnesium intake, mg/d 316 ± 101 323 ± 84 358 ± 78 <0.001
Fiber intake, g/d 22.2 ± 7.9 22.0 ± 6.6 23.1 ± 5.7 0.21
Alcohol intake2, g/d 2.0 [0.02-11.6] 3.5 [0.05-13.7] 2.0 [0.02-9.6] 0.06
Medication use
Antihypertensives, % 86 85 93 0.015
Number of antihypertensives* 2 [1-2] 2 [1-2] 2 [1-3] 0.97
CNI’s, n (%) 119 (57) 116 (56) 122 (59) 0.77
mTOR inhibitors, n (%) 6 (3) 1 (0.5) 3 (1) 0.24
Hemodynamic parameters
Systolic Blood Pressure, mmHg 136 ± 16 137 ± 18 135 ± 18 0.53
Diastolic Blood Pressure, mmHg 83 ± 11 84 ± 11 82 ± 11 0.053
Mean Arterial Pressure, mmHg 100 ± 11 102 ± 13 100 ± 12 0.14
Renal Function Parameters
Serum Creatinine, umol/l 128 [103-171] 121 [99-155] 126 [99-156] 0.21
Creatinine Clearance, ml/min 63 ± 27 68 ± 25 66 ± 25 0.12
eGFR (ml/min/1.73m2) 52 ± 21 54 ± 21 56 ± 20 0.26
Urinary Albumin Excretion, mg/24h 36.1 [9.7-176] 38.4 [8.5-149] 50.0 [11.9-202] 0.57
Proteinuria (≥0.5 g/24h), n (%) 45 (22) 48 (23) 45 (22) 0.98
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Serum Parameters
Urea, mmol/l 9.1 [6.9-13.5] 9.0 [7.0-12.7] 10.1 [8.1-13.9] 0.09
Cholesterol, mmol/l 4.9 [4.3-5.7] 5.1 [4.4-5.8] 5.1 [4.4-5.8] 0.47
HbA1c, % 5.8 ± 0.7 6.0 ± 5.8 6.2 ± 0.9 <0.001
Uric acid, mmol/l 0.44 ± 0.12 0.43 ± 0.11 0.44 ± 0.12 0.84
Urinary excretions, mmol/24h
Phosphate 23.4 ± 8.6 25.6 ± 8.7 26.2 ± 8.9 <0.001
Urea 344 ± 97 397 ± 111 430 ± 119 <0.001
Sodium 142 ± 54 167 ± 66 161 ± 61 <0.001
Potassium 67.4 ± 23.4 74.3 ± 24.7 77.8 ± 24.4 <0.001
Creatinine 11.4 ± 3.6 11.7 ± 3.2 11.7 ± 3.3 0.29
Net Acid Excretion 41.3 ± 20.0 46.7 ± 20.2 48.1± 22.3 0.003
Data are presented as mean ± SD, % or median [IQR]. Abbreviations: en%, energy percentage; 
BMI, body mass index; CNI, calcineurin inhibitor; mTOR, mammalian target of rapamycin; eGFR, 
estimated glomerular filtration rate; HbA1c, glycated hemoglobin. * among users
Protein intake and BP
Intake of energy-adjusted protein (total, animal, plant) tended to be inversely associated 
with BP, although the level of significance was not reached (Table 2). After adjustment for 
potential confounders, the regression coefficients for systolic BP were -2.22 (p=0.07), 
-1.07 (p=0.37) and -1.41 (p=0.19) per SD of total, animal and plant protein respectively. 
On secondary regression analyses with tertiles of energy adjusted protein intake (total, 
animal, plant) instead of with continuous values of protein intake, in that way forcing 
more contrast in protein intake, findings remained essentially similar. Median total 
protein intake in the lowest tertile was 73.0 g/d compared to 94.0 g/d in the highest 
tertile. Although SBP was 3.9 mmHg lower in the highest tertile of protein intake (133.8 
mmHg vs 137.7 mmHg in the lowest tertile), this difference did not reach statistical 
significance (p=0.2). Similar trends were found for the associations of animal and plant 
protein with BP (data not shown).
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Table 2  Regression coefficients of the association between energy adjusted total protein 
intake and blood pressure in RTR.
Exposure variable SD Model SBP (mmHg) DBP (mmHg) MAP (mmHg)
β/SD p β/SD p β/SD p
1 -0.39 0.59 -0.21 0.63 -0.27 0.59
Total protein (g/d) 12.0 g/d 2 -0.84 0.25 -0.40 0.39 -0.54 0.28
3 -2.22 0.07 -0.48 0.54 -1.06 0.22
1 0.23 0.74 -0.13 0.77 -0.01 0.98
Animal protein (g/d) 13.1 g/d 2 -0.22 0.76 -0.34 0.46 -0.29 0.55
3 -1.07 0.37 -0.47 0.53 -0.67 0.41
1 -1.22 0.08 -0.12 0.78 -0.49 0.31
Vegetable protein (g/d) 5.8 g/d 2 -1.14 0.10 -0.05 0.92 -0.41 0.40
3 -1.41 0.19 0.14 0.83 -0.37 0.62
Model 1: adjusted for age and gender; Model 2: additionally adjusted for BMI, smoking behavior, 
alcohol intake, antihypertensive drugs and time since transplantation; Model 3: additionally adjusted 
for total energy intake, urinary sodium and potassium excretion, intake of calcium, magnesium, 
carbohydrates, saturated fatty acids and polyunsaturated fatty acids. Abbreviations: SD, standard 
deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure.
Protein intake and renal function
Table 3 shows the regression coefficients for the association between energy-adjusted 
protein intake (total, animal, plant) and renal function, reflected by creatinine clearance, 
albuminuria and proteinuria. Total protein intake was significantly associated with 
creatinine clearance, independent of age and gender (β=2.17 per SD protein intake; 
p=0.05). However, the fully adjusted models for the association between protein 
intake and creatinine clearance yielded insignificant regression coefficients of 0.19 ml/
min (p=0.9), 0.17 ml/min (p=0.9) and 0.03 ml/min (p=0.9) per SD of total, animal and 
plant protein respectively. Also, protein intake was not associated with albuminuria or 
proteinuria in this RTR cohort, regardless of both protein type and the adjustments that 
were made (Table 3). In order to consider the effect of CNIs, we also performed an 
adjustment for CNI use in linear regression analyses which did not essentially change 
the findings in the complete cohort (data not shown).
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With tertiles of energy-adjusted protein intake (total, animal, plant) rather than continuous 
variables, results were essentially similar; creatinine clearance was 62.4 ml/min in the 
lowest tertile of energy-adjusted protein intake (median intake 73.0 g/d) versus 66.3 
ml/min in de highest tertile of energy-adjusted protein intake (median intake 94.0 g/d; 
p-trend=0.2). Also, differentiation between animal and plant protein did not alter previous 
findings (data not shown). With albuminuria, we did not observe significant differences 
across increasing tertiles of total protein intake (p = 0.15). However, with respect to the 
intake of energy adjusted animal protein, a significant trend was found. The highest 
tertile, with a median protein intake of 63 g/d had 66 mg/24h albuminuria, compared 
with 33 mg/24h albuminuria in the lowest tertile with a median animal protein intake of 41 
g/d (p-trend = 0.03). This was independent of age, gender, BMI, SBP, smoking behavior, 
alcohol intake, anti hypertensive drugs, time since transplantation and dietary factors. 
These differences in albuminuria were not seen across tertiles of plant protein intake. 
Discussion
To date, no evidence is available regarding the optimal level of protein intake and its 
favorable source (i.e. animal or plant protein) in stable RTR. Therefore, we examined 
dietary habits in RTR, with the main purpose to study whether dietary protein was 
associated with BP and renal function parameters in a large, single center RTR cohort. 
In our analyses among 625 RTR with a functioning graft for at least one year, average 
protein intake was 83 ± 12 g/d (~1.1 ± 0.3 g/kg/d), thus exceeding recommended 
values for RTR. Intake of other relevant dietary factors, i.e sodium, phosphorus, fiber 
and intake and composition of fat was not in compliance with dietary recommendations 
either. Dietary protein (total, plant, animal) was not associated with BP or creatinine 
clearance. Although an adverse renal effect of animal protein intake was suggested 
by a higher albuminuria in the highest tertile of animal protein intake compared to the 
lowest tertile, no continuous relation was found in linear regression analysis.
This is the first study providing detailed information on dietary habits in RTR. Several 
methodological aspects of the nutritional assessment deserve to be addressed. First, 
estimation of animal and plant protein intake was assessed by FFQs, based on self-report, 
which may have led to misclassification due to inadequacies in dietary recall. However, 
estimations of total protein intake based on FFQ were similar to estimations based on 
urinary urea excretion. We therefore do not expect much bias from misclassification 
regarding animal and plant protein either. Additionally, during the study, a dietary diary 
was kept for three consecutive days in a subgroup of 60 RTR and dietary data of both 
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FFQ and diaries were compared. Pearson correlations between FFQ and diaries were 
0.72 for energy intake, 0.64 for protein intake, 0.50 for fat intake and 0.69 for carbohydrate 
intake. These correlation coefficients were comparable with those observed in previous 
studies analyzing the validity of FFQs in population-based cohort studies 29. Second, our 
analyses are based on cross-sectional data with protein intake and BP being measured 
at the same moment. This makes it difficult to assess the temporal relationships in a 
potential association. For instance, patients with renal function decline might restrict their 
protein intake which might have manipulated potential associations. This is, however, 
unlikely, because no active intervention on protein intake is advocated in RTR when 
renal function decreases, until dialysis is re-started, to prevent induction of protein-
malnutrition in the face of continued immunosuppression. Third, it might be hypothesized 
that, as a result of heterogeneity of the RTR population (e.g. pharmacological regimens, 
diversity in allograft vintage), significant associations of dietary protein with BP might 
go unnoticed. However, despite possible blurring of potential associations due to these 
factors, classical factors associated with BP in the general population like age, gender, 
BMI and sodium intake were significantly positively associated with BP in our RTR 
population 9 thus supporting the power of our study to identify determinants of blood 
pressure in the current clinical context. Strengths of our study include the fact that, to 
our knowledge, this is the first study examining the association of dietary protein with BP 
and renal function in a large, stable RTR population, with the obvious limitation however, 
of its single-center nature that limits its generalizability. Extensive data collection made 
it possible to adjust for many potential confounders, including sodium intake reflected 
by urinary sodium excretion. Previous studies, in line with ours, have shown a firm and 
inextricable association between protein intake and sodium intake cross-sectionally 8, 30 
which therefore makes it difficult to distinguish between the effects of the separate 
dietary components on BP and renal function.
Our dietary inventory allows a detailed assessment of the dietary habits of the RTR 
population, albeit in a single center set-up. The dietary habits of our RTR generally are 
not quite optimal, as shown from their intake of macronutrients as well as sodium and 
phosphorus, which deviate from the available recommendations. Accordingly, dietary 
habits can be considered logical targets for intervention in RTR, but this renders it all the 
more important to reinforce the empirical basis in this population. 
Protein intake and BP
No significant associations of dietary protein with BP in RTR were seen, which suggests 
that dietary protein, within the range of intake in our population, is well tolerated in stable 
RTR. However, it might be hypothesized that the absence of a significant association 
is explained by the relatively small range of protein intake in our population. The SD 
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of unadjusted mean total protein intake in RTR was 20 g/d, which is smaller than the 
SD of 27 g/d in a big sample of the Dutch general population 31. RTR usually have a 
history of long term exposure to strict dietary restrictions, especially during the dialysis 
period, this may have modulated the eating habits of this specific population to fairly 
homogeneous pattern, which could mask a potential association of protein intake with 
BP. Nevertheless, repeating our multivariate analyses in tertiles instead of per SD, 
forcing more contrast in exposure, did not reveal significant associations either. Future 
studies could include RTR from different populations and countries to acquire a larger 
variation in protein intake or intervene on protein intake, by isocaloric exchange for other 
macro-nutrients.
Protein intake and renal function
The potentially deleterious effect of dietary protein on renal function, suggested by 
several previous studies 17, 18, 32-34, is ascribed to the induction of high intraglomerular 
pressure and concurrent hyperfiltration. This adverse phenomenon of dietary protein 
was not so pronounced in our study in stable RTR, as appears from the non-significant 
regression coefficients resulting from our statistical analyses. We did not see higher 
creatinine clearance or higher albuminuria or proteinuria in RTR with a higher total protein 
intake. However, a slightly, but significantly, higher albuminuria was seen in the highest 
tertile of animal protein, independent of a.o. age, gender, BMI, BP and dietary factors 
like energy and sodium intake. This significant association was not seen in tertiles of 
plant protein, suggesting that it is not protein per se that could influence albuminuria, 
but that differences exist between types of protein. One other study addressing the 
association between protein intake and renal function in RTR was performed by 
Bernardi et al. They studied the role of long-term dietary protein restriction on renal graft 
function in 42 post-transplant patients with signs of chronic rejection 33. Patients with 
moderate protein intake (0.73 ± 0.11 g/kg) maintained unchanged renal graft function, 
whereas patients with a high protein diet (1.4 ± 0.23 g/kg) ended up with a significantly 
lower graft function. However, during enrolment all patients received similar dietary 
recommendations and compliance with protein restriction was not pre-specified but 
based on urinary urea excretion. At the end of the study patients were compared in two 
groups stratified by compliance status. Moreover, the low protein diet was provided in 
combination with a low sodium and low lipid diet which makes it complicated to isolate 
the effects of moderate protein intake on renal function.
In conclusion, we found no clear-cut association of dietary protein with BP or creatinine 
clearance within the ranges of protein intake in our population consisting of 625 stable 
RTR. Although RTR in the highest tertile of animal protein intake had a higher urinary 
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albumin excretion compared to RTR in the lowest tertile, no continuous association was 
found between animal protein intake and albuminuria. In general, dietary habits in our 
RTR deviated from the available guidelines, with intake of protein, saturated fat, sodium 
and phosphorus being higher, and intake of polyunsaturated fat, carbohydrates and 
fiber being lower than recommended. These data prompt for further studies addressing 
the role of dietary factors in the cardiovascular and renal risk in RTR, including the 
effects of intervention studies. 
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Abstract
Background Acidosis is highly prevalent among renal transplant recipients (RTR) 
and adversely affects cardio-metabolic processes. Well-known factors contributing to 
acidosis are graft dysfunction and immunosuppressive drugs. Little is known about the 
potential influence of diet on acidosis in RTR. We examined the association of metabolic 
acid load with acidosis and with cardiovascular risk factors in RTR. Second we aimed to 
identify dietary factors associated with acidosis.
Methods We included 707 RTR. Metabolic acid load was assessed by measuring 24h 
urinary Net Acid Excretion (NAE; i.e. titratable acid + ammonium – bicarbonate). Acidosis 
was defined as serum [HCO3
-] < 24 mmol/L. Blood pressure and insulin resistance, 
reflected by HbA1c, were among cardiovascular risk factors. Diet was assessed with 
food frequency questionnaires. Linear regression analysis was applied to investigate 
the association between NAE and acidosis and between dietary factors and acidosis.
Results Mean age was 53±13y, 57% was male. Acidosis was present in 31% of RTR. 
NAE was associated with acidosis (serum HCO3-: β=-0.61 and serum pH: β=-0.010; both 
p<0.001). Patients with high intake of (animal) protein (i.e. from meat, cheese and fish) 
and low intake of fruits and vegetables had significantly lower serum HCO3
- and serum 
pH. No associations were observed between NAE and cardiovascular risk factors like 
hypertension and insulin resistance.
Conclusion In addition to conventional factors contributing to acidosis, diet might 
influence acid-base homeostasis in RTR. Higher intake of fruits and vegetables and 
lower animal protein intake is associated with less acidosis in RTR.
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Introduction
Worldwide, the prevalence of end stage renal disease (ESRD) is increasing rapidly 1. 
Although, kidney transplantation is the preferred treatment for patients with ESRD, 
successful transplantation is still associated with substantially elevated morbidity and 
mortality 2, 3. Many renal transplant recipients (RTR) have metabolic acidosis 4, 5 which 
may adversely affect cardio-metabolic processes, including blood pressure (BP) and 
insulin resistance as well as proper functioning of multiple tissues 4, 6, 7. Therefore, it 
is important to identify modifiable determinants of metabolic acidosis that might help 
improve acid-base homeostasis in RTR.
Diet can influence acid-base balance in humans 8-10. Potassium salts of metabolizable 
anions, like citrate, have an alkalinizing effect, whereas acid load originates from 
precursors like cationic amino acids and organic acids. Accordingly, fruits and vegetables 
contribute to base load whereas (animal) protein adds to acid load. The contemporary 
Western diet, including large amounts of animal products, generates an acid load that 
is not compensated for by the shortage of fruit and vegetable, subsequently inducing 
increasing but unnoticed metabolic acidosis 11.
The kidney plays an important role in acid-base homeostasis by excreting the excess 
of acids ingested. In general, persons consuming diets high in acid load have higher 
urinary acid excretion compared to persons eating diets rich in alkalinizing foods 12. In 
RTR however, the capacity to excrete acid is decreased due to impaired renal function. 
Therefore, it is hypothesized that RTR could benefit from dietary modifications, to 
improve acid-base homeostasis. Although post-transplant acidosis has been studied 
before 4, 5, to our knowledge no studies are available on the role of nutrition in acidosis 
in RTR.
We therefore examined whether NAE, reflecting metabolic acid load, was related 
to acidosis in a large RTR cohort. Second, we studied the association of NAE with 
cardiovascular risk factors like insulin resistance and high BP. Additionally, we aimed to 
identify dietary factors contributing to NAE in RTR, to provide tools for lowering acidosis 
in RTR.
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Methods
Design and study population 
We conducted cross-sectional analyses in a large, single-centre RTR cohort. We invited 
all adult RTR (age ≥ 18 years) with a functioning graft for at least one year who visited 
our outpatient clinic between 2008 and 2011. RTR were all transplanted in our center, 
had sufficient knowledge of the Dutch language and had no history of drug or alcohol 
addiction, as reported in their patient files. Patients with overt congestive heart failure 
and patients diagnosed with cancer other than cured skin cancer were not considered 
eligible for the study. In patients with fever or other signs of infection (e.g. complaints of 
urinary or upper respiratory tract infection), visits were postponed until symptoms had 
resolved. Of 817 initially invited RTR, 707 (87%) signed informed consent to participate. 
All but three were Caucasian. For analyses regarding dietary intake, we excluded all 
patients with missing dietary data, resulting in 625 RTR for analyses. RTR with complete 
data and RTR with missing data were similar regarding age, gender, body composition, 
eGFR and medication use. Of RTR that did not consent, we only recorded age, gender, 
body composition and eGFR. Compared to participating RTR, RTR that did not consent 
were slightly older (58±13 vs 53±13 years in both other groups) and had lower eGFR 
(47±19 vs 51±21 and 53±20 ml/min/1.73m2 for the RTR with missing and complete 
data respectively). The Institutional Review Board approved the study protocol (METc 
2008/186), which was in adherence to the Declaration of Helsinki.
Assessment of metabolic acid load
Participants were instructed to collect a 24 hour urine sample according to strict 
protocol at the day prior to their visit to the outpatient clinic. Urine was collected under 
oil and chlorhexidin was added as antiseptic agent. After completion, electrolytes 
(chloride, potassium, sodium, calcium and phosphate) were directly analyzed following 
standard laboratory procedures. Urine pH and titratable acid (TA) were measured 
with an automated titrator (Metrohm, 855 Robotic Titrosampler, Switzerland). Directly 
after collection, additional urine samples were stored at -80° Celsius and kept deeply 
refrigerated for a maximum of two years. Ammonium (NH4+) and bicarbonate (HCO3-
) were measured chromatographically in freshly thawed 24h urine samples (Waters, 
Alliance HT 2795 and Metrohm, type 861, Herisau, Switzerland respectively). Stability 
of both parameters over repeated freeze-thaw cycles was analyzed in advance of the 
study, rendering insignificant differences after thawing compared to the original mean 
values. NAE, the gold standard for measuring metabolic acid load, was calculated in the 
conventional manner as TA + NH4+ - HCO3- 13. 
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Assessment of diet and acid load
Diet was assessed using a semi quantitative food frequency questionnaire (FFQ) 
inquiring about intake of 177 items during the last month taking seasonal variations 
into account. The FFQ was developed at Wageningen University 14 and has been 
updated several times. For the present study, the FFQ was slightly modified for accurate 
assessment of protein intake, including types and sources of protein. For each item, the 
frequency was recorded in times per day, week, or month. The number of servings was 
expressed in natural units (e.g. slice of bread or apple) or household measures (e.g. 
cup or spoon). The questionnaire was self-administered and filled out at home. All FFQs 
were checked for completeness by a trained researcher and inconsistent answers were 
verified with the patients. Dietary data were converted into daily nutrient intake using the 
Dutch Food Composition Table of 2006 15. The validity of the FFQ in RTR was checked 
by comparing the estimated protein intake with calculations of protein intake according 
to the Maroni formula, based on 24h urinary urea excretion, reliably reflecting protein 
intake 16, 17. Based on this formula, protein intake was 85±21 g/d (~1.1±0.3 g/kg/d), 
similar to the estimates derived from the FFQ (83±20 g/d (~1.1±0.3 g/kg/d; p=0.3). Also, 
in a subgroup of 60 RTR, we compared dietary data of FFQ with three-day food records. 
Pearson correlations between FFQ and records were 0.72 for energy intake, 0.64 for 
protein intake (0.53 for animal protein; 0.73 for plant protein), 0.50 for fat intake and 0.69 
for carbohydrate intake, comparable with those observed in previous studies analyzing 
validity of FFQs in population-based cohort studies 18. Regarding fruit and vegetable 
intake, correlation coefficients were 0.66 and 0.41 respectively.
Dietary acid load was assessed with two validated methods. First, potential renal acid 
load (PRAL) was calculated using the algorithm described by Remer et al 10: PRAL 
(mEq/d) = 0.4888 x protein intake (g/d) + 0.0366 x Phosphorus (mg/d)–0.0205 x 
Potassium (mg/d) – 0.0125 x Calcium (mg/d) – 0.0263 x Magnesium (mg/d). Second, 
we estimated dietary acid load using the algorithm described by Frassetto et al 9: 
estimated net endogenous acid production (NEAP; mEq/d) = [54.5 x Protein intake (g/d) 
/ Potassium intake (mEq/d)] – 10.2.
Outcome measures
All measurements were performed after an 8-12h overnight fasting period. BP (mmHg) 
was measured semi-automatically according to strict protocol as described previously 
19. Measurements were performed every minute for fifteen minutes and the last three 
measurements were averaged. Renal function was assessed by estimating glomerular 
filtration rate (eGFR) applying the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation 20. Serum creatinine was determined using a modified version of 
the Jaffé method (MEGA AU 510, Merck Diagnostica, Darmstadt, Germany). Blood was 
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drawn in the morning after completion of the 24h urine collection. Concentrations of 
electrolytes and urea were measured using routine clinical laboratory methods, as were 
serum cholesterol, HbA1c and Nt-Pro-BNP-levels. Venous blood gas analyses were 
assessed photometrically. Acidosis was defined as serum [HCO3
-] < 24mmol/l.
Information on medical history and medication use was obtained from patient records. 
Data on smoking behavior (current, former, never) was obtained with an additional 
questionnaire. BMI was calculated as weight divided by height squared (kg/m2) and 
BSA was estimated applying the universally adopted formula of DuBois 21.
Statistical analyses
Data-analysis was performed using SPSS 18.0 (SPSS Inc., Chicago, USA). Skewed 
data were log-transformed for analyses (i.e. albuminuria, proteinuria, PTH, Nt-pro-BNP, 
triglycerides, cholesterol). Data are presented as mean ± standard deviation (SD), unless 
stated otherwise. Patient characteristics were calculated across gender stratified tertiles 
of NAE, controlled for BSA. P for trend was obtained by using medians as continuous 
variables in univariate linear regression analysis. For nominal and ordinal variables we 
applied the χ2-test and Jonckheere-Terpstra-test respectively. 
Linear regression was applied for the associations of NAE with acidosis and cardiovascular 
risk factors. Regression coefficients are given as standardized βs, referring to the number 
of standard deviations the dependent variable changes, per standard deviation increase 
of NAE. Adjustments were made for age, BSA and gender (model 1), use of medication 
(proliferation inhibitors, calcineurin inhibitors, RAS-inhibitors, sodium bicarbonate and 
diuretics (model 2) and eGFR (ml/min/1.73m2), time since transplantation (years) and 
smoking behavior (categories; model 3). To separate effects of low eGFR and metabolic 
acid load on acidosis in RTR, we performed regression analyses for 1) the association 
between eGFR and acidosis and 2) the association between NAE and acidosis. 
To identify dietary factors contributing to NAE, we calculated dietary intake across tertiles 
of NAE, controlling for BSA. Then we applied linear regression analyses, adjusting for 
age and gender (model 1) eGFR, time since transplantation and smoking behavior 
(model 2). Regression coefficients are given as change of NAE per SD increase of the 
dietary factor. A two-sided P value less than 0.05 was considered statistically significant.




Mean age was 53±13 years, 57% was male. BMI was 26.7 ± 4.8 kg/m2, with 59.4% 
of RTR being overweight (i.e. BMI≥25 kg/m2). Mean BP was 136±17 mmHg systolic 
and 83±11 mmHg diastolic; 91% of RTR had hypertension (i.e. BP≥140/90 or use of 
antihypertensive medication). Of 707 RTR, 637 (89%) used anti-hypertensive drugs; 
198 (30%) used one, 231 (35%) used two, and 159 (24%) used three or more different 
anti-hypertensive drugs. Calcineurin and proliferation inhibitors were used in 57% and 
83% of RTR respectively. Median prednisolone dose [interquartile range] was 10 [7.5-
10.0] mg/day. Only 3 RTR (0.4%) used sodium bicarbonate. Acidosis (i.e. serum HCO3- 
< 24mmol/l) was present in 31% of RTR and about half of these patients had a systemic 
pH < 7.35 (figure 1). RTR with acidosis had a significantly lower eGFR compared to 
non-acidotic RTR (44±20 ml/min/1.73m2 versus 56±19 ml/min/1.73m2 respectively; 
p<0.001).
Mean NAE was 40.7±18.1 mEq/d, ranging from 22.2±10.2 to 60.0±11.8 mEq/d across 
tertiles of NAE (table 1). NAE was positively associated with eGFR, use of mycophenolate, 
serum chloride and urinary excretion of ammonia, TA, phosphorus and sulphate, 
whereas NAE was inversely related to time since transplantation, use of azathioprine, 
serum and urine pH, and serum and urine bicarbonate. No significant differences were 
found regarding smoking behavior over tertiles of NAE.
Figure 1  Histogram of serum bicarbonate concentration in a single-center RTR cohort 
including 707 RTR with a functioning graft for at least one year. Metabolic acidosis (i.e. [HCO3-] 
< 24mmol/l) was present in 31% of RTR.
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Table 1 Characteristics of 707 renal transplant recipients (RTR) across gender stratified 
tertiles of urinary net acid excretion (NAE; mEq/24h) controlled for body surface area (BSA)
Gender stratified tertiles of 







NAE (mEq) 22.2 ± 10.2 39.8 ± 5.3 60.0 ± 11.8
Demographics
Age, years 54 ± 13 53 ± 13 52 ± 12 0.07
BSA, m2 1.94 ± 0.22 1.95 ± 0.22 1.93 ± 0.22 0.62
Current smokers, % 11 13 14 0.43
Diabetes Mellitus**, % 27 22 23 0.34
Hypertensives, % 91 92 89 0.50
Systolic BP, mmHg 136 ± 18 137 ± 17 136 ± 17 0.89
Diastolic BP, mmHg 83 ± 11 84 ± 10 83 ± 11 0.99
Renal parameters
Time since Rtx, y 7.7 [3.2-15.2] 5.8 [2.0-11.9] 4.3 [1.3-10.0] <0.001
Serum Creatinine, umol/L 139 [107-176] 121 [98-153] 116 [97-152] 0.006
eGFR, ml/min/1.73 m2 48 ± 20 54 ± 20 56 ± 20 <0.001
Albumin excretion, mg/24h 58 [11-202] 35 [9-200] 36 [12-124] 0.26
Proteinuria (≥0.5 g/24h), % 23 25 20 0.52
Medication users
Sodium bicarbonate, n 1 2 0 0.9
Antihypertensive drugs, % 88 90 86 0.65
Proliferation inhibitor, % 77 84 90 0.001
Mycophenolate, % 47 71 80 <0.001
Azathioprine, % 30 12 10 <0.001
Calcineurin inhibitor, % 57 58 57 0.88
Ciclosporin, % 37 44 37 0.95
Tacrolimus, % 17 16 20 0.53
Diuretics, % 49 36 37 0.01
Anti-diabetic drugs, % 15 16 14 0.66
Serum parameters
pH 7.38 ± 0.04 7.37 ± 0.05 7.36 ± 0.04 0.001
HCO3-, mmol/L 25.1 ± 3.0 24.7 ± 3.0 24.1 ± 3.2 0.004
v-pCO2, kPa 5.85 ± 0.80 5.86 ± 0.83 5.82 ± 0.82 0.71
Base excess 0.5 [-1.3-1.9] 0.2 [-1.9-1.5] -0.5 [-2.9-1.1] 0.001
Anion gap, mmol/L 11.1 ± 2.2 10.8 ± 2.1 10.7 ± 2.1 0.25
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Chloride, mmol/L 104.5 ± 3.4 105.3 ± 3.2 106.2 ± 3.7 <0.001
Phosphate, mmol/L 1.01 ± 0.22 0.97 ± 0.22 0.92 ± 0.19 <0.001
PTH, pmol/L 9.1 [5.9-15.6] 8.5 [5.0-13.9] 9.1 [6.3-14.4] 0.64
Albumin, mmol/L 42.5 ± 3.2 43.2 ± 2.9 43.4 ± 2.8 0.002
Cholesterol, mmol/L 5.30 [4.50-6.00] 5.00 [4.40-5.70] 4.90 [4.20-5.70] 0.04
HDL-cholesterol, mmol/L 1.30 [1.10-1.76] 1.30 [1.10-1.60] 1.30 [1.00-1.60] 0.53
Triglycerides, mmol/L 1.70 [1.29-2.30] 1.63 [1.22-2.34] 1.69 [1.16-2.21] 0.58
HbA1c, % 6.0 ± 0.7 6.0 ± 0.9 6.0 ± 0.8 0.91
hsCRP 1.9 [0.9-6.0] 1.6 [0.7-3.0] 1.4 [0.6-4.7] 0.06
Nt-pro-BNP 340 [143-787] 239 [96-594] 185 [85-442] 0.006
Urinary parameters
Ammonium, mEq/24h 13.3 ± 7.2 20.0 ± 7.6 32.2 ± 12.3 <0.001
Titratable Acid, mEq/24h 21.0 ± 7.6 30.2 ± 7.9 39.4 ± 11.4 <0.001
HCO3-, mEq/24h 7.2 [3.9-12.8] 4.2 [2.3-6.9] 3.3 [2.2-4.9] <0.001
pH 6.36 ± 0.46 6.00 ± 0.42 5.76 ± 0.45 <0.001
Urea, mmol/24h 341 ± 99 384 ± 101 452 ±119 <0.001
Creatinine, mmol/24h 11.1 ± 7.9 11.7 ± 3.4 12.7 ± 3.4 0.003
Phosphorus, mmol/24h 21.0 ± 7.8 25.1 ± 8.0 29.4 ± 8.5 <0.001
Sulphate, mmol/24h 15.2 ± 5.8 17.6 ± 5.4 20.9 ± 6.9 <0.001
Sodium, mmol/24h 147 ±65 155 ± 58 170 ± 60 <0.001
Potassium, mmol/24h 73.0 ± 25.1 72.9 ± 24.4 73.9 ± 24.0 0.72
Calcium, mmol/24h 2.1 [0.9-3.4] 2.5 [1.2-4.2] 2.5 [1.2-4.2] 0.08
Data are presented as mean ± SD, % or median [IQR]. Abbreviations: NAE, net acid excretion; BSA, 
body surface area; BP, blood pressure; RTx, renal transplantation; eGFR, estimated glomerular 
filtration rate; v-pCO2, venous partial pressure of CO2; PTH, parathyroid hormone; HbA1c, 
glycosylated haemoglobin; hsCRP, high-sensitive CRP; Nt-pro-BNP, N-terminal pro-Brain Natriuretic 
Peptide. * P-trend was tested by either entering the median values within tertiles into the model 
as covariate, by χ2-test or by Jonckheere-Terpstra test; **Diabetes Mellitus was defined as serum 
glucose ≥ 7mmol/L or use of anti-diabetic drugs.
NAE, acidosis and cardiovascular risk profile
The associations between NAE, serum HCO3- and various cardiovascular risk factors 
are shown in Table 2. After adjustment for age, gender, BSA, use of medication, eGFR, 
time since transplantation and smoking behavior, NAE was inversely associated with 
serum bicarbonate and serum pH (St. β=-0.16; p<0.001 and St. β=-0.18; p<0.001 
respectively). Similar associations were found between PRAL and NEAP and acidosis: 
adjusted regression coefficients (model 3) for the association of PRAL and NEAP with 
serum HCO3- were -0.13 and -0.12 respectively (both p=0.001). Standardized βs for the 
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associations of PRAL and NEAP with serum pH were -0.07; p=0.07 and -0.09 p=0.02 
respectively). In secondary analyses, the association of NAE with HCO3- and serum pH 
appeared to be significant in RTR with and without metabolic acidosis (all p<0.01; data 
not shown). 
Further analyses revealed standardized betas of 0.33 and 0.31 for the association 
of eGFR with serum [HCO3-] and serum pH respectively (both p<0.001), whereas 
standardized betas were -0.08 (p=0.005) and -0.10 (p=0.001) for the association of 
NAE with serum [HCO3-] and serum pH respectively. With respect to cardiovascular 
risk factors, NAE was inversely associated with total cholesterol (St. β=-0.10, p=0.02) 
and serum phosphate (St. β=-0.12, p=0.003) (model 3). Initially significant associations 
between NAE and serum albumin (inverse) and serum Nt-Pro-BNP (direct) disappeared 
after adjustment for eGFR, time since Rtx and smoking behavior (table 2). NAE was not 
related to BP and insulin resistance (table 2).
Dietary factors and NAE
Both formulas estimating dietary acid load were positively correlated with NAE, i.e. 
r=0.42 (p<0.001) for the correlation between PRAL and NAE and r=0.32 (p<0.001) for 
the correlation between NEAP and NAE. Dietary intake across gender stratified tertiles 
of NAE, controlled for BSA, is shown in table 3. Across tertiles, NAE was positively 
associated with total protein, animal protein, phosphorus and calcium (all p-trend<0.05). 
Regarding food groups, NAE was directly related to cheese intake (p-trend=0.001) and 
inversely related to fruit intake (p-trend=0.05). When analyzing continuously (table 4), 
NAE was positively associated with intake of total protein (β=2.88; p=0.001), animal 
protein (β=3.25; p<0.001), calcium (β=2.62; p=0.002) and phosphorus (β=2.51; 
p=0.004) after adjustment for age and gender. These associations remained essentially 
unchanged after adjustment for eGFR, time since transplantation and smoking behavior 
(total protein (β=2.17; p=0.006), animal protein (β=3.08; p<0.001), calcium (β=2.41; 
p=0.006) and phosphorus (β=2.28; p=0.008)). Translation to food groups showed that 
those nutrients might originate from meat, fish and cheese since significant associations 
were observed of NAE with meat (β=1.81; p=0.04); fish (β=1.91; (p=0.01); and cheese 
(β=3.07; p<0.001). Also, intake of bread was directly associated with NAE (β=2.10; 
p=0.02), whereas we observed inverse associations between NAE and intake of fruits 
(β=-1.77; p=0.04) and vegetables (β=-1.79; p=0.05).
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Table 3  Dietary intake of 625 renal transplant recipients across gender stratified tertiles of net 
acid excretion (NAE; mEq/d) controlled for body surface area (BSA).
Gender stratified tertiles of 








Energy intake, kCal/d 2141 ± 607 2252 ± 608 2174 ± 700 0.61
Protein intake, g/d (en%) 79 ± 20 (15.2) 83 ± 19 (14.7) 85 ± 20 (16.1) 0.02
Animal protein, g/d (en%) 50 ± 15 (9.6) 52 ± 15 (9.5) 54 ± 15 (10.4) 0.01
Vegetable protein, g/d (en%) 30 ± 9 (5.6) 32 ± 10 (5.8) 31 ± 10 (5.7) 0.48
Fat, g/d (en%) 87 ± 32 (36.0) 92 ± 31 (36.3) 89 ± 39 (36.6) 0.56
Carbohydrates, g/d (en%) 247 ± 75 (46.5) 259 ± 78 (46.1) 244 ± 80 (44.8) 0.67
Fiber, g/d 22 ± 7 24 ± 7 22 ± 7 0.54
Calcium, mg/d 1009 ± 353 1058 ± 358 1109 ± 420 0.01
Magnesium, mg/d 324 ± 86 345 ± 91 333 ± 91 0.34
Potassium, mg/d 3496 ± 867 3667 ± 912 3499 ± 906 0.34
Phosphorus, mg/d 1477 ± 387 1559 ± 374 1568 ± 420 0.02
Food groups
Meat, g/d 94 ± 40 97 ± 40 97 ± 40 0.47
Fish, g/d 11.4 [3.0-22.3] 11.7 [4.7-19.4] 10.7 [4.2-20.9] 0.17
Milk, g/d 116 ± 83 120 ± 81 114 ± 89 0.81
Cheese, g/d 32 ± 25 34 ± 26 41 ± 32 0.001
Fruit, g/d 161 ± 122 156 ± 117 140 ± 105 0.05
Vegetables, g/d 95 ± 58 99 ± 63 88 ± 52 0.23
Potatoes, g/d 134 ± 77 135 ± 72 125 ± 80 0.28
Bread, g/d 123 ± 54 145 ± 67 136 ± 58 0.03
Dietary acid load formulas
PRAL, mEq/d 0.32 [-8.1;7.2] 0.95 [-5.8;6.8] 5.1 [-3.2;11.1] <0.001
NEAP, mEq/d 39 ± 9 40 ± 8 42 ± 8 <0.001
Data are presented as mean ± SD, % or median [IQR]. Abbreviations: en%, energy percentage; 
PRAL, potential renal acid load; NEAP, net endogenous acid production. P-trend was tested by either 
entering the median values within tertiles into the model as covariate, by χ2-test or by Jonckheere-
Terpstra test.
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Table 4  Regression coefficients for the association of dietary factors with NAE/BSA*1.73 
(mEq/24h) in 625 patients





pNutrients lower upper lower upper
Energy intake, kCal/d 599 0.50 -1.37 2.38 0.60 0.33 0.03 0.63 0.76
Protein intake, g/d 20 2.88 0.93 4.83 0.001 2.17 0.12 4.20 0.006
Animal protein, g/d 15 3.25 1.21 5.29 <0.001 3.08 0.59 5.59 <0.001
Vegetable protein, g/d 9 0.70 -0.64 2.04 0.43 0.63 -2.12 3.39 0.41
Fat, g/d 32 0.45 -5.04 5.94 0.63 0.27 1.03 -0.49 0.74
Carbohydrate, g/d 73 -0.67 -3.78 2.44 0.45 -0.67 -1.95 0.61 0.57
Fiber, g/d 7 -0.67 -2.34 1.00 0.43 -0.63 -1.71 0.45 0.39
Calcium, mg/d 359 2.62 0.81 4.43 0.002 2.41 0.31 4.51 0.006
Magnesium, mg/d 85 1.36 -0.27 2.99 0.12 1.03 -0.82 2.88 0.16
Potassium, mg/d 872 0.39 -0.45 1.23 0.65 0.14 0.93 -0.65 0.89
Phosphorus, mg/d 390 2.51 0.68 4.34 0.004 2.28 0.03 4.53 0.008
Food groups
Meat, g/d 40 1.74 0.23 3.27 0.04 1.81 0.44 3.18 0.04
Fish, g/d 16 1.86 0.14 3.58 0.03 1.91 0.46 3.36 0.01
Milk, g/d 85 0.40 -1.16 1.96 0.65 0.65 -3.31 4.61 0.67
Cheese, g/d 28 3.04 1.11 4.97 <0.001 3.07 0.81 5.33 <0.001
Fruit, g/d 115 -1.65 -3.13 -0.17 0.05 -1.77 -3.46 -0.08 0.04
Vegetables, g/d 58 -1.55 -3.05 -0.17 0.04 -1.79 -3.90 -0.16 0.05
Potatoes, g/d 77 -1.15 -2.50 0.20 0.16 -1.21 -2.69 0.27 0.16
Bread, g/d 60 2.15 0.35 3.94 0.008 2.10 0.29 5.33 0.02
Dietary acid load formulas 
PRAL, mEq/d 12 3.37 1.79 4.95 <0.001 3.24 1.49 4.99 <0.001
NEAP, mEq/d 9 3.41 1.86 4.96 <0.001 3.38 1.62 5.14 <0.001
Model 1: adjusted for age (y) and gender; model 2: additionally adjusted for renal function (eGFR), 
time since transplantation (y) and smoking behavior; Abbreviations: BSA, body surface area; SD, 
standard deviation; 95% CI, 95% confidence interval; PRAL, potential renal acid load; NEAP, net 
endogenous acid production.
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Discussion
In this study, we examined the relation between diet and NAE (reflecting metabolic 
acid load). Additionally we studied the association of NAE with acidosis and various 
cardiovascular risk factors in 707 RTR. Acidosis was present in 31% of RTR. NAE was 
positively associated with acidosis, whereas no associations were observed with insulin 
resistance and high BP. NAE was higher in patients with higher intake of (animal) protein, 
(presumably from cheese, meat and fish) and calcium, and lower in patients with higher 
intakes of fruits and vegetables.
Strengths of our study include the large sample size and the novelty of our findings 
in this specific patient group. Furthermore, collection of 24h urine samples allowed 
direct measurement of NAE as marker of metabolic acid load in addition to estimation 
of dietary acid load based on dietary recall (PRAL and NEAP). This enabled us to verify 
internal consistency of our data and made our conclusions more reliable. Limitations 
are the observational and cross-sectional study design which does not allow for proving 
causality. However, although reverse causality should be considered, it seems unlikely 
that RTR with higher NAE would have adapted dietary habits, since the extent of 
urinary acid excretion goes unnoticed. Second, NAE is a marker of the total amount of 
acids ingested, and therefore reflects both acidity of the diet and use of acidifying (or 
alkalinizing) drugs. Nevertheless, both PRAL and NEAP were significantly associated 
with NAE which seems to validate NAE as marker of dietary acid load. Third, almost 
all RTR were Caucasian, which calls prudence to extrapolation of our findings to other 
ethnicities. Furthermore, although extensive data collection allowed controlling for many 
confounders residual confounding could have remained even in multivariable analysis, 
since it is hard to adjust completely for the severity of each factor. Therefore, prospective 
cohort and intervention studies in RTR are needed to confirm our results.
Previously, Ashurst et al. showed that CKD patients with persistent low serum bicarbonate 
levels had a larger annual decline in eGFR compared to patients with normal bicarbonate 
levels 22. In another study, they observed that CKD patients supplemented with sodium 
bicarbonate were less likely to develop ESRD, which is in line with findings of Phisitkul et 
al., who showed that treatment of metabolic acidosis with sodium citrate in patients with 
low GFR reduced progression of kidney disease 23, 24. Interestingly, a recently published 
study showed that reduction of dietary acid by increasing intake of fruits and vegetables 
lead to reduced kidney injury in subjects with CKD stage 2, which is in line with our 
findings in RTR 25.
Acidosis has since long been recognized as risk factor in RTR, and several potential 
causes have been suggested 26-30. Well known contributors to acidosis are reduced 
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nephron mass, resulting in decreased acid excretion, and use of pharmacological 
agents, like calcineurin inhibitors, that directly influence acid-base status but also play 
a significant role in renal acid handling. Thus far, no studies have been performed on 
the contribution of diet to acid-base status in RTR, despite the vast body of evidence 
that food intake does affect acid-base balance in both the general population and 
CKD patients 8, 10, 25. In line, we found protein intake to be directly associated with NAE 
in RTR. This finding was confirmed by significant associations between urinary urea, 
phosphorus and sulphate excretion, which all have been suggested reliable markers of 
protein intake 31, 32..
Although robust associations between NAE and acidosis in RTR were observed, no 
direct associations were found between NAE and cardiovascular risk factors, which 
is in contrast with findings of previous studies 33-36. Differences in outcomes might be 
explained by differences in study populations since previous studies were done in healthy 
subjects without use of medication. Since respectively 16% and 88% of RTR used anti-
diabetic and anti-hypertensive drugs, this might have interfered in the potentially existing 
associations between NAE and cardiovascular risk factors like insulin resistance and 
hypertension. Another explanation might be that potential adverse effects of acidosis 
on e.g. BP were not detected in this cross-sectional study because both parameters 
were measured at the same time. Unfavorable effects of acidosis on the long run might 
however become visible when prospective data were obtained.
If confirmed by prospective and intervention studies, our findings might have several 
implications for clinical practice. Since acidosis is highly prevalent among RTR, venous 
blood gas analysis should be performed occasionally since it provides important 
information on acid-base status relatively easily. If acidosis is confirmed, attention should 
be paid not only to known risk factors like graft function, but also to dietary habits. 
Either higher intake of fruits and vegetables or lower intake of (animal) protein should be 
advised. Based on our results, daily enrichment of the diet with 100 grams of vegetables 
and 100 grams of fruits, while eliminating 50 grams of meat and 20 grams of cheese, 
would decrease NAE with about 15 mEq/d. Accordingly, serum bicarbonate levels 
would increase with about 0.5 mmol/l. This increase might seem marginal, however, it 
would imply a reduction of the prevalence of acidosis of 5%, or 40 RTR of our cohort 
achieving appropriate bicarbonate levels by simple dietary modification.
Conclusion
Acidosis is highly prevalent in RTR. In addition to conventional factors contributing 
to acidosis in RTR, diet appeared to be associated with acid-base homeostasis. 
Modification of the diet, by increasing fruit and vegetable intake and decreasing intake 
of animal protein, might improve acid-base balance in RTR. 
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Abstract
Background The role of sulfur in post-transplant conditions is unclear. Sulfur may 
be protective by intermediate conversion to hydrogen sulfide (H2S) and thiosulfate 
(S2O32-; TS). However, sulfate, the end-product of sulfur-containing amino-acids (SAA), 
contributes to metabolic acid load (NAE) and may adversely influence acid-base 
homeostasis. We investigated the association of urinary sulfur metabolites with cardio-
metabolic parameters in renal transplant recipients (RTR), and analyzed their predictive 
capacity for mortality.
Methods Urinary sulfate and TS excretion was studied in 24h-urine from 707 RTR who 
were 5.4 [1.9-12.2] years after transplant surgery and 110 healthy controls. Diet was 
assessed for SAA content by food frequency questionnaires. Various cardio-metabolic 
risk factors, including hemodynamic parameters, Nt-pro-BNP, hs-CRP, HbA1c, eGFR, 
proteinuria and blood gases were measured.
Results Urinary sulfate was similar in RTR and controls while TS was higher in RTR than 
in controls. SAA intake was lower in RTR than in controls and significantly correlated 
with sulfate excretion but not with TS excretion. Sulfate was beneficially associated with 
eGFR, NAE, SBP, hs-CRP, Nt-Pro-BNP and proteinuria (all p≤0.005). TS was beneficially 
associated with eGFR, serum HCO3- and pH, hs-CRP and NT-Pro-BNP (all p≤0.001). 
During median follow-up of 27 [22-36] months, 47 RTR (7%) died. After adjustment for 
age, gender and renal function, Hazard Ratios for mortality were 0.87 (95%CI 0.82-0.92, 
p<0.001) and 0.60 (95% CI 0.41-0.59, p=0.01) for urinary sulfate and TS respectively.
Conclusion Urinary sulfate and TS excretion are beneficially associated with survival 
after renal transplantation, possibly by favorably influencing cardiovascular parameters. 
Despite a significant association of SAA with urinary sulfate and NAE, no adverse 
association was observed between sulfate and cardiovascular risk profiles and mortality. 
Intervention studies with exogenous sulfur are warranted to elucidate mechanisms 
underlying these beneficial and promising associations in RTR.
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Introduction
Renal transplantation is the preferred treatment for patients with end stage renal 
disease. However, despite improvement of quality of life and life expectancy in renal 
transplant recipients (RTR), morbidity and mortality rates remain high compared with 
the general population 1, 2. This likely has a multi-factorial origin since many risk factors, 
including cardiovascular disease, acidosis, low-grade inflammation and impaired graft 
function, are highly prevalent after transplantation 3-5. A pressing need exists to gain 
insight in mechanisms underlying post-transplant morbidity and mortality to provide 
therapeutic tools for improvement of patient and graft survival. Previously, nutritional 
factors including sodium and metabolic acid load appeared to be adversely associated 
with various cardiovascular and metabolic processes in RTR 6, 7.
In the past decades, interest in sulfur metabolism in humans has grown considerably, 
particularly with regard to the synthesis and function of hydrogen sulfide (H2S) 8-16. 
H2S is an endogenously produced gaseous compound and a signaling molecule with 
substantial biological potential, suggested to be beneficially involved in various (patho-)
physiological processes including blood pressure regulation, inflammation, angiogenesis 
and cytoprotection during hypoxia 8-16. H2S is synthesized by conversion of the amino 
acid cysteine, which is either directly ingested via food or originating from the essential 
amino acid methionine. A specific intermediate of the H2S metabolism is thiosulfate (TS, 
S2O32-), which is physiologically excreted in urine. Indeed, urinary TS has been reported 
to be linearly associated with inhaled or intravenously administered H2S, and might 
therefore, at least in part, reflect systemic H2S levels 17. Because of the protective effects 
of H2S, it can be hypothesized that increasing intake of sulfur containing amino acids 
(SAA) contributes to the synthesis of H2S and beneficially influences the cardiovascular 
profile and, consequently, patient survival. On the other hand, the major end-product 
of SAA is sulfate (SO42-) 18, 19 which is alleged adverse for its contribution to metabolic 
acid load and systemic acidosis, particularly in patients with impaired renal function 7. 
Therefore, it remains unclear what the role of the sulfur metabolism is in cardiovascular 
and metabolic health in RTR and whether sulfuric compounds should be considered 
beneficial or harmful.
We investigated the association of sulfur containing metabolites with cardiovascular and 
metabolic parameters in a large, well-defined cohort of stable RTR. Intake of protein, 
particularly SAA, and protein sources was assessed with food frequency questionnaires. 
In RTR and in healthy controls, we measured sulfate and thiosulfate and investigated the 
associations of these metabolites with cardiovascular and metabolic parameters in RTR. 
Additionally, we analyzed the association of urinary sulfate and thiosulfate excretion with 
mortality in RTR.
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Methods
Study populations
We invited all RTR (≥18 years) with a functioning graft for at least one year who visited 
our outpatient clinic between 2008 and 2010. RTR were all transplanted in the University 
Medical Center Groningen and had no history of drug or alcohol addiction. Of 817 initially 
invited RTR, 707 (87%) signed written informed consent to participate in this study. As 
a reference group, we included 110 subjects who were evaluated and approved for 
living kidney donation in our center. None had a history of kidney disease, diabetes or 
cardiovascular events. Hypertension, if present, was treated with a maximum of one 
antihypertensive drug. For analyses regarding dietary intake, we excluded patients with 
missing dietary data, resulting in 637 RTR eligible for analyses. The Institutional Review 
Board approved the study protocol (METc 2008/186), which was in adherence to the 
Declaration of Helsinki.
Assessment of dietary intake
Dietary intake was assessed with a validated semi-quantitative food frequency 
questionnaire (FFQ) that was developed at Wageningen University 20 and updated 
several times. For our study, the FFQ was slightly modified for accurate assessment 
of protein intake, including types and sources of protein. Validity of the FFQ in RTR 
was assessed as described previously 21. The FFQ inquired about intake of 177 food 
items during the last month taking seasonal variations into account. For each item, the 
frequency was recorded in times per day, week, or month. The number of servings was 
expressed in natural units (e.g. slice of bread or apple) or household measures (e.g. 
cup or spoon). The questionnaire was self-administered and filled out at home. All FFQs 
were checked for completeness by a trained researcher and inconsistent answers were 
verified with the patients. Dietary data were converted into daily nutrient intake using the 
Dutch Food Composition Table of 2006 22. 
Urine and plasma parameters
All participants were instructed to collect a 24-hour urine sample according to a strict 
protocol at the day prior to their visit to the outpatient clinic. Urine was collected under 
oil and chlorhexidin was added as antiseptic agent. Urinary sulfate was measured 
chromatographically (Metrohm, type 861, Herisau, Switzerland). Urinary thiosulfate 
was determined by a specific HPLC method as described previously 23, 24. Briefly, 25μL 
of urine was derivatized with 5 μl of 46 mM monobromobimane, 25 μl of acetonitrile, 
and 25 μl of 160 mM HEPES/16 mM EDTA pH 8 buffer (Invitrogen, Carlsbad, CA) 
for 30 minutes in the dark. Derivatization of thiol groups was stopped by 50 μl of 65 
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mM methanosulfonic acid (Fluka, Buchs, Switzerland) and proteins were removed by 
recentrifugation. Electrolytes (chloride, potassium, sodium, calcium and phosphate) 
were directly analyzed using standard laboratory procedures. Net acid excretion (NAE), 
the gold standard for assessing metabolic acid load, was calculated as titratable 
acid (TA) + ammonium (NH4+) – bicarbonate (HCO3-) 7,25. TA was measured with an 
automated titrator (Metrohm, 855 Robotic Titrosampler, Switzerland), NH4+ and HCO3- 
were measured chromatographically (Waters, Alliance HT 2795 and Metrohm, type 861, 
Herisau, Switzerland respectively). Blood was drawn in the morning after completion 
of the 24h urine collection. Venous blood gas analyses were assessed photometrically 
immediately after collection of blood samples. Plasma and urinary concentrations of 
electrolytes, phosphate, albumin and urea were measured using routine laboratory 
methods, as were serum cholesterol, HbA1c, hs-CRP and Nt-Pro-BNP-levels. Serum 
creatinine was determined using a modified version of the Jaffé method (MEGA AU 510, 
Merck Diagnostica, Germany). Renal function was assessed by estimating glomerular 
filtration rate (eGFR) applying the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation 26. Urinary albumin concentration was determined by nephelometry 
(Dade Behring Diagnostic, Marburg, Germany). Total urinary protein concentration was 
analyzed using the Biuret reaction (MEGA AU 510, Merck Diagnostica, Darmstadt, 
Germany). Proteinuria was defined as urinary protein excretion ≥0.5 g/24h.
Clinical parameters
All measurements were performed during a morning visit to the outpatient clinic after 
an 8-12h overnight fasting period. Blood pressure (mmHg) was measured according 
to a strict protocol as previously described 6. Participants were left alone in a room in 
half-sitting position while systolic blood pressure (SBP), diastolic blood pressure (DBP), 
mean arterial pressure (MAP) and heart rate were measured with a semi-automatic 
device (Dinamap® 1846, Critikon, Tampa, FL, USA). Measurements were performed 
every minute for fifteen minutes and the last three values were averaged. Information 
on participants’ health status, medical history, and medication use was obtained from 
patient records. Information on smoking behavior was obtained by using a questionnaire. 
Participants were classified as current, former or never smokers. Body weight and 
height were measured with participants wearing indoor clothing without shoes. BMI was 
calculated as weight divided by height squared (kg/m2) and Body Surface Area (BSA) 
was estimated applying the universally adopted formula of DuBois and DuBois 27.
Statistical analyses
Data-analysis was performed using SPSS 18.0 (Chicago, IL, USA). Normality was tested 
with the Kolmogorov-Smirnov test and skewed data were normalized for analyses by 
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logarithmic transformation (albuminuria, thiosulfate excretion, hs-CRP, Nt-Pro-BNP, 
protein excretion). Data are presented as mean ± standard deviation (SD), unless stated 
otherwise. Differences between RTR and healthy controls were tested with the t-test for 
independent samples, the Mann-Whitney-U-test or the chi-square test. The associations 
of (thio)sulfate-excretion with various cardiovascular factors were analyzed with linear 
regression analysis, with adjustment for age, gender and BSA (model 1) and cumulative 
additional adjustments for eGFR (model 2) and urinary sodium excretion and use of 
medication (antihypertensives, calcineurin inhibitors, proliferation inhibitors; model 3). 
To study the potential interdependence of both sulfur metabolites, we also adjusted 
for either thiosulfate or sulfate (model 4). The association of dietary intake with urinary 
sulfur metabolites was investigated with linear regression analyses adjusting for age 
and gender (model 1), BSA (model 2) and eGFR (model 3). Regression coefficients are 
given as beta or standardized beta, the latter referring to the number of SD a dependent 
variable changes, per SD increase of the independent variable (either sulfate or 
thiosulfate), allowing for comparison of the strength of the associations. In prospective 
analyses, we investigated associations of urinary sulfate and thiosulfate excretion with 
mortality in RTR. We performed crude Cox regression analyses (model 1) and analyses 
with adjustment for age, gender (model 2) and renal function (model 3). In all analyses, 
a two-sided P value less than 0.05 was considered statistically significant.
Results
The characteristics of RTR and controls are shown in table 1. For RTR, median time 
between transplantation and baseline measurements was 5.4 [1.9-12.2] years. The two 
groups were similar with respect to age, BMI and BSA. Men were overrepresented in 
the RTR-group compared to the control group. Urinary sulfate excretion did not differ 
between both groups (18.0±5.6 in controls vs 17.6±6.4 in RTR; p=0.29), but thiosulfate 
excretion was significantly higher in RTR compared to controls (7.0 [3.9-11.9] vs 2.1 
[0.29-10.1]; p<0.001). As anticipated, creatinine clearance was significantly lower in 
RTR than in healthy subjects (66±26 vs. 132±41 ml/min; p<0.001). Correspondingly, 
higher blood pressure values were observed in RTR than in controls (SBP 136±18 vs. 
125±15 mmHg, DBP 83±11 vs. 75±9 mmHg; both p<0.001), despite 89% of RTR using 
one or more antihypertensive drugs. Compared to controls, RTR had significantly higher 
serum levels of triglycerides, glycosylated hemoglobin (HbA1c), hs-CRP and Nt-pro-
BNP (all p<0.001). Serum albumin levels, serum pH and serum bicarbonate levels were 
lower and RTR were more likely to have metabolic acidosis (blood HCO3-< 24 mmol/l; 
p<0.001). Energy intake, as well as intake of total protein, plant protein, SAA and total 
fat was significantly lower in RTR than in controls. 
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Table 1 Characteristics of 110 healthy controls and 707 renal transplant recipients at the day 





(n = 707) p diff.
Urinary sulfate (mmol/24h) 18.0 ± 5.6 17.6 ± 6.4 0.29
Urinary thiosulfate (umol/24h) 2.1 [0.29-10.1] 7.0 [3.9-11.9] <0.001
Demographics
Age (years) 53± 10 53 ± 13 0.68
Male gender, n (%) 47 57 0.003
BMI (kg/m2) 26.5 ± 3.4 26.7 ± 4.8 0.73
BSA (m2) 1.97 ± 0.19 1.94 ± 0.22 0.20
Smoking behavior (current, %) 24 13 <0.001
Medication use
Anti-hypertensives, % 17 88 <0.001
Statins, % 6 53 <0.001
Hemodynamic parameters
SBP, mmHg 125 ± 15 136 ± 18 <0.001
DBP, mmHg 75 ± 9 83 ± 11 <0.001
MAP, mmHg 92 ± 10 100 ± 12 <0.001
Heart Rate, bpm 67 ± 10 69 ± 12 0.07
Renal Function parameters
Serum Creatinine, umol/L 73 [64-82] 125 [100-160] <0.001
eGFR, ml/min 93 ± 13 52 ± 20 <0.001
Proteinuria (≥ 0.5 g/d), % 0.5 24 <0.001
Albumin excretion 5.5 [3.1-8.3] 41.6 [10.6-179] <0.001
Serum parameters
Albumin, mmol/L 45.2 ± 2.5 43.0 ± 3.0 <0.001
Cholesterol, mmol/L 5.3 [4.5-5.9] 5.0 [4.3-5.8] 0.14
Triglycerides, mmol/L 1.1 [0.8-1.6] 1.7 [1.3-2.3] <0.001
HbA1c, % 5.55 ± 0.28 5.99 ± 0.83 <0.001
hsCRP,mg/L 1.2 [0.5-2.2] 1.6 [0.7-4.6] 0.001
Nt-pro-BNP, ng/L 38 [20-65] 254 [109-614] <0.001
Venous blood gas analyses
pH, kPa 7.38 ± 0.04 7.37 ± 0.04 0.02
pCO2, kPa 6.07 ± 0.79 5.85 ± 0.80 0.02
HCO3-, mmol/L 25.9 ± 1.7 24.6 ± 3.1 <0.001
Acidosis, %* 8 31 <0.001
Dietary Intake (FFQ)* 
Energy (kCal/d) 2335 ± 687 2175 ± 638 0.02
Protein, g/d 88 ± 23 82 ± 20 0.01
Animal protein, g/d 54 ± 17 52 ± 15 0.12
Plant protein, g/d 34 ± 10 30 ± 10 0.003
S-AA, g/d 2.63 ± 0.80 2.41 ± 0.68 0.01
Total Fat, g/d 96 ± 36 88 ± 34 0.05
Total Carbohydrates, g/d 263 ± 79 249 ± 78 0.08
Data are presented as mean ± SD, % or median [interquartile range]. Abbreviations: RTR: renal 
transplant recipients; BMI, body mass index; BSA, body surface area, SBP systolic blood pressure; 
DBP diastolic blood pressure; MAP, mean arterial pressure; eGFR, estimated Glomerular Filtration 
Rate; HbA1c glycosylated hemoglobine; hsCRP high-sensitive C-Reactive Protein; Nt-pro-BNP 
N-terminal pro-Brain Natriuretic Peptide; FFQ food frequency questionnaire; S-AA sulfur containing 
amino acids. * Acidosis was defined as blood HCO3
- < 24 mmol/L. P for difference was tested by 
the independent t-test, kruskal-wallis test or χ2-test. *data available in 637 of 707 RTR and in 110 
controls. 
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The regression coefficients for the associations of urinary sulfate and thiosulfate with 
cardiovascular parameters are presented in table 2a. After adjustment for potential 
confounders (model 3), urinary sulfate excretion was significantly inversely associated 
with SBP (β=-0.34; p=0.004), pulse pressure (β=-0.33; p<0.001), serum Nt-pro-BNP (β=-
0.03; p<0.001), serum hs-CRP (β=-0.04; p<0.001), serum HbA1c (β=-0.02; p=0.007) 
and proteinuria (β=-0.04; p=0.002). A direct association was observed between urinary 
sulfate excretion and eGFR (β=0.48; P<0.001). All observed associations remained 
significant after additional adjustment for urinary thiosulfate excretion. Thiosulfate 
excretion was significantly inversely associated with Nt-pro-BNP (β=-0.03; p<0.001), 
and hs-CRP (β=-0.02; p<0.001), also after adjustment for sulfate excretion (model 4). 
A direct association was observed between thiosulfate and eGFR (β=0.34; p<0.001. 
Associations of sulfate and thiosulfate with metabolic parameters are shown in table 
2b. Sulfate was positively associated with NAE (β=1.33; p<0.001), reflecting metabolic 
acid load, but no association was seen with serum HCO3- β=1.03; p=0.13) or serum 
pH (β=0.001; p=0.55). For thiosulfate, no association was observed with NAE, however 
direct associations were observed with venous HCO3- (β=0.03; p<0.001) and venous 
pH (β=0.01; p<0.001). Again, these associations remained significant after additional 
adjustment for urinary sulfate excretion. The standardized betas of the associations of 
sulfur containing metabolites with cardiovascular and metabolic parameters (model 3), 
allowing for mutual comparison of the strengths of associations, are depicted in Figure 
1a and Figure 1b respectively.
The regression coefficients for the association of dietary (protein) and urinary (thio)
sulfate excretion are shown in table 3. After adjustment for age, gender, BSA and renal 
function, significant positive associations were observed between urinary sulfate and 
intake of total protein (St. β=0.22; p<0.001), animal protein (St. β=0.23; p<0.001), 
vegetable protein (St. β=0.08; p=0.03) and intake of SAA (St. β=0.20-0.24; p<0.001). 
No such associations were observed between dietary protein and urinary thiosulfate 
excretion. 
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Figure 1a  Regression coefficients for the association of urinary sulfate and thiosulfate 
excretion with cardiovascular parameters. Associations are adjusted for age, gender, BSA, 
eGFR, time since transplantation, UNaV and drugs (antihypertensives, CNI, proliferation 
inhibitors). Regression coefficients are given as standardized betas, referring to the number 






Figure 1b  Regression coefficients for the association of urinary sulfate and thiosulfate 
excretion with metabolic parameters. Associations are adjusted for age, gender, BSA, eGFR, 
time since transplantation, UNaV and drugs (antihypertensives, CNI, proliferation inhibitors). 
Regression coefficients are given as standardized betas, referring to the number of SD the 
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Sulfate, thiosulfate and mortality
Median follow-up from baseline was 27 [22-36] months. During this prospective follow-
up, 47 (7%) RTR died. RTR who died had significantly lower urinary excretion of sulfate 
and thiosulfate than RTR who survived during follow-up (13.2±5.5 vs 17.9±6.3 mmol/24h, 
p<0.001 for sulfate and 5.4 [2.8-8.5] vs 7.2 [4.0-12.1] umol/24h, p=0.01 for thiosulfate). 
According to gender-stratified tertiles of sulfate, incidence of mortality during follow-up 
was 31 out of 203 (15%) for the lowest tertile, while this was 10 out of 226 (4%) and 6 out 
of 229 (3%) in the middle and highest tertiles respectively (log-rank test p<0.001, figure 
2a). According to increasing gender-stratified tertiles of thiosulfate, these numbers were 
21 (10%), 16 (7%) and 7 (3%) respectively (log-rank test p=0.02, figure 2b). Results 
of Cox regression analyses for mortality in RTR are shown in table 4. After adjustment 
for age, gender and renal function (model 3), sulfate and thiosulfate were significantly 
associated with mortality with hazard ratios of 0.87 [0.82-0.92], p<0.001 and 0.60 [0.41-
0.89], p=0.01 respectively. 
Figure 2  Kaplan-Meier curves for patient survival according to urinary sulfate (a) and 
thiosulfate (b) excretions.
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Table 4  Cox regression analyses for prediction of patient mortality based on urinary 
excretion of sulfate and thiosulfate 
Sulfate Thiosulfate
HR [95% CI] p HR [95% CI] p
Model 1 0.87 [0.83-0.92] <0.001 0.59 [0.42-0.85] 0.004
Model 2 0.86 [0.81-0.91] <0.001 0.55 [0.38-0.80] 0.002
Model 3 0.87 [0.82-0.92] <0.001 0.60 [0.41-0.89] 0.01
Thiosulfate was log-transformed for analyses. 
Model 1: crude model; 
Model 2 adjusted for age and gender; 
Model 3, as model 2, additionally adjusted for renal function (CKD-EPI)
Discussion
The cardinal finding of the present study is the significant association of urinary sulfur 
metabolites with a favorable cardiovascular risk profile and with improved survival in 
RTR. These associations were found despite the observed direct association of urinary 
sulfate with the allegedly adverse metabolic acid load. Also, RTR had a markedly 
elevated excretion of urinary thiosulfate, but not sulfate, compared with healthy controls. 
Our findings suggest a protective role for sulfur metabolites in cardiovascular changes 
following renal transplantation and in patient survival long-term after transplantation.
Humans depend on exogenous sources for their sulfur supplies as sulfur enters the 
body mainly as a constituent of the sulfur containing amino acids (SAA) cysteine and 
methionine. In line with previous studies, we observed a significant direct association 
between intake of SAA and urinary sulfate excretion 18, 19. SAA are eventually converted 
to sulfate and are allegedly adverse for their contribution to metabolic acid load, which 
has previously been shown to be associated with the extent of acidosis in RTR 7. In 
accordance, a significant association between intake of SAA and net acid excretion 
was found, the latter reflecting metabolic acid load 25. Nevertheless, regarding systemic 
metabolic parameters, we observed no significant association of sulfate with blood 
pH and HCO3-. The opposite held true for TS, showing significant direct associations 
with both blood pH and HCO3-, which could suggest a favorable role for TS in acid-
base homeostasis, given the large body of RTR experiencing systemic acidosis7. The 
significance and mechanism underlying this association is not yet clear and needs 
further elucidation.
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Regarding cardiovascular parameters, we observed beneficial associations of TS 
with Nt-Pro-BNP, hs-CRP and eGFR. Since TS is a central metabolite in the metabolic 
pathway of H2S, a gaseous transmitter known for its protective role in several pathological 
processes such as inflammation and hypertension, a potential explanation for our 
findings might be involvement of H2S. H2S is synthesized endogenously by the activity 
of three major enzymes, cystathionine-β-synthetase (CBS), cystathionine-γ-lyase (CSE) 
and 3-mercaptopyruvate sulfurtransferase (MPST) that all use the amino acid L-cysteine 
as their main substrate 28. CSE, the most predominant enzyme in cardiovascular tissue, 
is expressed in endothelial and smooth muscle cells. In the vasculature, H2S is known 
to function as an endothelial cell-relaxing factor. Accordingly, CSE-/- mice have a slightly 
higher blood pressure than wild-type mice 29. Endothelial derived H2S also functions as 
a promoter of angiogenesis and as an inhibitor of leukocyte adhesion, thereby reducing 
inflammation 8, 14. Recently, Tokuda et al reported that inhalation of H2S prevented 
endotoxin-induced systemic inflammation and even prolonged survival in endotoxaemic 
mice 30. H2S eventually gets degraded to TS, which is partly re-used as sulfur donor to 
form a new H2S molecule, partly converted to sulfite, the latter being oxidized to sulfate 
and physiologically excreted in the urine. A certain amount of TS however, is excreted 
directly in the urine, possibly as ‘spillover’ of H2S synthesis and might therefore at least in 
part reflect systemic levels of H2S 31. Another potential explanation for our findings might 
be that TS itself underlies the favorable associations with cardiovascular parameters in 
RTR. TS has been reported to exert protective activities in several pathophysiological 
processes such as oxidative stress 32. Also, TS has recently been shown to completely 
prevent vascular calcifications in uremic rats 33. Moreover, TS can safely be administered 
to humans and is well tolerated 23. 
Unexpectedly, similar beneficial associations were observed for sulfate, with even 
additional favorable associations with SBP, pulse pressure, HbA1c and proteinuria. This 
was in contrast with our hypothesis that urinary sulfate, reflecting intake of acidifying SAA 
and metabolic acid load, contributes to systemic acidosis and related complications like 
hypertension and insulin resistance, particularly in patients with impaired renal function7. 
An explanation might be that part of the excreted sulfate has been incorporated in the 
H2S and/or TS synthesis as well, which is in line with previous studies showing that 
systemically applied H2S is excreted as either TS or sulfate 31, 34. This could also explain 
our findings of survival benefit in RTR with either higher urinary sulfate or higher TS 
excretion.
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In our study, unlike sulfate, thiosulfate was not associated with dietary sulfur intake. 
Although the synthesis of H2S, and consequently TS, depends on the intake of SAA, 
particularly methionine, the rate-limiting step is the presence of specific enzymes such 
as CBS and CSE. The absence of any association of TS with dietary intake could be 
explained by an excess presence of SAA. We observed significantly higher urinary 
excretion of thiosulfate in RTR compared with healthy controls. This was quite surprising, 
since it might be expected that RTR, known to be at high cardiovascular risk compared 
to the general population, excrete less of an indicator of the allegedly favorable H2S 
metabolism. It seems unlikely that differences in dietary (protein) intake between both 
groups underlie the differences in urinary TS excretion, since intake was lower in RTR 
compared with controls. Possibly, the higher urinary thiosulfate excretion reflects a 
compensatory response to meet the increased demand for cardiovascular protection in 
RTR. It could also be that prednisolone treatment in RTR explains the difference, since 
it is known that glucocorticoids induce CBS activity in the liver 35.
Strengths of our study include the large sample size of this specific patient group 
consisting of well defined, stable RTR. Extensive data collection, including data from 
24h urine samples and dietary intake allowed for adjustment for many confounders. 
We acknowledge, however, that there are also limitations. The present study is an 
observational epidemiological study, which makes it difficult to conclude on causality. 
Since little is known on the role of sulfur in cardiovascular health in RTR and the sulfur 
handling in the kidney, a third factor might underlie the observed associations. For 
example, it can be hypothesized that higher urinary excretion of sulfur compounds is 
caused by decreased tubular reabsorption due to renal damage, which itself is well 
known to be associated with cardiovascular risk. However, the association between 
urinary sulfur metabolites and cardiovascular parameters remained significant 
in multivariate regression analyses, including renal function, suggesting that this 
association is independent of confounding factors. Nevertheless, residual confounding 
could have remained, since it is hard to completely adjust for the severity of each risk 
factor. Additionally, our study population consisted predominantly of Caucasian people, 
which calls prudence to extrapolation of our results to populations of other ethnicities. 
The detailed metabolic determinants influencing urinary excretions of both sulfate and 
TS are not clear thus far and require further elucidation. Additional studies could focus 
on the H2S and TS metabolism and the involved enzymes, to reveal the mechanism 
underlying the observed associations and to investigate the potentially beneficial effects 
of sulfur suppletion. 
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Conclusion
Post-transplant conditions are associated with markedly increased risk for cardiovascular 
diseases compared with healthy individuals. The observed beneficial associations of 
urinary sulfur metabolites with cardiovascular parameters and patient survival in our 
transplant cohort might point towards a protective role of components in the sulfur 
metabolism. Long-term intervention studies with exogenous sulfur, either from the diet 
or pharmacological agents such as sodium thiosulfate, are warranted to clarify the exact 
role and underlying mechanisms of the sulfur metabolism in cardiovascular health and 
survival in RTR.
Acknowledgments
The current manuscript was supported by Top Institute (TI) Food and Nutrition, which 
is a public/private partnership that generates vision on scientific breakthroughs in food 
and nutrition, resulting in the development of innovative products and technologies. 
Partners are major Dutch Food companies and research organizations. This does not 
alter the authors’ adherence to the policies of the ‘American Journal of Transplantation’ 
on sharing data and materials. We thank Beatrix Blanchard for her valuable help in 
measuring urinary thiosulfate concentrations.
94  |  Chapter 5
References
1.  Aakhus S, Dahl K, Wideroe TE: Cardiovascular morbidity and risk factors in renal transplant 
patients. Nephrol Dial Transplant 14: 648-654, 1999 
2.  Kreis HA, & Ponticelli C: Causes of late renal allograft loss: Chronic allograft dysfunction, death, 
and other factors. Transplantation 71: SS5-9, 2001 
3.  Lentine KL, Schnitzler MA, Abbott KC, Li L, Burroughs TE, Irish W, Brennan DC: De novo congestive 
heart failure after kidney transplantation: A common condition with poor prognostic implications. 
Am J Kidney Dis 46: 720-733, 2005 
4.  Yakupoglu HY, Corsenca A, Wahl P, Wuthrich RP, Ambuhl PM: Posttransplant acidosis and 
associated disorders of mineral metabolism in patients with a renal graft. Transplantation 84: 1151-
1157, 2007 
5.  Kreis HA, & Ponticelli C: Causes of late renal allograft loss: Chronic allograft dysfunction, death, 
and other factors. Transplantation 71: SS5-9, 2001 
6.  van den Berg E, Geleijnse JM, Brink EJ, van Baak MA, Homan van der Heide JJ, Gans RO, Navis 
G, Bakker SJ: Sodium intake and blood pressure in renal transplant recipients. Nephrol Dial 
Transplant 2012 
7.  van den Berg E, Engberink MF, Brink EJ, van Baak MA, Joosten MM, Gans ROB, Navis G.J., 
Bakker SJL: Dietary acid load and metabolic acidosis in renal transplant recipients. Clin.J.Am.Soc.
Nephrol. (Provisionally Accepted) 2012 
8.  Szabo C, & Papapetropoulos A: Hydrogen sulphide and angiogenesis: Mechanisms and 
applications. Br J Pharmacol 164: 853-865, 2011 
9.  Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino 
G, Wallace JL, Fiorucci S: 5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl 
ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive 
effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther 319: 447-458, 2006 
10.  Chen CQ, Xin H, Zhu YZ: Hydrogen sulfide: Third gaseous transmitter, but with great pharmacological 
potential. Acta Pharmacol Sin 28: 1709-1716, 2007 
11.  Blackstone E, Morrison M, Roth MB: H2S induces a suspended animation-like state in mice. 
Science 308: 518, 2005 
12.  Blackstone E, & Roth MB: Suspended animation-like state protects mice from lethal hypoxia. Shock 
27: 370-372, 2007 
13.  Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, Barodka VM, Gazi FK, Barrow 
RK, Wang R, Amzel LM, Berkowitz DE, Snyder SH: Hydrogen sulfide as endothelium-derived 
hyperpolarizing factor sulfhydrates potassium channels. Circ Res 109: 1259-1268, 2011 
14.  Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL: Hydrogen sulfide is an 
endogenous modulator of leukocyte-mediated inflammation. FASEB J 20: 2118-2120, 2006 
15.  Bos EM, Leuvenink HG, Snijder PM, Kloosterhuis NJ, Hillebrands JL, Leemans JC, Florquin S, van 
Goor H: Hydrogen sulfide-induced hypometabolism prevents renal ischemia/reperfusion injury. J 
Am Soc Nephrol 20: 1901-1905, 2009 
16.  Bos EM, Snijder PM, Jekel H, Weij M, Leemans JC, van Dijk MC, Hillebrands JL, Lisman T, van Goor 
H, Leuvenink HG: Beneficial effects of gaseous hydrogen sulfide in hepatic ischemia/reperfusion 
injury. Transpl Int 25: 897-908, 2012 
17.  Kangas J, & Savolainen H: Urinary thiosulphate as an indicator of exposure to hydrogen sulphide 
vapour. Clin Chim Acta 164: 7-10, 1987 
18.  Sabry ZI, Shadarevian SB, Cowan JW, Campbell JA: Relationship of dietary intake of sulphur 
amino-acids to urinary excretion of inorganic sulphate in man. Nature 206: 931-933, 1965 
19.  Wilson HE: Studies in nitrogen and sulphur metabolism. Biochem J 20: 76-83, 1926 
20.  Feunekes GI, Van Staveren WA, De Vries JH, Burema J, Hautvast JG: Relative and biomarker-
based validity of a food-frequency questionnaire estimating intake of fats and cholesterol. Am J 
Clin Nutr 58: 489-496, 1993 
Sulfur and Cardiovascular Risk  |  95
5
21.  van den Berg E, Engberink MF, Brink EJ, van Baak MA, Gans ROB, Navis G.J., Bakker SJL: Dietary 
protein, blood pressure and renal function in renal transplant recipients. Br.J.Nutr. (Provisionally 
Accepted) 2012 
22.  The Hague: Dutch food composition table (NEVO 2006) NEVO tabel 2006 (dutch nutrient databank: 
NEVO table 2006) : Voorlichtingsbureau voor de voeding. 
23.  Farese S, Stauffer E, Kalicki R, Hildebrandt T, Frey BM, Frey FJ, Uehlinger DE, Pasch A: Sodium 
thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers. Clin J Am Soc 
Nephrol 6: 1447-1455, 2011 
24.  Newton GL, Dorian R, Fahey RC: Analysis of biological thiols: Derivatization with monobromobimane 
and separation by reverse-phase high-performance liquid chromatography. Anal Biochem 114: 
383-387, 1981 
25.  Frassetto LA, Lanham-New SA, Macdonald HM, Remer T, Sebastian A, Tucker KL, Tylavsky FA: 
Standardizing terminology for estimating the diet-dependent net acid load to the metabolic system. 
J Nutr 137: 1491-1492, 2007 
26.  Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF,3rd, Feldman HI, Kusek JW, Eggers P, 
Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): 
A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009 
27.  Dubois D DE: Clinical calorimetry. A formula to estimate the approximate surface area if height and 
weight be known. Arch Int Med : 863-871, 1916 
28.  Szabo C: Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 6: 917-935, 2007 
29.  Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang S, Snyder SH, 
Wang R: H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine 
gamma-lyase. Science 322: 587-590, 2008 
30.  Tokuda K, Kida K, Marutani E, Crimi E, Bougaki M, Khatri A, Kimura H, Ichinose F: Inhaled hydrogen 
sulfide prevents endotoxin-induced systemic inflammation and improves survival by altering sulfide 
metabolism in mice. Antioxid Redox Signal 17: 11-21, 2012 
31.  Levitt MD, Furne J, Springfield J, Suarez F, DeMaster E: Detoxification of hydrogen sulfide and 
methanethiol in the cecal mucosa. J Clin Invest 104: 1107-1114, 1999 
32.  Hayden MR, & Goldsmith DJ: Sodium thiosulfate: New hope for the treatment of calciphylaxis. 
Semin Dial 23: 258-262, 2010 
33.  Pasch A, Schaffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S: Sodium thiosulfate prevents 
vascular calcifications in uremic rats. Kidney Int 74: 1444-1453, 2008 
34.  Whitfield NL, Kreimier EL, Verdial FC, Skovgaard N, Olson KR: Reappraisal of H2S/sulfide 
concentration in vertebrate blood and its potential significance in ischemic preconditioning and 
vascular signaling. Am J Physiol Regul Integr Comp Physiol 294: R1930-7, 2008 
35.  Ratnam S, Maclean KN, Jacobs RL, Brosnan ME, Kraus JP, Brosnan JT: Hormonal regulation of 
cystathionine beta-synthase expression in liver. J Biol Chem 277: 42912-42918, 2002 

6
Reduced Urinary NO2/NO3-excretion is Associated  
with an Adverse Cardiovascular Risk Profile  
in Renal Transplant Recipients
  
In preparation




Lisette E. den Boef
Reinold O.B. Gans
Stephan J.L. Bakker
Harry van Goor 
98  |  Chapter 6
Abstract
Background Cardiovascular risk is high in renal transplant recipients (RTR) and a 
leading cause for graft loss and mortality. Since endothelial dysfunction is common in 
RTR, reduced nitric oxide production might relate to an increased cardiovascular risk 
profile in RTR. Aims of this study were to investigate nitric oxide production in RTR vs 
controls, to identify determinants of nitric oxide production in RTR and the association of 
nitric oxide with cardiovascular risk factors in RTR.
Methods We included 707 outpatient RTR (age 53±13 yrs, 57% male, time since 
transplantation 5.4 [1.9-12.2] yrs) and 107 healthy controls (53+10 yrs, 47% male). 
Systemic NO production was assessed by measurement of 24h urinary excretion of its 
stable end products NO2/NO3 (NOx). Detailed data on diet (questionnaires) and drugs 
were obtained to assess exogenous NO-sources (mainly vegetables). Cardiovascular 
risk factors (blood pressure, pulse pressure, heart rate, Nt-pro-BNP, hs-CRP, HbA1c, 
renal function, albuminuria) were measured.
Results NOx was markedly lower in RTR than in controls (588 [400-812] vs. 1020 [796-
1285] nmol/24h, p<0.001), while vegetable intake was similar (92±57 vs. 93±58 g/d, 
p=0.9) albeit approximately half of the WHO-recommended intake. Gender, vegetable 
intake and renal function were independent determinants of NOx in RTR. Systolic and 
diastolic BP were 136±18 and 83±11 mmHg respectively; creatinine clearance was 66±26 
ml/min. In linear regression analyses, urinary NOx excretion was inversely associated 
with SBP (β=-0.29; p=0.005), pulse pressure (β=-0.16; p=0.02), heart rate (β=-0.19 
p=0.008), hs-CRP (β=-0.02 p=0.008), Nt-pro-BNP (β=-0.003, p<0.001) and HbA1c 
(β=-0.01 p=0.05) and positively with creatinine clearance (β=0.51, p=0.002), independent 
of age, sex, body surface area, drug use and vegetable intake. No association was 
observed with albuminuria.
Conclusion The pronounced reduction in urinary NOx excretion in RTR compared to 
controls, and its robust, independent association with an adverse cardiovascular risk 
profile points towards a role for endogenous nitric oxide in increased cardiovascular 
risk in RTR.
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Introduction
Worldwide, the prevalence of end stage renal disease (ESRD) is increasing rapidly, 
without indication of a slowing down in rate1. Kidney transplantation is the preferred 
treatment for patients with ESRD since it reduces mortality risk and improves quality of 
life for patients on dialysis2. However, even after successful transplantation, both long 
term allograft and patient survival are limited. The main reason for these poor outcomes 
is the high prevalence of post-transplant cardiovascular disease, eventually leading 
to graft loss or death3, 4. Another reason is the gradual decline in graft function due to 
chronic renal transplant dysfunction, ultimately requiring re-transplantation or return to 
dialysis5, 6.
The gaseous transmitter nitric oxide (NO) is considered a crucial signaling molecule 
involved in various physiological processes like regulation of vascular tone7, adhesion 
of inflammatory cells8, smooth muscle cell proliferation9 and platelet aggregation10. 
Endothelial NO synthase (eNOS) is the major enzyme in the vascular wall producing NO 
and inhibition of this enzyme in experimental animal studies readily results in glomerular 
and systemic hypertension11. Also, findings from experimental studies in renal tissue 
of patients following kidney transplantation suggest a role for NO in acute and chronic 
transplant rejection12, 13. In several other patho-physiological human conditions such 
as hypercholesterolemia, atherosclerosis and hypertension both impaired eNOS and 
endothelial dysfunction are observed, suggesting a causative link between those two 
factors14-16. Whether NO also plays a role in the increased cardiovascular risk and 
endothelial dysfunction long-term after renal transplantation remains to be elucidated.
Some recent studies suggest that NO can be converted from exogenous inorganic 
nitrate, mainly originating from vegetables, and that nitrate supplementation may 
have therapeutic effects in renal and cardiovascular disease17, 18. Since prior to 
renal transplantation dialysis patients receive stringent dietary guidelines to restrict 
potassium intake by reducing intake of vegetables, it can be hypothesized that potential 
NO deficiency in RTR occurs due to perseverance with these dietary guidelines after 
transplantation.
In this study, we compared urinary NOx-excretion, reflecting NO-production, between 
RTR and healthy controls. Second, we studied whether potential differences in urinary 
NOx-excretion could be explained by differences in dietary habits. Third, we investigated 
whether urinary NOx-excretion was associated with the cardiovascular risk profile in 
RTR.
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Methods
Study populations 
We invited all RTR (≥ 18 years) with a functioning graft for at least one year who visited 
our outpatient clinic between 2008 and 2010. RTR were all transplanted in our center 
and had no history of drug or alcohol addiction. Of 817 initially invited RTR, 707 (87%) 
signed written informed consent to participate in this study. As a healthy reference 
group, we included 107 subjects who were evaluated for living kidney donation in 
our center during the same period. None had a history of kidney disease, diabetes or 
cardiovascular events. Hypertension, if present, was treated with a maximum of one 
antihypertensive drug. For analyses regarding dietary intake, we excluded all patients 
with missing dietary data, resulting in 637 RTR and 95 healthy controls for the analyses. 
The Institutional Review Board approved the study protocol (METc 2008/186), which 
was in adherence to the Declaration of Helsinki.
Assessment of nitric oxide production
NO has a short biological half-life and is rapidly converted into its stable metabolites, 
nitrite (NO2) and nitrate (NO3), that both are physiologically excreted in the urine. 
Measurement of combined urinary nitrite and nitrate (NOx) excretion is widely used as 
a marker of NO production 19, 20. We colorimetrically measured urinary NOx excretion 
applying the Griess reaction after reduction of nitrate to nitrite in 24-hour urine samples. 
All participants collected urine according to the gold standard. In advance of the urine 
collection, an antiseptic agent (chlorhexidine) was added to the urine container to 
prevent bacterial growth and subsequent increased amounts of nitrite 21.
Assessment of dietary intake
Dietary intake was assessed using a validated semi quantitative food frequency 
questionnaire (FFQ) that inquired about intake of 177 food items during the last month, 
taking seasonal variations into account. For each item, the frequency was recorded 
in times per day, week, or month. The number of servings was expressed in natural 
units (e.g. slice of bread or apple) or household measures (e.g. cup or spoon). The 
questionnaire was self-administered and filled out at home. All FFQs were checked for 
completeness by a trained researcher and inconsistent answers were verified with the 
patients. Validity of the FFQ in RTR was assessed as described previously 22. Dietary 
data were converted into daily nutrient intake using the Dutch Food Composition Table 
of 2006 23.
NOx and Cardiovascular Risk  |  101
6
Outcome measures
All measurements were performed during a morning visit to the out-patient clinic after 
an 8-12h overnight fasting period. Blood pressure (mmHg) was measured according 
to a strict protocol as previously described24. Participants were left alone in a room in 
half-sitting position while systolic blood pressure (SBP), diastolic blood pressure (DBP), 
mean arterial pressure (MAP) and heart rate were measured with a semi-automatic 
device (Dinamap® 1846, Critikon, Tampa, FL, USA). Measurements were performed 
every minute for fifteen minutes and the average value of the last three measurements 
was used in the analyses. Blood was drawn in the morning after completion of the 24h 
urine collection. Plasma and urinary concentrations of electrolytes, phosphate, albumin 
and urea were measured using routine clinical laboratory methods, as were serum 
cholesterol, HbA1c, hs-CRP and Nt-Pro-BNP-levels. Serum creatinine was determined 
using a modified version of the Jaffé method (MEGA AU 510, Merck Diagnostica, 
Darmstadt, Germany). Renal function was assessed by calculating the estimated 
glomerular filtration rate (eGFR) applying the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation 25. In a subgroup consisting of 201 RTR, GFR was 
measured by constant low dose infusion of the radio-labeled tracer 125I-iothalamate, 
as described by Visser and Apperloo et al. 26, 27. Simultaneously, effective renal plasma 
flow (ERPF) was measured as the clearance of 131I-hippurate. Filtration fraction (FF) was 
calculated as GFR/ERPF x 100. 
Information on participants’ health status, medical history, and medication use was 
obtained from patient records. Information on smoking behavior was obtained by using 
a questionnaire. Participants were classified as current smokers, former smokers, or 
never smokers. Body weight and height were measured with participants wearing 
indoor clothing without shoes. Body Mass Index (BMI) was calculated as weight divided 
by height squared (kg/m2) and Body Surface Area (BSA) was estimated applying the 
universally adopted formula of DuBois and DuBois 28.
Statistical analyses
Data-analysis was performed using SPSS version 18.0 software (SPSS Inc., Chicago, 
IL, USA). Normality was tested with the Kolmogorov-Smirnov test and skewed data were 
normalized for analyses by either logarithmic transformation (urinary albumin excretion, 
hs-CRP and Nt-pro-BNP) or by extracting the square root of original values (24h urinary 
NOx-excretion). Data in text and tables are presented as mean ± standard deviation 
(SD), unless stated otherwise. Differences between RTR and healthy controls were tested 
with the t-test for independent samples, the Mann-Whitney-U-test or the chi-square test. 
To visualize potential associations of NOx-excretion with several parameters in RTR, we 
divided the study population into gender-stratified tertiles of NOx-excretion. P-trends 
102  |  Chapter 6
over tertiles of NOx-excretion were then obtained using univariate regression analyses, 
Kruskal-Wallis test or chi-square test. The associations of several cardiovascular factors 
with NOx-excretion were investigated with multivariable linear regression analysis, 
with adjustment for age (continuous) and gender (Model 1), subsequently for BSA 
(continuous; Model 2) and eGFR (continuous; Model 3). In model 4, an additional 
adjustment was made for urinary magnesium reflecting intake of vegetables. Linear 
regression coefficients are given as standardized betas (st. β), to allow for comparison 
of the regression coefficients. Within all statistical analyses, a two-sided P value less 
than 0.05 was considered statistically significant.
Results
The characteristics of RTR and healthy controls are shown in table 1. The two groups 
were similar with respect to age, BMI and BSA. Men were overrepresented in the RTR-
group compared to the healthy controls. Urinary NOx-excretion was significantly lower 
in the RTR group than in the healthy controls (median [interquartile range] 588 [400-
812] nmol/24h versus 1020 [796-1285] nmol/24h, p<0.001). As anticipated, creatinine 
clearance was significantly lower in RTR than in healthy subjects (66±26 vs. 132±41 
ml/min; p<0.0001). Accordingly, blood pressure was significantly higher in RTR than 
in controls (SBP 136±18 vs. 125±15 mmHg, p<0.001; DBP 83±11 vs. 75±9; p<0.001), 
despite 89% of RTR using one or more antihypertensive drugs. Compared to healthy 
controls, RTR had significantly higher serum levels of triglycerides, glycated hemoglobin 
(HbA1c), hs-CRP and Nt-pro-BNP (all p<0.001).
Data on dietary habits of 95 healthy controls and 637 RTR are shown in table 2. Caloric 
intake was significantly lower in RTR compared to healthy controls, which accounted for 
the other differences found in intake. Controlling for caloric intake, dietary habits were 
similar between RTR and controls, both regarding macro- and micronutrients. Vegetable 
intake did not differ between both groups (93±58 g/d vs 92±57; p=0.9)
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Table 1 Characteristics of 107 healthy controls and 707 renal transplant recipients at the day 
of their visit to the outpatient clinic.
Characteristics Healthy controls(n =107)
RTR
(n = 707) p diff
NOx excretion (nmol/24h) 1020 [796-1285] 588 [400-812] <0.001
- Nitrite (nmol/24h) 0 [0-0] 0.77 [0.0-2.8] <0.001
- Nitrate (nmol/24h) 1010 [795-1285] 565 [385-806] <0.001
Demographics
Age (years) 53± 10 53 ± 13 0.68
Male gender, n (%) 47 57 0.003
Waist Circumference, cm) 91.0 ± 10.5 98.6 ± 14.8 <0.001
BMI (kg/m2) 26.5 ± 3.4 26.7 ± 4.8 0.73
BSA (m2) 1.97 ± 0.19 1.94 ± 0.22 0.20
Current smoker, (%) 24 13 <0.001
Hemodynamic parameters
Systolic BP, mmHg 125 ± 15 136 ± 18 <0.001
Diastolic BP, mmHg 75 ± 9 83 ± 11 <0.001
MAP, mmHg 92 ± 10 100 ± 12 <0.001
Heart Rate, bpm 67 ± 10 69 ± 12 0.07
Renal Function parameters
Serum Creatinine, umol/L 73 [64-82] 125 [100-160] <0.001
Creatinine Clearance (ml/min) 132 ± 41 66 ± 26 <0.001
eGFR, ml/min 93 ± 13 52 ± 20 <0.001
Albumin excretion 5.5 [3.1-8.3] 41.6 [10.6-179] <0.001
Serum parameters
Sodium, mmol/L 142 ± 1.9 141 ± 2.8 <0.001
Potassium, mmol/L 3.84 ± 0.26 3.98 ± 0.47 0.004
Chloride, mmol/L 106 ± 2.1 105 ± 3.5 0.006
Urea, mmol/L 5.7 [4.9-6.6] 9.6 [7.2-13.4] <0.001
Albumin, mmol/L 45.2 ± 2.5 43.0 ± 3.0 <0.001
Cholesterol, mmol/L 5.3 [4.5-5.9] 5.0 [4.3-5.8] 0.14
Triglycerides, mmol/L 1.1 [0.8-1.6] 1.7 [1.3-2.3] <0.001
HbA1c, % 5.55 ± 0.28 5.99 ± 0.83 <0.001
hsCRP,mg/L 1.2 [0.5-2.2] 1.6 [0.7-4.6] <0.001
Nt-pro-BNP, ng/L 38 [20-65] 254 [109-614] <0.001
Data are presented as mean ± SD, % or median [interquartile range]. Abbreviations: NOx combined 
urinary nitrite/nitrite excretion, BSA, body surface area, BMI, body mass index; BP blood pressure; 
MAP mean arterial pressure, eGFR, estimated Glomerular Filtration Rate; HbA1c glycated 
hemoglobine; hsCRP high-sensitive C-Reactive Protein; Nt-pro-BNP N-terminal pro-Brain Natriuretic 
Peptide. P for difference was tested by the independent t-test, kruskal-wallis test or χ2-test.
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Table 2 Dietary habits of 93 healthy controls and 637 renal transplant recipients based on 
food frequency questionnaires and urinary excretion rates.
Characteristics Healthy controls(n = 93)
RTR
(n = 637) p diff
Dietary intake (nutrients)
Calories, kcal 2309 ± 743 2175 ± 637 0.02
Protein, g/d (en%) 86 ± 24 (15.3) 82 ± 20 (15.5) 0.03 (0.24)
Animal protein, g/d (en%) 54 ± 18 (9.5) 52 ± 15 (9.8) 0.17 (0.11)
Vegetable protein, g/d (en%) 33 ± 11 (5.8) 31 ± 10 (5.7) 0.01 (0.29)
Total fat, g/d (en%) 94 ± 38 (36.1) 88 ± 34 (36.2) 0.06 (0.78)
Total carbohydrates, g/d (en%) 260 ± 88 (45.3) 249 ± 78 (45.8) 0.10 (0.27)
Calcium, g/d 1.11 ± 0.45 1.05 ± 0.38 0.05
Potassium, g/d 3.66 ± 1.00 3.53 ± 0.89 0.08
Magnesium, mg/d 355 ± 101 331 ± 90 0.002
Dietary intake (food groups)
Meat, g/d 94 ± 42 95 ± 40 0.72
Milk, g/d 114 ± 110 117 ± 85 0.74
Cheese, g/d 42 ± 34 35 ± 28 0.01
Fruit, g/d 157 ± 114 152 ± 115 0.6
Vegetables, g/d 92 ± 57 93 ± 58 0.9
Potatoes, g/d 118 ± 69 130 ± 77 0.04
Bread, g/d 144 ± 69 133 ± 61 0.04
Urinary excretion, mmol/24h
Creatinine 13.8 ± 4.2 11.8 ± 5.2 <0.001
Potassium (ratio with creatinine) 89 ± 29  (6.9) 73 ± 24  (6.5) <0.001 (0.22)
Magnesium (ratio with creatinine) 5.3 ± 1.8  (0.42) 3.4 ± 1.6  (0.31) <0.001 (<0.001)
Calcium (ratio with creatinine) 5.4 ± 2.4  (0.42) 2.9 ± 2.4  (0.26) <0.001 (<0.001)
Sodium (ratio with creatinine) 212 ± 80  (16.2) 157 ± 62  (13.9) <0.001 (<0.001)
Data are presented as mean ± SD or median [interquartile range]. Abbreviations: en% energy 
percentage. P for difference was tested by the independent t-test, kruskal-wallis test or χ2-test.
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As urinary NOx-excretion in RTR was significantly higher in men than in women (605 [448-
829] nmol/24h vs 548 [350-771] nmol/24h resp.; p=0.006), characteristics are presented 
according to gender stratified tertiles of urinary NOx-excretion (table 3) with 57% of RTR 
being male in each tertile. Median NOx-excretion ranged from 326 [220-399] in the 
lowest tertile, through 588 [526-651] nmol/24h in the middle tertile to 916 [812-1072] 
nmol/24h in the highest tertile. With increasing NOx-excretion, RTR were significantly 
younger. In the lowest tertile of NOx-excretion, RTR had a significantly higher blood 
pressure despite more use of antihypertensive medication as compared to the highest 
tertile (MAP 101 mmHg vs 98 mmHg; p=0.04). Renal function, reflected by eGFR, 
increased significantly over tertiles of NOx-excretion (p<0.001) whereas albuminuria 
decreased (p=0.04). Compared with the highest tertile of urinary NOx-excretion, RTR in 
the lowest tertile had higher serum HbA1c (6.1±1.0 vs. 5.9±0.7; p=0.01), higher serum 
hs-CRP (1.8 [0.9-5.6] vs 1.3 [0.6-3.7]; p=0.05) and higher Nt-pro-BNP (440 [181-1086] 
vs 158 [69-368]; p<0.001). 
The regression coefficients for the association of urinary NOx with various cardiovascular 
risk factors are given in table 4. After adjustment for potential confounders (model 4), 
urinary NOx-excretion was inversely associated with systolic blood pressure (st. β=-
0.29; P=0.005), mean arterial pressure (st. β=-0.17; p=0.02), heart rate (st. β=-0.19; 
p=0.008), serum hs-CRP (st. β=-0.02; p=0.008), serum Nt-pro-BNP (st. β=-0.03; 
p<0.001), and HbA1c (st. β=-0.01; p=0.05). A significant positive association was found 
between NOx-excretion and estimated GFR (st. β=0.36; P=0.002). In the subgroup 
consisting of 201 RTR who underwent GFR measurement according to gold standard, 
we observed significant direct associations of urinary NOx-excretion with true GFR (st. 
β=0.24, p=0.002) and ERPF (st. β=0.28, p<0.001), independent of age, gender, BSA, 
smoking behavior, urinary sodium excretion and use of calcineurin inhibitors, diuretics 
and beta-blockers. No significant association was found between urinary NOx-excretion 
and filtration fraction.
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Table 3 Characteristics of 707 renal transplant recipients across gender stratified tertiles of 
combined urinary nitrite/nitrate excretion (nmol/24h) 







NOx excretion, nmol/24h 326 [220-399] 588 [526-651] 916 [812-1072]
Demographics
Age, y 54 ± 13 53 ± 13 52 ± 12 0.04
Waist, cm 99 ± 16 99 ± 14 98 ± 15 0.33
BMI, kg/m2 26.9 ± 5.1 26.5 ± 4.6 26.6 ± 4.7 0.52
BSA, m2 1.93 ± 0.24 1.95 ± 0.20 1.95 ± 0.22 0.36
Current smokers, % 12 12 14 0.63
Hemodynamic parameters
Systolic BP, mmHg 138 ± 18 136 ±17 134 ± 17 0.005
Diastolic BP, mmHg 83 ± 12 83 ± 10 82 ± 11 0.31
MAP, mmHg 101 ± 13 101 ±11 99 ± 12 0.05
Heart Rate, bpm 55 ± 14 54 ± 13 52 ± 12 0.16
Medication use
Hypertensives, % 94 85 86 0.006
RAS, % 54 42 48 0.17
Diuretics, % 50 40 33 <0.001
Beta-blocker 71 62 58 0.004
Antidiabetics, % 21 12 14 0.04
Statins, % 55 51 52 0.58
Proliferation inhibitor, % 80 83 86 0.14
Calcineurin inhibitor, % 70 53 50 <0.001
Renal Function parameters
Time since Rtx, y 5.0 [1.4-11.0] 5.8 [2.0-12.6] 6.0 [3.0-12.3] 0.19
Serum Creatinine, umol/L 143 [110-188] 122 [97-154] 115 [98-144] <0.001
Creatinine Clearance (ml/min) 54 ± 25 69 ± 25 75 ± 24 <0.001
eGFR, ml/min 46 ± 21 54 ±19 57 ± 18 <0.001
Albumin excretion 61 [13-223] 35 [11-178] 32 [9-138] 0.04
Serum parameters
Sodium, mmol/L 141 ± 3 141 ± 3 141 ± 3 0.61
Albumin, mmol/L 42.4 ± 3.2 42.9 ± 2.8 43.6 ± 2.8 <0.001
Cholesterol, mmol/L 5.2 [4.4-6.0] 4.9 [4.3-5.8] 5.0 [4.3-5.7] 0.10
LDL-cholesterol, mmol/L 2.9 [2.4-3.6] 2.9 [2.3-3.4] 2.8 [2.3-3.6] 0.77
Triglycerides, mmol/L 1.78 [1.31-2.58] 1.67 [1.28-2.13] 1.56 [1.15-2.19] 0.29
HbA1c, % 6.1 ± 1.0 6.0 ± 0.8 5.9 ± 0.7 0.01
hsCRP,mg/L 1.8 [0.9-5.6] 1.6 [0.6-5.2] 1.3 [0.6-3.7] 0.05
Nt-pro-BNP, ng/L 440 [181-1086] 244 [97-502] 158 [69-368] <0.001
Data are presented as mean ± SD, % or median [IQR]. Abbreviations: NOx combined urinary 
nitrate/nitrite excretion; BMI, body mass index; BSA, body surface area, BP, blood pressure; MAP 
mean arterial pressure; RAS, renin-angiotensin-system; RTx, renal transplantation; eGFR, estimated 
glomerular filtration rate; HbA1c glycated hemoglobin; hsCRP, high-sensitive CRP; Nt-pro-BNP, 
N-terminal pro-Brain Natriuretic Peptide; PTH, parathyroid hormone; * P-trend was tested by either 
entering the median values within tertiles into the model as covariate, by χ2-test or by Jonckheere-
Terpstra test.
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Tabel 4 Regression coefficients for the association of urinary NOx with several cardiovascular 
risk factors in 707 renal transplant recipients. 
Cardiovascular 
risk factor
Model 1 Model 2 Model 3 Model 4
St. β p St. β p St. β p St. β p
SBP, mmHg -0.31 0.001 -0.28 0.004 -0.27 0.007 -0.29 0.005
DBP, mmHg -0.12 0.05 -0.11 0.08 -0.11 0.09 -0.11 0.09
MAP, mmHg -0.14 0.04 -0.17 0.01 -0.16 0.02 -0.17 0.02
Heart rate, bpm -0.17 0.01 -0.21 0.003 -0.22 0.001 -0.19 0.008
hs-CRP*, mg/l -0.03 0.001 -0.02 0.002 -0.02 0.003 -0.02 0.008
Nt-pro-BNP*, ng/l -0.06 <0.001 -0.04 <0.001 -0.03 <0.001 -0.03 <0.001
HbA1c, % -0.01 0.02 -0.01 0.002 -0.01 0.01 -0.01 0.05
Albuminuria*, g/24h -0.01 0.21 0.01 0.47 0.001 0.95 -0.003 0.80
eGFR, ml/min 0.63 <0.001 # # 0.42 <0.001 0.36 0.002
GFR**, ml/min 0.31 <0.001 # # 0.23 0.002 0.24 0.002
ERPF**, ml/min 0.34 <0.001 # # 0.28 <0.001 0.28 <0.001
FF** 0.14 0.07 # # 0.06 0.41 0.07 0.39
Regression coefficients are given as standardized betas, i.e change of cardiovascular risk factor in 
SD, per SD increase of urinary NOx excretion. Abbreviations: BP, blood pressure; MAP mean arterial 
pressure; hs-CRP, high-sensitive CRP; Nt-pro-BNP, N-terminal pro-Brain Natriuretic Peptide; HbA1c 
glycated hemoglobin; eGFR, estimated glomerular filtration rate; ERPF effective renal plasma flow; 
FF filtration fraction. Model 1: adjusted for age (y), gender and BSA (m2); Model 2: additionally 
adjusted for renal function (eGFR), Model 3: additionally adjusted for smoking behavior, urinary 
sodium excretion, medication use (calcineurin inhibitor, diuretic, beta-blocker), Model 4 additionally 
adjusted for 24h urinary magnesium excretion *Log-transformed for analyses **Analyses performed 
in a subgroup of 201 RTR
Discussion
The main finding of this study is the significant association between urinary NOx-
excretion, reflecting systemic nitric oxide, and the extent of various cardiovascular risk 
factors in RTR. The associations remained significant after adjustment for age, gender, 
BSA, renal function, medication use and markers of vegetable intake. Second, we 
observed markedly lower urinary NOx-levels in RTR compared to healthy controls. Our 
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findings are consistent with our hypothesis that hampered NO is directly connected 
to endothelial dysfunction and increased cardiovascular risk long-term after renal 
transplantation.
Several mechanisms may underlie the decreased urinary NOx-excretion in RTR. These 
could either involve impaired synthesis, excessive oxidative degradation or both. NO is 
generated from L-arginine which is converted by nitric oxide synthase (NOS). In healthy 
subjects, the majority of the L-arginine in the circulation is synthesized by the kidney 
and the majority of L-arginine is eventually salvaged by reabsorption in the proximal 
tubules29, 30. Therefore, decreased NO production in RTR might have been caused 
by renal dysfunction which is in line with several studies that observed lower renal 
L-arginine release in patients with chronic kidney disease31. Previous studies suggested 
exogenous nitrate from vegetables to be a source of endogenously produced NO and 
consequently a potential target for treatment of cardiovascular disease 17, 18. However, 
the observed differences in urinary NOx excretion between RTR and healthy controls 
was not explained by differences in dietary intake of exogenous NO-sources, since 
vegetable intake was similar between both groups. Within our transplant group, 
however, we observed higher urinary NOx-excretion in RTR with higher intake of 
vegetables, suggesting that exogenous nitrate donors might contribute to enhanced 
endogenous NO production. Yet, adjustment for markers of vegetable intake did not 
alter the associations between urinary NOx and various cardiovascular parameters in 
RTR, which suggests that systemic NO has a protective potential irrespective of the 
original source of the nitrogen.
Another factor potentially contributing to the decreased NO production in RTR is an 
increase in endogenous NOS inhibitors like asymmetric dimethylarginine (ADMA), a 
competitive inhibitor of NOS which has previously been found to be elevated in ESRD 
patients as well 32, 33. Elevated plasma ADMA levels might be the consequence of a 
lack of the ADMA-degrading enzymes dimethylarginine dimethylaminohydrolase 1 and 
2 (DDAH1 and 2) which in healthy subjects are highly expressed in the kidney and 
vasculature 34, both tissues being affected in RTR. Endothelial and renal dysfunction 
in RTR might therefore lead to decreased DDAH levels, subsequent increased ADMA 
levels leading to enhanced NOS-inhibition and decreased NO production, which paves 
the way to an increased susceptibility to cardiovascular disease and progression of renal 
dysfunction, a hypothesis that is supported by several previous studies as well as by our 
findings 35. Another potential factor underlying the lower urinary NOx excretion in RTR 
compared to healthy controls might be an excessive degradation due to the continuous 
state of oxidative stress, characterized by an extensive production of oxygen radicals 
(O2-) which, together with NO, leads to formation of peroxynitrite and subsequently 
nitrotyrosin, causing injury to proteins and tissues 36, 37.  
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Since RTR are prone to cardiovascular and inflammatory events, possibly due to 
endothelial dysfunction, it could very well be a shortage of endothelial NOS (eNOS) 
playing a cardinal role in these pathofysiological processes. However, whether it is 
primarily endothelial dysfunction that subsequently leads to decreased NO production 
or vice versa, and whether NO should be considered a biomarker or a causative factor 
in the development of CVD in RTR remains to be solved. Nevertheless, a decline in 
NO production, either primary or secondary, ultimately leads to pathological vascular 
conditions due to loss of the protective potential of NO. As a consequence, inflammation, 
enhanced vascular constriction and platelet aggregation might occur, all of these 
processes in turn affecting the endothelium and its NO synthesizing potential indicating 
that a reduction in NO is at least involved in the progression of CVD in RTR. In line, 
Albrecht et al. demonstrated a combination of decreased urinary NOx excretion and loss 
of glomerular eNOS expression in biopsy specimens diagnosed as either acute rejection 
or chronic renal transplant failure 12, 13. Since endothelial NO production has important 
functions with respect to inhibition of platelet aggregation and vascular smooth muscle 
cell proliferation, the diminished activity of endothelial NO production during both acute 
rejection and chronic renal transplant failure, might underlie the high prevalence of 
inflammation, cardiovascular diseases and mortality among RTR. Our findings of highly 
significant associations of urinary NOx excretion with blood pressure, heart rate, NT-pro-
BNP, HbA1c and hs-CRP, all known to be associated with vascular conditions, make 
NO production and endothelial function attractive central pathophysiological factors in 
the treatment of post-transplant CVD and mortality. Therefore, modulation of the NO 
system by restoring eNOS expression or endothelial NO availability could receive more 
attention in the renal transplantation setting. 
We have to acknowledge that the present study has some limitations. Its cross-
sectional design makes causality hard to prove. Also, since the study population 
almost entirely consisted of Caucasian RTR, the applicability of our results to racially 
diverse RTR populations remains limited. Also, our study is a single-center study which 
might limit generalizability. On the other hand, the large size of the study population 
involved, the large diversity in times since transplantation, the use of 24 hour urine 
samples for inference of NO production and the extensive data collection, including 
dietary intake, allowing for adjustment for many potential confounders, renders our 
finding of a significant association between hampered NO production and the extent of 
cardiovascular risk in RTR reliable and robust.
Large, long-term intervention studies on influencing endothelial NO synthesis in stable 
human renal transplant recipients are lacking. New studies in RTR should focus on either 
administration of NO substrates, like L-arginine, or NO donors like nitrate. Although 
vegetable intake in RTR was similar compared with healthy controls, we can not 
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exclude a potentially beneficial long-term effect of increased vegetable intake in RTR. 
A promising new player in the field of NO donors might also be nitrite. Recently, Kelpke 
et al observed the transplanted kidney to be protected against ischemic/reperfusion 
injury after administration of sodium nitrite ultimately leading to improved post-transplant 
kidney function.
In conclusion, post-transplant conditions are associated with a markedly increased 
risk for cardiovascular events. The observed tapering of NO production following renal 
transplantation may be representative for endothelial damage and by itself play a role 
in the progression of structural or functional vascular changes. These results prompt for 
the evaluation of long-term administration of NO donors for treatment or even prevention 
of post-transplantation cardiovascular disease. 
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Abstract
Background Vitamin K is essential for activation of γ-carboxyglutamate (Gla)-proteins 
including the vascular calcification inhibitor matrix Gla-protein (MGP). Insufficient vitamin 
K intake leads to production of uncarboxylated, mostly inactive proteins and contributes 
to an increased cardiovascular risk. In kidney transplant recipients, cardiovascular risk 
is high but vitamin K intake and status have not been defined. We investigated dietary 
vitamin K intake, vascular vitamin K status and its determinants in kidney transplant 
recipients. 
Methods We estimated vitamin K intake in a cohort of kidney transplant recipients 
(n=60) with stable renal function (creatinine clearance 61 [42-77] (median [interquartile 
range]) ml/min), who were 75 [35-188] months after transplantation, using three-day food 
records and food frequency questionnaires. Vascular vitamin K status was assessed by 
measuring plasma desphospho-uncarboxylated MGP (dp-ucMGP).
Results Total vitamin K intake was below the recommended level in 50% of patients. 
Lower vitamin K intake was associated with less consumption of green vegetables 
(33 vs 40 g/d, p=0.06) and increased dp-ucMGP levels (621 vs 852 pmol/L, p<0.05). 
Accordingly, dp-ucMGP levels were elevated (>500 pmol/L) in 80% of patients. 
Multivariate regression identified creatinine clearance, coumarin use, body mass index, 
high sensitivity-CRP and sodium excretion as independent determinants of dp-ucMGP 
levels.
Conclusion In a considerable part of the kidney transplant population, vitamin K intake 
is too low for maximal carboxylation of vascular MGP. The high dp-ucMGP levels may 
result in an increased risk for arterial calcification. Whether increasing vitamin K intake 
may have health benefits for kidney transplant recipients should be addressed by future 
studies.
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Introduction
Vitamin K deficiency is increasingly recognized as a risk factor for cardiovascular 
morbidity and mortality in renal patients 1, 2. Vitamin K refers to a set of different fat-
soluble vitamins occurring as phylloquinone (vitamin K1) or a series of vitamins 
commonly termed menaquinones (vitamin K2). The main sources of vitamin K1, the 
most prominent form of vitamin K in the Western diet, are green vegetables and dairy 
products. Vitamin K2 comes from fermented food such as cheese and curd 3, 4, and is 
mainly considered to be produced by bacterial flora in the intestinal tract. Both vitamers 
serve as cofactors for modifying glutamate into gamma-carboxylated glutamate (Gla) 
residues in biological active proteins, including matrix Gla protein (MGP) 5. In addition, 
vitamin K2 is a membrane-bound electron carrier in mitochondria 6. MGP, which is 
synthesized by vascular smooth muscle cells and chondrocytes, is an important inhibitor 
of vascular calcification 7. Poor vitamin K status due to poor intake or the use of vitamin K 
antagonists results in high uncarboxylated MGP (ucMGP) levels and is associated with 
vascular calcification, both in populations with and without renal disease 7, 8. The plasma 
desphospho-ucMGP (dp-ucMGP) fraction is considered a marker for vascular vitamin 
K status 9, 10. The actual contribution of dietary vitamin K intake to the vascular vitamin K 
status is not yet known, supplementation with menaquinone-7 (one of the K2 vitamins) 
may reduce dp-ucMGP levels in hemodialysis patients 11.
It has recently been demonstrated that the majority of hemodialysis patients have vitamin 
K deficiency as reflected by high dp-ucMGP levels 1, as well as low vitamin K intake 12. 
Their low vitamin K intake may derive from the dietary regimen generally prescribed 
to hemodialysis patients, which includes restriction of sodium and potassium intake. 
Therefore dialysis patients limit their intake of mainly green vegetables and cheeses, i.e 
food products that are rich in vitamin K1 and K2, respectively. Factors other than dietary 
intake such as compromised renal function may contribute to the vitamin K status as 
well13. The vitamin K insufficiency present in the majority of hemodialysis patients may 
contribute to their strongly increased risk for arterial calcification development14-16.
Although cardiovascular morbidity and mortality after kidney transplantation are lower 
compared to any of the dialysis modalities, the risks are considerably higher than those 
in the general population 17. Whether vitamin K insufficiency is also common in kidney 
transplant recipients is unknown, but several factors associated with reduced vitamin 
K status such as impaired renal function remain present in many patients after kidney 
transplantation, and thus could affect vitamin K status. A recent study documented 
that kidney transplant recipients consume less sodium and potassium than the general 
population 18, but their dietary vitamin K intake has not been documented. 
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The objective of this study was to determine the intake of vitamin K1, vitamin K2 and 
total vitamin K and vascular vitamin K status, by measuring desphospho-ucMGP (dp-
ucMGP) levels, in kidney transplant recipients. Furthermore, we aimed to identify dietary 
factors that are associated with vitamin K status in this patient group. 
Materials and methods
Ethics statement
The study was approved by the medical ethics committee of the University of Groningen 
(METc 2008/186), and all participants provided written informed consent. All clinical 
investigations have been conducted according to the principles expressed in the 
Declaration of Helsinki.
Study population
No formal power calculation was performed for this explorative observational study. 
Kidney transplant recipients attending the outpatient clinic of the University Medical 
Center Groningen were recruited. Patients with a minimum age of 18 years and able 
to return completed food records were eligible, irrespective of gender, the underlying 
primary renal disease, the presence of cardiovascular disease, diabetes mellitus, or 
other traditional cardiovascular risk factors. Exclusion criteria were known malignancy, 
abnormal liver function tests, history of gastrointestinal disease or metabolic disease, or 
active infection. In total, 60 patients with a functioning kidney graft for at least one year 
were enrolled. 
Standard immunosuppressive therapy was as follows: from 1968 until 1989 prednisolone 
(10 mg/day) and azathioprine (100 mg/day). From January 1989 until February 1993 
ciclosporin standard formulation (Sandimmune, Novartis; 10 mg/kg; trough levels of 
175–200 mg/l in first 3 months, 150 mg/l between 3 and 12 months post-transplant 
and 100 mg/l thereafter) combined with prednisolone (starting with 20 mg/day, rapidly 
tapered to 10 mg/day). From March 1993 until May 1996 ciclosporin microemulsion 
(Neoral, Novartis Pharma b.v., Arnhem, The Netherlands; 10 mg/kg; trough levels idem) 
and prednisolone. From May 1996 to date mycophenolate mofetil (MMF) (Cellcept, 
Roche b.v., Woerden, The Netherlands; 2 g/day) was added. Current medication was 
extracted from the medical records.
Vitamin K intake
Dietary intake was assessed using a dietary diary that was kept during three consecutive 
days in advance of the patients’ visit to the outpatient clinic. All patients adhered to 
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their normal dietary habits. A trained researcher checked whether diaries were filled 
out properly, and if necessary additional information was obtained about unusual or 
missing reports. Intake was recorded in household measurements and standard portion 
sizes. For calculations of the intakes of total energy and nutrients, we used the Food 
Calculation System (BAS nutrition software 2004, Arnhem, The Netherlands) in which 
Dutch food composition database NEVO 2006 was included19. Concentrations of vitamin 
K1 and K2 (MK-4 through MK-10) of 260 foods have been added to the NEVO (2006) 
food database, as described previously15. Dietary intake of total vitamin K, vitamin K1 
and vitamin K2 from three consecutive days were averaged and used for analysis. 
The U.S. Dietary Reference Intake for an adequate intake of vitamin K for adult men is 
120 micrograms/day and for adult women 90 micrograms/day20.
Habitual dietary intake
Additional information on dietary intake was obtained using a semi quantitative food 
frequency questionnaire (FFQ) that inquired about intake of 177 food items. For each 
item, the frequency was recorded in times per day, week, or month. The number of 
servings per frequency was expressed in natural units or household measures. The 
questionnaire was self-administered and filled out at home. Before participation in this 
study, all patients were carefully instructed by a trained researcher on how to complete 
the three day dietary diaries. In addition, similar written instructions were provided at 
the first page of the diary. The FFQs were checked for completeness and inconsistent 
answers were verified with the patients. Additionally, all participants were instructed to 
collect a 24 hour urine sample according to a strict protocol. In addition, excretion of 
several urinary components was measured to infer dietary intake of additional dietary 
nutrients like sodium and potassium.
Vitamin K status
Blood was drawn after an 8-12h overnight fasting period in the morning after completion 
of the dietary diary. Vitamin K status was assessed by measuring dp-ucMGP. Before 
serum preparation, blood was kept for 20 min at room temperature. Plasma and serum 
were prepared by standard centrifugation and stored at -80 °C until testing. 
Circulating dp-ucMGP levels were determined in citrated plasma using a dual-antibody 
ELISA (VitaK BV Maastricht The Netherlands). In this assay, the capture antibody is 
directed against the non-phosphorylated MGP sequence 3-15 and the detection 
antibody against the ucMGP sequence 35-49 or the carboxylated MGP sequence 35-
54, respectively, as described previously 2, 13. Vitamin K insufficiency was defined as 
dp-ucMGP levels of > 500 pmol/L 13.
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Additional parameters
Renal function was assessed by calculating 24h urinary creatinine clearance (ml/
min). Serum creatinine levels were determined using a modified version of the Jaffé 
method (MEGA AU 510, Merck Diagnostica, Darmstadt, Germany). Plasma and urinary 
concentrations of electrolytes and urea were measured using routine clinical laboratory 
methods, as were serum cholesterol, N-terminal-pro-brain natriuretic peptide (NT pro-
BNP), high sensitivity CRP. Information on patients’ health status, medical history and 
medication use was obtained from patient records. Questionnaires were used to obtain 
information on smoking behavior. Participants were classified as current smokers, former 
smokers, or never smokers. Body weight and height were measured while participants 
wore indoor clothing without shoes. Body Mass Index (BMI) was calculated as weight 
divided by height squared (kg/m2). 
Statistical analysis
Anthropometric, clinical and laboratory parameters were compared between subjects 
with normal versus poor vitamin K intake using the Mann-Whitney non-parametric test 
or chi square test where appropriate. Similar analyses were performed to compare the 
characteristics of patients with normal versus elevated plasma dp-ucMGP levels.
Subsequently, linear regression analysis was performed to identify independent 
determinants of plasma dp-ucMGP levels, according to a gradual modeling approach. 
We started with a model containing age, gender, and renal function. Subsequently, 
parameters that significantly differed between subjects with normal versus poor vitamin 
K status were subsequently put into the regression model. If significant, the parameter 
remained in the model; if not significant, the parameter was removed from the model. 
This strategy was chosen to avoid a too large number of degrees of freedom when all 
possible covariates were put into the model at once. Non-normally distributed variables 
were transformed to the natural log before entering into the regression model. 
Data are presented as mean±standard deviation or median (interquartile range), 
depending on their distribution (normal or non-normal, respectively), or percentages. 
A two-sided p-value <0.05 was considered statistically significant Statistical analyses 
were performed using SPSS 15.0 for Windows (SPSS Corp. Chicago, IL).
Results
The study population consisted of 30 male and 30 female kidney transplant recipients, 
who were at median 75 [interquartile range 35-188] months after kidney transplantation. 
Creatinine clearance was 61 ml/min [42-77 ml/min]. A detailed overview of baseline 
parameters is presented in Table 1.
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As shown in Table 1, total vitamin K intake was below the recommended level in 50% 
of all subjects, both in men and women. Lower vitamin K intake was associated with 
increased dp-ucMGP levels reflecting vascular vitamin K insufficiency. Patients with a 
low total vitamin K intake were more likely to have been on dialysis prior to transplantation 
and had a trend towards longer dialysis vintage (p=0.05). Their diet contained more 
sodium, as reflected by an increased 24h-urinary sodium excretion (p=0.001), and less 
dietary fiber (p=0.02), with similar caloric intake between both groups. Dietary protein 
intake was positively associated with 24h-urinary urea excretion (r=0.566, p<0.001), 
and dietary potassium intake was positively associated with 24h-potassium excretion 
(r=0.468, p<0.001), suggesting that dietary diary information was representative of the 
actual intake as reflected by the 24h-urinary excretion. Analysis of the intake of specific 
dietary products (Table 2) from food frequency questionnaires revealed that patients 
with poor vitamin K intake tended to eat less green vegetables (p=0.056), the most 
prominent dietary source of vitamin K1, as compared to subjects with normal vitamin K 
intake. Conversely, patients with poor vitamin K intake tended to use more milk (p=0.06). 
A more detailed overview of dietary intake for both groups is provided in Supplementary 
Table S1. 
Eighty percent of kidney transplant recipients had elevated dp-ucMGP levels, both 
in males (24/30) and in females (24/30). Vitamin K status was lower in patients on 
calcineurin inhibitors than in patients not using these drugs (dp-ucMGP levels 855 
[590-1350] vs 616 [472-888] pmol/L, p=0.006). On the contrary, dp-ucMGP levels 
were lower in subjects on azathioprine or cellcept (721 [504-917] vs 1073 [870-1733] 
pmol/L, p=0.008) compared with patients not on these drugs. Separate analyses for 
both drugs revealed that patients on mycophenolate mofetil had lower dp-ucMGP levels 
as compared to those not on mycophenolate mofetil (591 [479-897] vs 917 [741-1412] 
pmol/L, p=0.002), but the use of azathioprine did not influence dp-ucMGP levels (882 
[703-1088] vs 726 [491-1091] pmol/L, p=0.14). In patients using vitamin K antagonists 
(n=6), dp-ucMGP levels were higher than in patients not on vitamin K antagonists 
(n=54) with 725 pmol/L (516-923) vs 2079 pmol/L (1.658-2.272), p<0.001). Patients with 
elevated dp-ucMGP levels were more likely to have been on dialysis (96% vs 75%, 
p=0.02) and tended to have had longer dialysis vintage (41 (17-61) vs 18 (1-30) months, 
p=0.05) compared to patients with normal dp-ucMGP levels. Furthermore, patients with 
increased dp-ucMGP also had lower creatinine clearance (60 (45-75) vs 78 (52-83) 
ml/min, p=0.04), higher levels of albuminuria (119 (62-304) vs 51 (30-75), p=0.003, 
and tended to have higher NTproBNP levels (262 (118-825) vs 147 (70-355), p=0.054) 
compared to patients with normal dp-ucMGP. All other variables (listed in Table 1) were 
not significantly different between vitamin K sufficient and insufficient patients.
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Table 1  Patient characteristics according to total vitamin K intake. 





Gender (male), n (%) 30 (50%) 15 (50%) 15 (50%) 0.99
Age, years 55±10 55±11 56±10 0.84
BMI, kg/m2 26.2±4.6 23.8± 3.8 26.2± 4.4 0.03
SBP, mmHg 135±17 136±16 133±17 0.45
Current or previous smoking 31 (52%) 20 (67%) 11 (37%) 0.02
Presumed cause of ESRD, n (%) 
Glomerulonephritis/vasculitis 10 (17%) 5 (17%) 5 (17%) 0.99
Membranous glomerulopathy/ FSGS 1 (2%) 1 (3%) 0 (0%) 0.33
Vascular disease/ hypertension 5 (8%) 4 (13%) 1 (3%) 0.17
IgA nephropathy                                                                          5 (8%) 0 (0%) 5 (17%) 0.02
ADPKD and MCKD                            17 (28%) 9 (30%) 8 (27%) 0.78
Diabetic nephropathy       1 (2%) 1 (3%) 0 (0%) 0.33
Urological origin    7 (12%) 1 (3%) 6 (20%) 0.05
Other/unknown                                                                              14 (23%) 9 (30%) 5 (17%) 0.23
Transplant characteristics 
Time since transplantation, months 75 (35-188) 65 (34-179) 93 (33-199) 0.44
Type of last transplant
Living donor      16 (26.7%) 10 (33%) 6 (20%) 0.25
Cadaveric donor 44 (73.3%) 20 (67%) 24 (80%) 0.25
Transplants received 
Kidney only 57 (95%) 28 (93%) 29 (97%) 0.57
Simultaneous liver-kidney 2 (3.3%) 1 (3%) 1 (3%) 0.98
Simultaneous pancreas-kidney 1 (1.7%) 1 (3%) 0 (0%) 0.33
Dialyis prior to transplantation 55 (92%) 25 (83%) 30 (100%) 0.02
Dialysis vintage, months           31 (17-59) 28 (5-49) 45 (23-67) 0.05
Diabetes 8 (13%) 4 (13%) 4 (13%) 0.97
Hypertension 56 (93%) 30 (100%) 26 (87%) 0.04
Hypercholesterolemia       43 (72%) 20 (67%) 34 (77%) 0.40
Previous CVD 9 (15%) 5 (17%) 4 (13%) 0.73
Current medication use                                              
Immunosuppressive drugs 
Prednisolon 59 (98%) 30 (100%) 29 (97%) 0.33
Calcineurin inhibitor 34 (57%) 14 (47%) 20 (67%) 0.12
Ciclosporin 26 (76%) 10 (71%) 16 (80%) 0.12
Tacrolimus 8 (24%) 4 (29%) 4 (20%) 0.99
Mycophenolate mofetil 39 (65%) 21 (70%) 18 (60%) 0.43
Azathioprine         12 (20%) 7 (23%) 5 (17%) 0.53
mTOR inhibitor  2 (3%) 2 (7%) 0 (0%) 0.16
Statins  36 (60%) 17 (57%) 19 (63%) 0.61
Diuretics 16 (27%) 6 (20%) 10 (33%) 0.25
β-Blockers 40 (67%) 20 (67%) 20 (67%) 0.99
RAS-inhibitors 28 (47%) 11 (37%) 16 (53%) 0.20
Calcium channel blockers 12 (20%) 6 (20%) 6 (20%) 0.99
Coumarin 6 (10%) 1 (3%) 5 (17%) 0.09
Aspirin                        15 (25%) 9 (30%) 6 (20%) 0.38
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Serum hsCRP, mg/dL 0.11 (0.04-0.28) 0.11 (0.04-0.15) 0.15 (0.05-0.49) 0.16
Serum creatinine, mg/dL 1.5 (1.2-1.8) 1.4 (1.3-1.8) 1.5 (1.2-1.9) 0.91
Serum uric acid, mg/dL 7.2 (5.8-8.4) 6.7 (5.7-8.0) 7.5 (6.1-8.6) 0.20
Serum total cholesterol, mg/dL 189 (170-228) 189 (174-224) 197 (162-232) 0.95
Serum NT pro-BNP, pg/mL 245 (113-719) 151 (106-476) 281 (130-863) 0.27
dp-ucMGP, pmol/L 753 (543-1091) 621 (481-927) 852 (620-1350) 0.04
Urinary sodium, mmol/24h 144±60 115± 41 153±52 0.001
Urinary urea nitrogen, mg/24h 11 (9-12) 11 (9-13) 11 (9-12) 0.66
Urinary potassium, mmol/24h 72±23 75± 22 71±21 0.13
Urinary albumin, mg/24h 94 (48-247) 63 (36-246) 120 (73-248) 0.11
Creatinine clearance, mL/min 64±26 59±19 63± 24 0.69
Dietary Intake (Recomm. Intake34)
Vitamin K1, µg/day 73 (36-153) 150 (110-270) 36 (23-60) <0.001
Vitamin K2, µg/day 14 (5.3-25.3) 14 (4.7-29) 14 (5.8-23) 0.62
Total vitamin K, µg/day (M:120, F:90) 90 (53-175) 171 (138-283) 54 (45-77) <0.001
Total kCal/day (M:2300, F:1800) 2204±533 2222±538 2211±477 0.80
Total protein, g/day (10-35%a) 78.2 (67.8-86.1) 85±21 81±14 0.29
Vegetable protein 28.7 (24.8-36.8) 33±8 31±8 0.14
Animal protein 47.9 (40.5-54.0) 52±18 50±11 0.53
Carbohydrates, g/day (45-65%a) 183.9 (2.4-259.8) 269±83 259±59 0.19
Total fat, g/day (20-35%a) 73.0 (58.0-91.8) 85±25 88±26 0.71
Saturated fatty acids 27.0 (20.7-33.1) 30±11 31±9 0.46
Mono-unsaturated fatty acids 22.1 (18.2-29.4) 29±9 29±9 0.92
Poly-unsaturated fatty acids 14.2 (11.7-19.4) 19±6 20±8 0.83
Dietary fiber, g/day (M: 28, F: 22) 19.9 (0.04-26.6) 22.3 (0.4-29.2) 12.8 (0.02-21.9) 0.02
Potassium, mg/day (4700) 2986 (131-3881) 3811±745 3480±620 0.11
Alcohol, g/day (M<20, F<10) 10.8 (0-207.2) 3.2 (0-181.9) 21.7 (0.1-249.5) 0.05
Normal intake was defined as >120 µg/day (males; M) or >90 µg/day (females, F)20. P value for 
comparison of subjects with normal vs poor vitamin K intake was obtained with the Mann Whitney U 
test. Nutritional goals apply to ages 51 years and older. a Percentage of total energy intake
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; ADPKD, autosomal dominant 
polycystic kidney disease; MCKD, medullary cystic kidney disease; CVD, cardiovascular disease; 
mTOR, mammalian target of rapamycin; hsCRP, high-sensitivity C-reactive protein; NT-proBNP, N 
terminal-pro brain natriuretic peptide; MGP, matrix gla protein.
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Table 2 Habitual dietary intake per vitamin K-containing food component assessed by food 
frequency questionnaires 





Green Vegetables, g/d 39.8 [31.2-55.8] 32.6 [21.3-46.8] 0.06
Broccoli, cauliflower, g/d 14.9 [12.0-20.9] 11.6 [8.3-17.5] 0.05
Lettuce, spinach, endive, g/d 24.4 [16.4-36.8] 19.4 [6.9-30.5] 0.08
Cheese, g/d 27.4 [20.8-44.7] 27.2 [20.0-39.8] 0.47
Butter, g/d 34.6 [18.0-52.6] 25.6 [18.0-47.6] 0.47
Oil, g/d 0.62 [0.0-4.8] 0 [0.0-1.9] 0.19
Meat, g/d 32 [14.3-34.4] 26.9 [19-39] 0.42
Milk, g/d 146 [52-300] 259 [159-313] 0.06
Normal intake was defined as >120 µg/day (males; M) or >90 µg/day (females, F)20 Data are 
expressed as median [interquartile range]
Upon multivariate analysis creatinine clearance, coumarin use, body mass index, 
24h-urinary sodium excretion (borderline) and high sensitivity CRP (borderline) were 
independent determinants of the vascular vitamin K status (Table 3). NT-proBNP levels 
and the type of immunosuppressive therapy were not significant determinants of vitamin 
K status in the multivariate model; their significance was lost when creatinine clearance 
was present in the model.
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Table 3 Determinants of vascular vitamin K status (plasma dp-ucMGP)
Model St. β p
Model 1: Age, gender, creatinine clearance
Age 0.17 0.21
Gender -0.17 0.22
Creatinine clearance -0.43 0.001
Model 2: Model 1 + coumarin use
Creatinine clearance -0.32 0.002
Coumarin use (0=no, 1=yes) 0.52 <0.001
Model 3: Model 2 + albuminuria
Creatinine clearance -0.37 0.01
Coumarin use (0=no, 1=yes) 0.36 0.02
Albuminuria 0.04 0.79
Model 4: Model 3 + pre-transplant dialysis
Creatinine clearance -0.33 0.002
Coumarin use (0=no, 1=yes) 0.50 <0.001
Pre-transplant dialysis 0.18 0.07
Model 5: Model 4 + high sensitivity CRP
Creatinine clearance -0.37 0.001
Coumarin use (0=no, 1=yes) 0.32 0.009
Pre-transplant dialysis (0=no, 1=yes) 0.18 0.09
High sensitivity CRP 0.27 0.03
Model 6: Model 5 + BMI
Creatinine clearance -0.45 <0.001
Coumarin use (0=no, 1=yes) 0.36 0.001
Pre-transplant dialysis (0=no, 1=yes) 0.16 0.09
High sensitivity CRP 0.19 0.08
Body mass index 0.37 0.001
Model 7: Model 6 + 24h-urinary sodium excretion
Creatinine clearance -0.51 <0.001
Coumarin use (0=no, 1=yes) 0.31 0.005
Pre-transplant dialysis (0=no, 1=yes) 0.09 0.36
High sensitivity CRP 0.18 0.09
Body mass index 0.35 0.001
24h-urinary sodium excretion 0.22 0.05
Determinants of dp-ucMGP levels, reflecting vascular vitamin K status, analyzed by stepwise 
multivariate linear regression analysis. Abbreviations: dp-ucMGP, desphospho-uncarboxylated 
matrix gla protein; CRP, C-reactive protein; Non-parametric variables (creatinine clearance, 
albuminuria, high sensitivity CRP) were Ln-transformed before entering into the model.
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Discussion
The current study shows for the first time that both insufficient vitamin K intake and 
vascular vitamin K insufficiency (deduced from circulating dp-ucMGP levels) are very 
common in a population of stable kidney transplant recipients. Vitamin K deficiency in 
kidney transplant recipients has been reported previously by means of a coagulopathy 
responsive to vitamin K treatment in case series 21. Mazzaferro et al recently argued 
that total MGP levels in kidney transplant recipients were close to normal 22; however 
their study did not differentiate between carboxylated and uncarboxylated MGP which 
is important given the role for vitamin K in MGP carboxylation. When dp-ucMGP, an 
appropriate marker of vascular vitamin K status 2-4, was taken into account specifically 
in our study, we found clear indications of vascular vitamin K insufficiency in the majority 
of kidney transplant recipients. 
Dietary recommendations for an adequate intake of vitamin K are based on the hepatic 
vitamin K1 requirement to for coagulation factor synthesis 20. It does not account for 
vitamin K2 requirement to inhibit vascular calcification. The actual necessary amount of 
vitamin K intake based on the role of extra-hepatic vitamin K-dependent proteins is still 
unknown but studies suggest that dietary recommendations for vitamin K are too low to 
ensure full carboxylation of MGP 8. Indeed, in our study even the subjects with adequate 
vitamin K intake according to U.S. guidelines 20 still had median dp-ucMGP levels above 
the recommended level of 500 pmol/L, suggesting vascular vitamin K insufficiency. This 
suggests that either kidney transplant recipients should be recommended to increase 
their dietary vitamin K intake beyond amounts recommended to the general population, 
or these patients should be supplemented with extra vitamin K.
Whether for vascular vitamin K status the intake of vitamin K2 is superior to vitamin K1 is 
uncertain, but the intake of vitamin K2 appears to be more important than vitamin K1 to 
prevent coronary heart disease 14. Furthermore, in a recent pilot study in hemodialysis 
patients, a reduction of dp-ucMGP was dose-dependently achieved by treatment 
with vitamin K2 11. This can be mechanistically explained by the fact that the main 
transporters of vitamin K1 are triglyceride-rich lipoproteins that are retained by the liver 
and serve as a cofactor for proteins involved in coagulation. The vitamin accumulation 
and use in extrahepatic tissues such as the vascular wall, is low. Vitamin K2 on the other 
hand is transported not only by triglyceride-rich lipoproteins, but also by low density 
lipoproteins, the main carrier system to extrahepatic tissues 23. In our study, subjects with 
poor vitamin K intake had increased dp-ucMGP levels (lower vascular vitamin K status) 
compared to those with normal vitamin K intake. On the other hand, dietary vitamin K 
intake (neither vitamin K1 nor K2 or total vitamin K) was not an independent determinant 
of dp-ucMGP levels upon multivariate analysis. This suggests that either other factors 
Vitamin K status after Renal Transplantation  |  125
7
such as renal function, together with coumarin use as an iatrogenic factor, are more 
important determinants of vascular vitamin K status in this population. Dietary intake of 
vitamin K2 intake may also be an inappropriate reflection of the actual amount of vitamin 
K2 generated by intestinal micro-organisms. The composition of the intestinal flora, and 
importantly the presence of Bacteroides species, the main producers of vitamin K2 24, is 
influenced by dietary factors including fibers 25. The subjects with poor vitamin K intake 
in our population ate significantly less fiber than those with normal vitamin K intake; this 
may have affected intestinal vitamin K2 production. 
The observation that vascular vitamin K insufficiency was more common than may 
be expected by vitamin K intake alone could be explained for a considerable part by 
the contribution of renal function impairment. Our data confirm the previously known 
relationship between renal function22, 26 and dp-ucMGP levels and the influence of vitamin 
K antagonists11. Whether, as in hemodialysis patients11, vitamin K2 supplementation 
may also reduce dp-ucMGP levels in kidney transplant recipients, especially those with 
compromised renal function, remains to be addressed in prospective trials. Our finding 
that vascular vitamin K status was associated with body mass index in multivariate 
analysis is in line with previous studies linking vitamin K status with parameters of glucose 
metabolism and atherosclerosis 27. The borderline significant association between dp-
ucMGP levels and 24h-urine sodium excretion suggests that high dietary sodium intake 
may negative affect vitamin K metabolism. Although vitamin K deficiency 1, 2 and high 
sodium intake 28 have both been associated with adverse cardiovascular outcomes, 
their possible interactions have not been addressed.
We found a trend towards an inverse relationship between vitamin K status and low-
grade inflammation. Cell culture studies have shown anti-inflammatory effects of vitamin 
K in lipopolysaccharide-treated fibroblasts through inhibition of interleukin-6 29. In 
animals, a vitamin K-deficient diet enhanced the expression of inflammatory genes, 
which was reversed by vitamin K1-supplemented diets; furthermore the supplemented 
diet suppressed the inflammatory response induced by lipopolysaccharide 30. Recently, 
both plasma vitamin K status and intake were inversely related to inflammatory markers 
in a human general population cohort 31.
The reduced vascular vitamin K status in patients on calcineurin inhibitors is in line 
with the increased risk of cardiovascular complications in patients on these drugs, 
particularly ciclosporin 32. On the other hand, in our multivariate analysis of determinants 
of vitamin K status, none of the immunosuppressive drugs remained in the model after co-
adjustment for creatinine clearance, suggesting that the differences in vitamin K status 
can be explained by differences in creatinine clearance. A recent report suggested 
that MGP levels were higher in patients on mTOR inhibitors 33; unfortunately our cohort 
contained only two patients using this class of drugs.
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Our study has the limitation of being a relatively small single center study in Caucasian 
patients only, so the generalizability of our findings will require support by studies 
in other populations. The limited sample size may have influenced the results of 
multivariate regression analysis, e.g. regarding the role of immunosuppressive regimens 
as determinants of vitamin K status. Furthermore, although dp-ucMGP levels have been 
associated with cardiovascular morbidity and mortality in the chronic kidney disease 
population 1, 2, these associations have not yet been established for the kidney transplant 
population.
In conclusion, we found that elevated dp-ucMGP levels, reflecting vascular vitamin K 
insufficiency, is common in kidney transplant recipients. Poor vitamin K intake is common 
in renal transplant recipients, and our data suggest that other factors including renal 
function may contribute to poor vascular vitamin K status as well. Correction of vitamin 
K status might be clinically relevant, given the known associations of vascular vitamin 
K deficiency with cardiovascular outcomes. Whether this can be achieved by relatively 
simple dietary measures in kidney transplant recipients should be addressed in future 
prospective studies.  
Acknowledgements
We thank Twan Storteboom and Bettine Haandrikman for their technical assistance.
Vitamin K status after Renal Transplantation  |  127
7
References
1.  Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, 
Djuric Z, Damjanovic T, Ketteler M, Vermeer C, Dimkovic N, Floege J, Schurgers LJ: Circulating 
nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 
22: 387-395, 2011 
2.  Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun 
G, Massy ZA: The circulating inactive form of matrix gla protein is a surrogate marker for vascular 
calcification in chronic kidney disease: A preliminary report. Clin J Am Soc Nephrol 5: 568-575, 
2010 
3.  Shearer MJ, Bach A, Kohlmeier M: Chemistry, nutritional sources, tissue distribution and metabolism 
of vitamin K with special reference to bone health. J Nutr 126: 1181S-6S, 1996 
4.  Schurgers LJ, & Vermeer C: Determination of phylloquinone and menaquinones in food. effect of 
food matrix on circulating vitamin K concentrations. Haemostasis 30: 298-307, 2000 
5.  Price PA, & Williamson MK: Primary structure of bovine matrix gla protein, a new vitamin 
K-dependent bone protein. J Biol Chem 260: 14971-14975, 1985 
6.  Vos M, Esposito G, Edirisinghe JN, Vilain S, Haddad DM, Slabbaert JR, Van Meensel S, Schaap 
O, De Strooper B, Meganathan R, Morais VA, Verstreken P: Vitamin K2 is a mitochondrial electron 
carrier that rescues pink1 deficiency. Science 336: 1306-1310, 2012 
7.  Murshed M, Schinke T, McKee MD, Karsenty G: Extracellular matrix mineralization is regulated 
locally; different roles of two gla-containing proteins. J Cell Biol 165: 625-630, 2004 
8.  Schurgers LJ, Teunissen KJ, Knapen MH, Kwaijtaal M, van Diest R, Appels A, Reutelingsperger 
CP, Cleutjens JP, Vermeer C: Novel conformation-specific antibodies against matrix gamma-
carboxyglutamic acid (gla) protein: Undercarboxylated matrix gla protein as marker for vascular 
calcification. Arterioscler Thromb Vasc Biol 25: 1629-1633, 2005 
9.  Rennenberg RJ, de Leeuw PW, Kessels AG, Schurgers LJ, Vermeer C, van Engelshoven JM, 
Kemerink GJ, Kroon AA: Calcium scores and matrix gla protein levels: Association with vitamin K 
status. Eur J Clin Invest 40: 344-349, 2010 
10.  Shea MK, O’Donnell CJ, Vermeer C, Magdeleyns EJ, Crosier MD, Gundberg CM, Ordovas JM, 
Kritchevsky SB, Booth SL: Circulating uncarboxylated matrix gla protein is associated with vitamin 
K nutritional status, but not coronary artery calcium, in older adults. J Nutr 141: 1529-1534, 2011 
11.  Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann 
S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ: Effect of vitamin K2 
supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. 
Am J Kidney Dis 59: 186-195, 2012 
12.  Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns 
EJ, Herfs M, Vermeer C, Laverman GD: Vitamin K intake and status are low in hemodialysis patients. 
Kidney Int 82: 605-610, 2012 
13.  Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewe RB, 
Brandenburg VM, Bekers O, Vermeer C: Characterisation and potential diagnostic value of 
circulating matrix gla protein (MGP) species. Thromb Haemost 104: 811-822, 2010 
14.  Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, 
Witteman JC: Dietary intake of menaquinone is associated with a reduced risk of coronary heart 
disease: The rotterdam study. J Nutr 134: 3100-3105, 2004 
15.  Beulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, Witteman JC, Grobbee 
DE, van der Schouw YT: High dietary menaquinone intake is associated with reduced coronary 
calcification. Atherosclerosis 203: 489-493, 2009 
16.  Weijs B, Blaauw Y, Rennenberg RJ, Schurgers LJ, Timmermans CC, Pison L, Nieuwlaat R, Hofstra 
L, Kroon AA, Wildberger J, Crijns HJ: Patients using vitamin K antagonists show increased levels of 
coronary calcification: An observational study in low-risk atrial fibrillation patients. Eur Heart J 32: 
2555-2562, 2011 
17.  Oterdoom LH, de Vries AP, van Ree RM, Gansevoort RT, van Son WJ, van der Heide JJ, Navis G, 
de Jong PE, Gans RO, Bakker SJ: N-terminal pro-B-type natriuretic peptide and mortality in renal 
transplant recipients versus the general population. Transplantation 87: 1562-1570, 2009 
128  |  Chapter 7
18.  van den Berg E, Geleijnse JM, Brink EJ, van Baak MA, Homan van der Heide JJ, Gans RO, Navis 
G, Bakker SJ: Sodium intake and blood pressure in renal transplant recipients. Nephrol Dial 
Transplant 27: 3352-3359, 2012 
19.  The Hague: Dutch food composition table (NEVO 2006) NEVO tabel 2006 (dutch nutrient databank: 
NEVO table 2006): Voorlichtingsbureau voor de voeding. 
20.  National Academy of Sciences, Institute of Medicine, Food and Nutrition Board (2001): Dietary 
reference intakes for vitamin A, vitamin K, arseni, boron, chromium, copper, iodine, iron, manganese, 
molybdenum, nickel, silicon, vanadium, and zinc. national academy press, washington D.C. 
21.  Prasad GV, Abidi SM, McCauley J, Johnston JR: Vitamin K deficiency with hemorrhage after kidney 
and combined kidney-pancreas transplantation. Am J Kidney Dis 33: 963-965, 1999 
22.  Mazzaferro S, Pasquali M, Pugliese F, Barresi G, Carbone I, Francone M, Sardella D, Taggi F: 
Serum levels of calcification inhibition proteins and coronary artery calcium score: Comparison 
between transplantation and dialysis. Am J Nephrol 27: 75-83, 2007 
23.  Schurgers LJ, & Vermeer C: Differential lipoprotein transport pathways of K-vitamins in healthy 
subjects. Biochim Biophys Acta 1570: 27-32, 2002 
24.  Ramotar K, Conly JM, Chubb H, Louie TJ: Production of menaquinones by intestinal anaerobes. J 
Infect Dis 150: 213-218, 1984 
25.  Salyers AA, Palmer JK, Wilkins TD: Degradation of polysaccharides by intestinal bacterial enzymes. 
Am J Clin Nutr 31: S128-S130, 1978 
26.  Moe SM, Reslerova M, Ketteler M, O’neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent 
W, Chen NX: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic 
kidney disease (CKD). Kidney Int 67: 2295-2304, 2005 
27.  Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T: Serum 
osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 
diabetes mellitus. J Clin Endocrinol Metab 94: 45-49, 2009 
28.  Lambers Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, de Graeff PA, de 
Zeeuw D: Moderation of dietary sodium potentiates the renal and cardiovascular protective effects 
of angiotensin receptor blockers. Kidney Int 82: 330-337, 2012 
29.  Reddi K, Henderson B, Meghji S, Wilson M, Poole S, Hopper C, Harris M, Hodges SJ: Interleukin 
6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by 
naphthoquinone (vitamin K) compounds. Cytokine 7: 287-290, 1995 
30.  Ohsaki Y, Shirakawa H, Hiwatashi K, Furukawa Y, Mizutani T, Komai M: Vitamin K suppresses 
lipopolysaccharide-induced inflammation in the rat. Biosci Biotechnol Biochem 70: 926-932, 2006 
31.  Shea MK, Booth SL, Massaro JM, Jacques PF, D’Agostino RB S, Dawson-Hughes B, Ordovas JM, 
O’Donnell CJ, Kathiresan S, Keaney JF,Jr, Vasan RS, Benjamin EJ: Vitamin K and vitamin D status: 
Associations with inflammatory markers in the framingham offspring study. Am J Epidemiol 167: 
313-320, 2008 
32.  Margreiter R, & European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study 
Group: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal 
transplantation: A randomised multicentre study. Lancet 359: 741-746, 2002 
33.  Gungor O, Kircelli F, Carrero JJ, Hur E, Demirci MS, Asci G, Toz H: The effect of immunosuppressive 
treatment on arterial stiffness and matrix gla protein levels in renal transplant recipients. Clin 
Nephrol 75: 491-496, 2011 
34.  U.S. Department of Agriculture U.S. Department of Health and Human Services: Dietary guidelines 
for americans. [Electronic version]. 20122010 
8
Summary, Discussion and Future Perspectives
  
130  |  Chapter 8
Summary, Discussion and Future Perspectives  |  131
8
Summary
Worldwide, the prevalence and incidence of end stage renal disease (ESRD) is 
increasing steadily1, 2, most likely attributable to increasing occurrence of lifestyle 
associated diseases such as diabetes type 2 and hypertension 3-6. These disorders 
together account for more than 60% of the incident ESRD cases nowadays. Also in 
the Netherlands these trends are observed. Last year, the total number of patients with 
treated ESRD grew with about 1,900 and reached almost 16,000 patients, which is 1 
patient per 1000 inhabitants7. Of these patients, 60 percent, or 10,000 ESRD patients, 
have a functioning renal graft nowadays. In barely ten years, the number of ESRD 
patients with a functioning graft has doubled and the prevalence continues to increase 
impressively. These rising numbers can be attributed not only to the increase in the 
number of patients who receive a renal graft but also to improved survival after renal 
transplantation8, 9. Indeed, graft survival over the first year post-transplantation has 
increased remarkably from 40 percent in the 1970’s to over 90 percent in present days for 
recipients of deceased donor kidneys 2. Unfortunately, long term graft and also patient 
survival have hardly improved over the last decades. Renal transplant recipients are 
confronted with frequent occurrence of cardiovascular morbidity, which is the leading 
cause of graft loss and mortality10, 11 . Also, patients are commonly afflicted by metabolic 
disorders due to impaired renal function and adverse effects of long-term drug use12-14. 
Therefore, attention should be focused on the search for tools to help improve long-term 
health after transplantation. Since lifestyle modifications, including dietary habits, have 
been proven to play a role in health status in the general population and in CKD patients 
15-20, we hypothesized that nutritional factors could provide new targets for intervention in 
renal transplant recipients as well to improve long-term morbidity and mortality. 
The aim of this thesis was to document the nutritional intake in a large cohort consisting 
of stable renal transplant recipients with a functioning graft for at least one year and to 
compare their dietary habits with those in a healthy reference group. Second, we aimed 
to investigate the associations of several nutritional factors with cardiovascular, metabolic 
and renal risk profiles long-term after renal transplantation to identify potential targets 
for intervention to help prevent morbidity and mortality in renal transplant recipients. In 
chapter two, we investigated habitual sodium intake in renal transplant recipients as 
compared to a healthy reference group and studied its association with blood pressure. 
In the general population, and in particular in CKD patients, dietary sodium is a well 
established risk factor for hypertension21-25, a condition that is highly prevalent in renal 
transplant recipients as well 26. We found habitual sodium intake to be considerably 
lower in renal transplant recipients than in healthy controls. Nevertheless, the majority 
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of patients still exceeded the daily amount as recommended in current international 
guidelines27, 28. Higher sodium intake was associated with higher systolic and diastolic 
blood pressure. Based on our data, it can be inferred that compliance with the maximally 
recommended daily intake would reduce mean systolic and diastolic blood pressure 
with approximately 5 mmHg and 3 mmHg respectively in our transplant population. 
These findings suggest that better control of sodium intake can lead to clinically relevant 
improvement of blood pressure in renal transplant recipients. However, a drawback 
of cross-sectional dietary studies is the firm and sometimes inextricable association 
between several nutrients. Indeed, in line with previous studies29, 30, our study showed a 
close relation between sodium and protein. Both factors have been extensively studied 
for their potential influence on blood pressure in the general population and their joint 
presence in foods makes it difficult to distinguish between the effects of the separate 
dietary components on blood pressure. Therefore, in chapter three we had a closer 
look on the potential effects of dietary protein on blood pressure and renal function 
in renal transplant recipients. In non-transplant renal populations, dietary protein can 
affect renal haemodynamics as well as renal protein loss 31-33.
Concern exists that high protein intake induces high intraglomerular pressure and 
concurrent hyperfiltration, eventually leading to kidney damage and subsequent 
hypertension. In line, there is evidence that patients with chronic kidney disease benefit 
from a protein restricted diet 34, 35. In our study among 625 renal transplant recipients, 
however, we did not find a continuous association of dietary protein with renal function 
or blood pressure, regardless of the type of protein (animal or protein). This was despite 
an average total protein intake of 1.1 g/kg/d, which exceeded the recommended values 
for renal patients (0.6-0.8 g/kg/d) 36. Our study, therefore, did not support the hypothesis 
that high protein adversely influences renal function or blood pressure in RTR, at least 
within the range of the total protein intake we documented in our study population. 
One may hypothesize that potentially existing associations between protein intake and 
BP would go unnoticed as the majority of RTR use antihypertensive drugs. However, 
classical factors associated with BP in the general population such as age, gender 
and sodium intake (chapter two) were associated with BP in our RTR, which supports 
the power of our study to identify determinants of blood pressure in the current clinical 
context. 
Despite the absence of an association between dietary protein and cardio-renal 
parameters, protein intake still might affect post-transplant conditions by contributing 
to metabolic parameters. Previous studies have shown that diet influences acid-base 
balance in the general population 37-40. Dietary acid load originates from precursors like 
cationic amino acids and organic acids, while potassium salts of metabolizable anions, 
like citrate, have an alkalinizing effect 39, 41. Since the kidney plays an important role in 
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acid-base homeostasis by excreting the excess of acids ingested 42-44, we hypothesized 
that renal transplant recipients, who obviously have a decreased capacity to excrete 
acid due to impaired renal function, might be at particular risk to develop diet induced 
acidosis and that they could benefit from dietary modifications to improve acid-base 
homeostasis. 
In chapter four, we investigated whether metabolic acid load was related to acidosis in 
renal transplant recipients and whether dietary factors could be identified that influence 
metabolic acid load and subsequent acidosis. We found that of the 707 renal transplant 
recipients participating in our study, 31% had acidosis, defined as serum [HCO3
-] lower 
than 24 mmol/L. In addition to conventional factors contributing to acidosis in renal 
transplant recipients, such as age and graft dysfunction, acidosis was also associated 
with urinary net acid excretion (NAE). Measurement of NAE is the gold standard for 
assessing metabolic acid load 45, and is based on 24 hour urinary excretion of titratable 
acid, ammonium and bicarbonate. The significant associations between NAE and 
serum [HCO3-] that we found, were consolidated by significant associations between 
acidosis and two validated algorithms estimating dietary acid load based on dietary 
recall (Potential Renal Acid Load (PRAL)39 and Net Endogenous Acid Production 
(NEAP)37). PRAL and NEAP, and accordingly NAE, were higher in patients with higher 
intake of (animal) protein and calcium, and lower in patients with higher intakes of fruits 
and vegetables. 
Based on the obtained data, it could be inferred that by rather simple dietary modification, 
about 5% of included renal transplant recipients with acidosis could achieve appropriate 
serum [HCO3-] levels. Based on these findings and given the high prevalence of acidosis 
long-term after renal transplantation, occasional venous blood gas analyses could aid 
in clinical practice. If acidosis is confirmed, medical practitioners should pay attention 
not only to known risk factors like graft function, but also to dietary habits since dietary 
intervention might improve long-term post-transplant outcomes. 
The observed robust association between animal protein intake and acidosis in renal 
transplant recipients could very well point towards specific constituents of animal 
protein, rather than protein as a whole, contributing to acidosis. The sulfur containing 
amino acids (SAA), methionine and cysteine, which are known for their acidifying 
properties through conversion to sulfuric acid 38, 46, could account for our findings as 
they are predominantly found in animal protein. Indeed, we found significantly higher 
urinary sulfur excretion along with urinary net acid excretion. Considering the above, 
it might be suggested that renal transplant recipients should restrict intake of sulfur 
containing amino acids to improve acid-base homeostasis. On the other hand, SAA 
are the main substrate for endogenous synthesis of hydrogen sulfide (H2S), which is a 
gaseous signaling molecule with substantial biological potential 47-50. H2S is suggested 
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to be beneficially involved in various (patho-)physiological processes including blood 
pressure regulation, inflammation, and cytoprotection during hypoxia which suggests 
a favorable role for SAA. These conflicting hypotheses on the role of sulfur were the 
focus of chapter five, where we explored the associations of the two most important 
urinary sulfur metabolites, sulfate and thiosulfate (TS), with cardiovascular and 
metabolic parameters in renal transplant recipients. Also, we analyzed the predictive 
capacity of both sulfur parameters for mortality. Sulfate was assumed to predominantly 
reflect dietary intake 51, 52, whereas TS is considered a specific intermediate of the H2S 
metabolism 53. Indeed, we observed a significant association of SAA intake with urinary 
sulfate, but not with thiosulfate. Remarkably, we found both urinary sulfate and urinary 
thiosulfate to be associated with a favorable cardio-metabolic risk profile in our renal 
transplant cohort. We also observed a significant predictive capacity of both sulfate 
and thiosulfate for incidence of mortality in our transplant cohort, also after adjustment 
for age, gender and graft function. Regarding TS, these findings were according to our 
primary hypothesis, since TS is assumed, at least in part, to reflect rate of endogenous 
H2S synthesis. However, it might also be TS itself underlying the favorable association 
with cardiovascular parameters and patient survival since TS has been reported to 
exert protective activities in several pathophysiological processes as well, such as 
oxidative stress and vascular calcifications54, 55. In contrast, the beneficial associations 
of urinary sulfate with cardiovascular parameters and patient survival were quite 
puzzling, particularly because we observed significant association of urinary sulfate 
with metabolic acid load, which is suggested to have adverse effects on post-transplant 
conditions, as described in chapter four. Although it is difficult to conclude on causality 
in an observational study, a potential explanation for these associations might be that 
part of the excreted sulfate, like thiosulfate, has been incorporated in the H2S synthesis. 
This would be in line with previous studies showing that systemically applied H2S is 
excreted as either TS or sulfate 56, 57. Another intriguing finding in this study was that 
renal transplant recipients had a significantly higher excretion of thiosulfate compared 
with healthy subjects. This was quite surprising, since it might be expected that RTR, 
known to be at high cardiovascular risk compared to the general population, excrete 
less of an indicator of the allegedly favorable H2S metabolism. Perhaps this higher 
TS excretion reflects a compensatory response, or up-regulation of H2S and/or TS 
synthesis, to meet the increased demand for cardiovascular protection in renal transplant 
recipients. Obviously, long-term intervention studies with exogenous sulfur, either from 
the diet or pharmacological agents such as sodium thiosulfate, are warranted to clarify 
the exact role and underlying mechanisms of the sulfur metabolism in cardiovascular 
health in RTR. Notwithstanding the cross-sectional character of the study design, which 
warrants prudence in the drawing of firm conclusions, the results presented in chapter 
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five gave us the idea that 1) endogenously produced gaseous transmitters might play 
a significant role in long-term cardiovascular health after renal transplantation and 2) 
exogenous sources, e.g. from diet, might contribute to synthesis of these compounds, 
making dietary modification a valuable target in the management of post-transplant 
cardiovascular disease. 
In chapter six we elaborated on these hypotheses and focused on nitric oxide (NO), 
another gaseous transmitter known to be involved in various physiological processes 
including regulation of vascular tone, adhesion of inflammatory cells and smooth 
muscle cell proliferation 58-60. Some recent studies suggested that NO can be converted 
from exogenous inorganic nitrate, mainly originating from vegetables, and that nitrate 
supplementation may have therapeutic effects in renal and cardiovascular disease 61, 
62. Since NO itself can poorly be measured, as it has a short biological half-life, we 
estimated endogenous NO synthesis by measuring plasma and urinary nitrate and 
nitrate (NOx), which are stable end-products of NO and widely used as a marker of NO 
63, 64. Compared with healthy controls, renal transplant recipients had significantly lower 
urinary NOx-excretion despite similar intakes of vegetables. These lower levels could 
be explained by either impaired NO synthesis due to endothelial or graft dysfunction 65, 
66, or excessive degradation as consequence of the continuous state of oxidative stress. 
Intriguingly, these urinary NOx-excretion levels were robustly associated with the extent 
of various cardiovascular risk factors, such as blood pressure, heart rate, hs-CRP and 
Nt-pro-BNP, even after adjustment for several confounders such as age, gender, renal 
function, medication use and vegetable intake, which is consistent with our hypothesis 
that hampered NO is directly connected to endothelial dysfunction. These results 
prompt for the evaluation of long-term administration of NO donors for treatment or even 
prevention of post-transplantation cardiovascular disease in renal transplant recipients. 
Despite similar intakes of vegetables in both healthy controls and renal transplant 
recipients, we found vegetable intake to be an independent determinant of urinary 
NOx excretion within our renal transplant cohort. The low urinary levels of NOx in our 
transplant cohort might therefore at least partly be explained by insufficient vegetable 
intake, which was far below the daily amounts as advocated by the universally adopted 
dietary approaches to stop hypertension (DASH) diet 67. 
This restricted intake could be a relic of the rigid dietary regimen that has been 
prescribed to the majority of our transplant cohort during the dialysis episode preceding 
renal transplantation to prevent hyperkalemia. Importantly, a concomitant adverse effect 
of this regimen is the occurrence of deficiencies of nutrients predominantly present in 
vegetables, such as vitamin K. Vitamin K deficiency is increasingly recognized as a 
risk factor for cardiovascular morbidity and mortality in renal patients 68, 69. An important 
function of vitamin K is the carboxylation, or biological activation, of matrix glutamate 
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protein (MGP), which inhibits vascular calcification 70, 71. Poor vitamin K status, as a 
consequence of poor nutritional intake, results in high uncarboxylated MGP levels which 
is shown to be associated with vascular calcification. The combined observation of low 
vegetable intake and signs of endothelial dysfunction in our transplant population, might 
point toward vitamin K deficiency as underlying mechanism. 
Therefore, in chapter seven we focused on the association of vitamin K intake with 
vascular vitamin K status in renal transplant recipients. In contrast with all other studies 
described in this thesis, we obtained data on vitamin K intake from dietary diaries 
instead of food frequency questionnaires. Data from diaries in general is more accurate 
and gives a better reflection of the intake over de preceding days. However, keeping 
a diary by patients on one hand, and processing the data by the researcher on the 
other, is very labor-intensive and time consuming 72. Therefore, for logistic reasons, we 
obtained data on vitamin K intake from a small subgroup (n=60) of our renal transplant 
cohort. We found that dietary vitamin K intake was below recommendations in 50% of 
our renal transplant cohort. Even more important was that vascular vitamin K status was 
insufficient in the majority of renal transplant recipients, reflected by elevated plasma 
uncarboxylated MGP levels. In addition, we observed that renal transplant recipients 
with vitamin K insufficiency were more likely to experience low-grade inflammation, which 
itself is supposed to contribute to or reflect increased cardiovascular risk after renal 
transplantation 73-75. Whether increased intake of vitamin K influences cardiovascular 
calcifications, either via improvement of the inflammatory state should best be proven in 
randomized controlled prospective intervention studies.
Summary, Discussion and Future Perspectives  |  137
8
Discussion
In this thesis, we studied the dietary patterns of renal transplant recipients long-term 
after transplant surgery. Second we investigated the association of several nutrients 
with various cardiovascular, metabolic and renal risk parameters in our search for 
modifiable dietary components that might contribute to improved outcomes after renal 
transplantation. 
In comparison with the available general guidelines for a good clinical health, renal 
transplant recipients deviated significantly. With respect to nutrients, intake of sodium, 
protein, phosphorus and saturated fat were higher than advocated, whereas intake of 
poly-unsaturated fats, carbohydrates and fiber were lower than the daily recommended 
amounts. In comparison with a healthy reference group consisting of potential living 
kidney donors, absolute intake of nutrients was lower in renal transplant recipients, 
which for the first time became visible in chapter two where 24-hour urinary sodium 
excretion was 20% lower compared with healthy controls. We concluded that renal 
transplant recipients apparently were more compliant to sodium restricted diets, likely 
as a result of intense dietary counseling during the course of renal disease and post-
transplantation follow-up. However, when additional dietary data became available in 
subsequent studies, described in chapter four, five and six, we found out that it was 
primarily the absolute, or caloric intake that was lower rather than the composition of 
the diet. One could hypothesize that RTR would give desirable answers when filling in a 
dietary questionnaire, rendering biased results. However, comparison of data obtained 
from FFQ with those obtained from urinary urea excretion, the latter obviously resistant 
to pleasing behavior, yielded similar results.
Despite the lower and seemingly adequate total dietary intake in RTR, we observed 
a contradictory average body mass index over 26.5 kg/m2 which, according to the 
WHO guidelines, is defined as overweight. Potential explanations for these paradoxical 
findings might be the sedentary lifestyle which is commonly seen after renal 
transplantation. Other explanations might be an altered metabolism due to long-term 
use of immunosuppressive drugs, which have been shown to contribute to diabetes 
and dyslipidemia. Additional adverse effects of these agents include changes of 
intestinal flora and, as a potential consequence, an altered absorption and handling 
of nutrients. A third factor potentially underlying these conflicting phenomena is an 
increased extracellular volume as a result of fluid retention caused by corticosteroids 
and renal impairment or cardiac failure that is not compensated for by diuretics. A 
fourth potentially underlying factor could be a difference in muscle mass, which likely 
was present, as reflected by the difference in 24h urinary creatinine excretion between 
RTR and healthy controls. Irrespective of the mechanism underlying the discrepancy 
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of intake and BMI, our findings support our primary hypothesis that it is not merely 
caloric intake that plays a role in post-transplant conditions, but also diet composition. 
Indeed, in all our statistical analyses on the associations of dietary factors with health 
parameters in our transplant cohort, our findings remained essentially unchanged after 
adjustment for body composition, which even more points towards the quality of the diet 
that should receive proper attention.
With one single exception, the studies described in this thesis have a cross-sectional 
design and therefore are subject to certain limitations. One of the drawbacks of cross-
sectional data is that both intake of dietary factors and the outcome variables are 
assessed at the same moment in time, which makes it difficult to address the temporality 
of the associations we found. It is possible that renal transplant recipients that perceived 
increased cardiovascular, metabolic or renal risk changed their overall dietary habits, 
either themselves or after medical advice, resulting in erroneous conclusions. However, 
we consider intentional dietary changes in renal transplant recipients unlikely, since 
many of the outcome parameters we investigated, such as acid-base-parameters, renal 
function and low-grade inflammation are often asymptomatic, and do not lead to changes 
in dietary recommendations. Additionally, in clinical practice, most of these symptoms 
are considered present as a matter of course, and also are more likely to be treated with 
pharmacological agents than with dietary intervention. Another limitation that applies to 
the majority of our studies is the use of questionnaires that depend on adequate dietary 
recall of our patients. Although the use of questionnaires is a generally accepted tool for 
the inquiry of foods and beverages in epidemiological studies, some misclassification 
might still occur. To verify the data obtained from food frequency questionnaires, we 
validated those against 60 dietary diaries or, if possible, against urinary excretions. 
We found correlations that were comparable with those observed in previous studies 
analyzing validity of FFQs in population-based cohort studies. Nevertheless, some 
random misclassification of dietary intake remains inevitable, though it would have 
weakened the observed associations between dietary factors and clinical parameters 
rather than that they spuriously would have become into existence.
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Future Perspectives and Clinical Implications
We showed in several cross-sectional studies that dietary intake is associated with 
various post-transplant conditions such as blood pressure, acid-base homeostasis 
and low-grade inflammation, all very prevalent in renal transplant recipients. A quick 
search on Pubmed learns that hardly any data are available yet on the role of nutrition 
long-term after transplant surgery. Considering the cross-sectional design of our studies 
and its inherent limitations, our findings constitute dangerous ground to jump to firm 
conclusions. It goes without saying that our findings and conclusions require further 
consolidation and confirmation. It would be informative to investigate in a prospective 
study whether the nutritional factors under study in this thesis also predict hard end-
points such as cardio-vascular events, graft failure or patient mortality. In chapter five 
we had a first look on the association of sulfur metabolites, partly reflecting intake of 
sulfur containing amino acids, with incidence of mortality in renal transplant recipients 
and found sulfate and thiosulfate to be significant predictors for overall death long-term 
after transplantation. These promising longitudinal data support our cross-sectional 
findings of the association between sulfur metabolites and a favorable cardiovascular 
risk profile in RTR. Nevertheless, despite a consolidation of the beneficial relation 
between sulfur metabolites and post-transplant conditions, the observational nature of 
these longitudinal data still calls prudence to drawing firm conclusions as it provides no 
conclusive evidence for the protective potential of exogenous sulfur.
An elegant way to investigate the effects of sulfur on cardiovascular health and patient 
survival would be to perform a prospective intervention study in renal transplant recipients. 
In the study described in chapter five, an association of urinary sulfate and thiosulfate 
was observed with incidence of mortality within a relatively short period of follow-up 
(median 17 months), indicating that in an intervention study, with even larger contrasts 
in exposure, the potential effects of exogenous sulfur on hard outcome variables might 
be detected within a foreseeable amount of time. If such a study would be performed, 
taking for granted that time and financial measures are at unlimited disposal, a large, 
multi-center randomized controlled trial in stable renal transplant recipients would be 
the study of choice. The trial could include three groups of patients with one control 
group receiving a standard Western diet. A second group could receive a diet rich 
in methionine and cystein containing foods, such as poultry, oats and eggs. In prior 
analyses, intake of sulfur containing amino acids correlated well with urinary sulfate 
excretion, indicating that habitual diet indeed contributes to the systemic sulfur pool. 
The third study group could receive a Western diet, like the control group, however, 
with additional daily oral application of sodium thiosulfate as principal source of sulfur. 
Sodium thiosulfate is not yet registered; however, it is widely used as antidote to cyanide 
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poisoning or as treatment of calciphylaxis in hemodialysis patients with end stage renal 
disease and is well tolerated. Adherence to the interventions could be assessed by 
dieticians and by biochemical measurements during monthly visits to the outpatient 
clinic. Outcome variables in this study could include change, from baseline to the 
end of intervention, in the cardiovascular and metabolic parameters as investigated in 
chapter five, with specific focus on hemodynamics, vascular calcification status and 
inflammation.
If the findings in this thesis are confirmed by longitudinal data or preferably, by long-term 
intervention studies, this could have several clinical implications. Awareness should be 
raised among renal transplant recipients as well as among clinicians on diet composition 
and on its role in post-transplant physical health. During follow-up, attention should be 
directed not only to conventional factors contributing to post-transplant cardiovascular 
and metabolic morbidity, such as graft function, but also to nutritional habits of our 
patients. Regular involvement of a dietician at the outpatient clinic could prove to be 
useful in helping our patients to gain insight in their dietary habits and to achieve an 
optimal diet. Even slight dietary modifications might already improve long-term morbidity 
in renal transplant recipients and improve long-term graft and even patient survival.
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Wereldwijd is het aantal patiënten met eindstadium nierfalen in de afgelopen decennia 
gestaag toegenomen. Nederland telt momenteel ruim 16.000 patiënten met nierfalen, 
wat neerkomt op 1 patiënt per 1000 inwoners. De belangrijkste oorzaak voor deze 
stijging ligt in de toename van leefstijl gerelateerde verschijnselen als hypertensie, 
overgewicht en diabetes mellitus type 2, die alle erkende risicofactoren vormen voor de 
ontwikkeling van nierschade.
Het merendeel van de patiënten met nierfalen start met nierdialyse als 
nierfunctievervangende therapie. Hoewel hierdoor de levensverwachting duidelijk wordt 
verbeterd, is het sterftecijfer onder dialysepatiënten nog altijd erg hoog; na aanvang 
van nierdialyse is slechts de helft van alle patiënten na drie jaar nog in leven.
Voor patiënten met eindstadium nierfalen vormt niertransplantatie de behandeling van 
eerste keuze. Niet alleen maakt het nierdialyse overbodig en verbetert het daarmee 
de kwaliteit van leven, ook is de levensverwachting van niertransplantatiepatiënten 
vele malen beter ten opzichte van die van dialysepatiënten. Mede dankzij de 
introductie van nieuwe afweeronderdrukkende medicijnen komt acute afstoting van de 
transplantaatnier steeds minder vaak voor. Toch is op lange termijn ook niertransplantatie 
niet zaligmakend. Zelfs na een succesvolle niertransplantatie gaat de helft van alle 
getransplanteerde nieren 12 tot 25 jaar na transplantatie verloren. Een van de oorzaken 
hiervoor is het feit dat een groot aantal niertransplantatiepatiënten komt te overlijden 
met een nog functionerende transplantaatnier. Hart- en vaatziekten, waaronder 
hypertensie, vaatverkalking en schade aan de binnenbekleding van bloedvaten, 
vormen de belangrijkste doodsoorzaak bij niertransplantatiepatiënten en de mortaliteit 
ten gevolge hiervan is vijfmaal hoger in vergelijking met de algemene bevolking. Het is 
om die reden van cruciaal belang dat er gezocht wordt naar mogelijkheden om hart- en 
vaatziekten na niertransplantatie te voorkomen en daarmee de langetermijnoverleving 
van niertransplantatiepatiënten te verbeteren. 
In de afgelopen decennia is veel onderzoek gedaan naar de relatie tussen verschillende 
voedingselementen en het cardiovasculair risico in de algemene bevolking. 
Veranderingen van leefstijl, waaronder de aanpassing van voedingsgewoonten, zijn 
effectief gebleken in het voorkómen van hart- en vaatziekten en dragen daarmee bij 
aan een gezondere overleving. Wat de rol van voeding is bij niertransplantatiepatiënten 
is tot op heden nooit goed onderzocht. Omdat niertransplantatiepatiënten om 
uiteenlopende redenen een zeer specifieke populatie vormen, kunnen resultaten uit 
onderzoeken in de algemene bevolking niet een op een worden geëxtrapoleerd naar 
deze patiëntengroep. Wegens het gebrek aan wetenschappelijk bewijs betreffende de 
rol van voeding in de gezondheid van niertransplantatiepatiënten, zijn er voor hen tot 
op heden geen gefundeerde voedingsrichtlijnen beschikbaar. Voor zowel medici als 
voor transplantatiepatiënten is het daarom onduidelijk wat de optimale samenstelling 
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van het dieet zou moeten zijn ter verbetering van de cardiovasculaire gezondheid van 
niertransplantatiepatiënten. 
Een van de doelen van dit proefschrift is om de voedingsgewoonten van een groot cohort 
niertransplantatiepatiënten in kaart te brengen en deze te vergelijken met die van gezonde 
personen. Daarnaast onderzoeken we wat de relatie is van verschillende voedingsfactoren 
met het verhoogde risico op hart- en vaatziekten bij niertransplantatiepatiënten, opdat 
handvatten worden verkregen om uiteindelijk gerichte interventies te kunnen verrichten 
om de hoge morbiditeit en mortaliteit onder niertransplantatiepatiënten te verlagen. 
Voor dit onderzoek hebben 707 niertransplantatiepatiënten, die allen in het Universitair 
Medisch Centrum Groningen hun niertransplantatie hebben ondergaan, de bereidheid 
getoond om mee te werken.
Om een beeld te krijgen van de voedingsgewoonten van deze niertransplantatiepatiënten 
hebben we gebruik gemaakt van twee verschillende methoden. Ten eerste hebben 
we aan alle patiënten voedingsvragenlijsten, zogenaamde ‘Food Frequency 
Questionnaires’ voorgelegd. Dit zijn wereldwijd erkende vragenlijsten die een beeld 
geven van de voeding over de laatste maanden. Met name voor het analyseren van 
de inname van macronutriënten, zoals eiwit, is deze methode geschikt, vooral in grote 
cohorten. Ten tweede hebben we alle niertransplantatiepatiënten gedurende 24 uur al 
hun urine laten verzamelen. Deze 24-uurs urine, mits zorgvuldig verzameld, vormt een 
‘vingerafdruk’ van de voeding die iemand recent heeft binnengekregen. Deze methode, 
hoewel arbeidsintensiever dan het invullen van een vragenlijst, heeft de voorkeur 
wanneer het gaat om het analyseren van bijvoorbeeld zoutinname, omdat het zout dat 
in de urine gemeten wordt, onder normale omstandigheden nagenoeg gelijk is aan de 
hoeveelheid die met de voeding het lichaam is binnengekomen. Waar mogelijk hebben 
we de resultaten van beide meetmethoden onderling vergeleken, ter analyse van de 
consistentie en validiteit van onze onderzoeksresultaten.
In hoofdstuk twee hebben we onderzocht hoeveel zout niertransplantatiepatiënten 
gebruiken en in hoeverre zoutinname bij hen geassocieerd is met bloeddruk. In de 
algemene bevolking is een hoge zoutinname een bekende risicofactor voor hypertensie, 
maar of het ook bij niertransplantatiepatiënten bijdraagt aan een hoge bloeddruk is nooit 
onderzocht. We zagen dat niertransplantatiepatiënten significant minder zout gebruiken 
dan personen uit een gezonde controlegroep, maar desondanks veel meer dan in de 
richtlijnen voor de algemene bevolking wordt geadviseerd. Een hogere zoutinname 
was significant geassocieerd met een hogere bloeddruk. Uit onze studieresultaten 
kan worden afgeleid dat niertransplantatiepatiënten, indien ze zich zouden houden 
aan de aanbevolen hoeveelheid zout, een beduidend lagere bloeddruk zouden 
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hebben. Daarmee zou het risico op hart- en vaatziekten kunnen worden beperkt. Een 
schaduwzijde van bovengenoemde studie is het feit dat het eten van meer zout veelal 
gepaard gaat met de intake van andere voedingsstoffen. Zo hebben eerdere studies 
aangetoond dat mensen die veel zout eten, automatisch ook veel eiwitten binnenkrijgen 
door het gezamenlijk voorkomen in voeding. 
Om die reden hebben we in hoofdstuk drie de inname van eiwitten apart onder 
de loep genomen. Het is bekend dat voedingseiwitten invloed uitoefenen op de 
bloeddoorstroming van de nier en daarmee kunnen bijdragen aan nierschade, juist bij 
nierpatiënten. In lijn daarmee is het feit dat patiënten met chronische nierziekten baat 
hebben bij een eiwitarm dieet. In niertransplantatiepatiënten vonden we hiervoor echter 
geen aanwijzingen. Nierfunctie noch bloeddruk waren geassocieerd met de inname van 
eiwitten, ongeacht de bron van eiwit, terwijl de gemiddelde inname van eiwit ver boven 
de geadviseerde hoeveelheid bij nierpatiënten lag. Onze studie suggereert daarmee 
dat voedingseiwitten, zij het binnen de range die we gedocumenteerd hebben in onze 
studiepopulatie, geen nadelige gevolgen hebben op nierfunctie en bloeddruk. Hoewel 
geopperd zou kunnen worden dat eventuele gevolgen van eiwitten op de bloeddruk 
teniet worden gedaan door de grote hoeveelheden bloeddrukverlagende middelen die 
door niertransplantatiepatiënten worden gebruikt, zagen we dat bekende risicofactoren, 
zoals leeftijd, geslacht en zoutinname, wel degelijk geassocieerd waren met bloeddruk 
in onze onderzoekspopulatie. 
Het is overigens niet gezegd eiwitten helemaal niet van invloed zijn op de gezondheid 
van niertransplantatiepatiënten. Voedingseiwitten hebben namelijk ook invloed op het 
zuur-base evenwicht doordat ze opgebouwd zijn uit onder andere aminozuren die 
bijdragen aan de metabole zuurbelasting van het lichaam. Aangezien de nieren een 
belangrijke rol spelen bij het uitscheiden van een teveel aan zuur, veronderstelden 
we dat niertransplantatiepatiënten, ten gevolge van hun verminderde nierfunctie, 
een verhoogd risico lopen op metabole acidose, ten dele geïnduceerd door het 
dieet. In hoofdstuk vier onderzochten we of metabole zuurbelasting door de voeding 
daadwerkelijk gerelateerd was aan metabole acidose en of er voedingsfactoren konden 
worden geïdentificeerd die acidose beïnvloeden. Van de 707 niertransplantatiepatiënten 
had 31% een metabole acidose, blijkens een bicarbonaat concentratie in het bloed 
die lager was dan 24 mmol/L. Aan de hand van de 24-uurs urine hebben we bij alle 
patiënten de metabole zuurbelasting (Net Acid Excretion; NAE) gemeten volgens 
de gouden standaard. We zagen dat de mate van acidose significant geassocieerd 
was met de NAE en dat patiënten met een grotere inname van (dierlijke) eiwitten 
en calcium een significant grotere kans hadden op acidose dan patiënten die veel 
groenten en fruit aten. De geobserveerde samenhang tussen eiwitten en metabole 
acidose in niertransplantatiepatiënten zou verklaard kunnen worden door specifieke 
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bestanddelen van eiwitten, in plaats van eiwitten in hun geheel. Zo zouden bijvoorbeeld 
de zwavelbevattende aminozuren, methionine and cysteine, die veel voorkomen in 
dierlijke eiwitten, verantwoordelijk kunnen zijn voor de verzurende werking van eiwitten 
door omzetting naar sulfaat. Dit suggereert dat niertransplantatiepatiënten geadviseerd 
moet worden de inname van zwavelbevattende eiwitten te beperken. Aan de andere 
kant vormt zwavel een belangrijk bestanddeel van sulfidegas (H2S), dat juist een 
gunstige werking heeft op bloeddrukregulatie, ontstekingsremming en weefselbehoud 
tijdens lage zuurtstofdruk. Deze tegenstrijdigheid vormde de basis voor de studie 
zoals beschreven in hoofdstuk vijf waarin we de samenhang bestudeerden tussen de 
belangrijkste zwavelhoudende metabolieten (sulfaat en thiosulfaat) en cardiovasculaire 
en metabole parameters. Ook hebben we gekeken naar de voorspellende waarde 
van deze zwavelhoudende stoffen voor sterfte. Sulfaat is hierbij een reflectie van de 
inname van zwavelbevattende eiwitten, terwijl thiosulfaat een intermediair is in het H2S-
metabolisme. Dit laatste bleek ook uit de significante associatie tussen inname van 
zwavelbevattende eiwitten en het urine sulfaatgehalte, die niet gevonden werd tussen 
zwavelbevattende eiwitten en het urine thiosulfaatgehalte. Opvallend was dat zowel 
urinesulfaat als urinethiosulfaat geassocieerd was met een gunstig cardiovasculair 
risicoprofiel. We vonden zelfs dat de concentraties van zowel sulfaat als thiosulfaat 
in de urine van voorspellende waarde waren voor sterfte, waarbij een hogere waarde 
in de urine tot minder sterfte leidt. Voor thiosulfaat was dit volgens onze primaire 
hypothese, aangezien thiosulfaat, in meer of mindere mate, een reflectie is van de 
endogene synthese van H2S. De gevonden gunstige associatie tussen urine sulfaat en 
sterfte was echter haaks op onze primaire hypothese, vooral omdat we een significante 
associatie vonden tussen de inname van zwavelbevattende eiwitten en NAE, zoals 
beschreven in hoofdstuk vier. Een mogelijke verklaring hiervoor zou kunnen zijn dat 
een deel van het uitgescheiden sulfaat, net als het thiosulfaat, ingelijfd is geweest in 
de H2S-synthese. Longitudinale interventiestudies met exogeen zwavel, uit de voeding 
dan wel uit farmacologische preparaten, zullen uitsluitsel moeten geven over de 
daadwerkelijke rol, en het onderliggende mechanisme, van het zwavelmetabolisme 
in de cardiovasculaire gezondheid van niertransplantatiepatiënten. Niettegenstaande 
de cross-sectionele studieopzet van hoofdstuk vijf, deden de verkregen resultaten 
ons veronderstellen dat niet alleen endogeen geproduceerde ‘gasotransmitters’ zoals 
H2S een belangrijke rol zouden kunnen spelen in cardiovasculaire gezondheid na 
niertransplantatie, maar ook dat voeding van belang zou kunnen zijn bij de synthese 
van deze gasverbindingen. In hoofdstuk zes zijn we hierop verder gegaan waarbij we 
hebben gekeken naar stikstofgas (NO) dat ook zijn gunstige werking heeft bewezen 
in verschillende fysiologische processen zoals de regulatie van de vaatweerstand, 
ontstekingsprocessen en de celdeling van gladde spiercellen. Eerdere studies hebben 
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gesuggereerd dat NO kan worden omgezet uit anorganisch nitraat, dat veel voorkomt 
in groenten, en dat nitraatsuppletie therapeutische effecten heeft bij patiënten met 
nierziekten of hart- en vaatziekten. Omdat NO-gas vluchtig is en derhalve niet goed 
kan worden gemeten, hebben we de restproducten van NO, nitriet- en nitraat (NOx), 
in de urine als maat genomen voor het endogeen gevormde NO, zoals dat wereldwijd 
ook wordt gedaan. Het urine NOx-gehalte was sterk en gunstig geassocieerd met 
verschillende cardiovasculaire risicofactoren zoals bloeddruk, hartslag, ontsteking en 
hartfalen. Deze bevindingen stroken met de hypothese dat verminderde NO-synthese 
direct verband houdt met verminderde endotheelfunctie. Verder zagen we dat de inname 
van groenten een onafhankelijke determinant was van het urine- NOx-gehalte, maar ook 
dat de hoeveelheid groenten die niertransplantatiepatiënten dagelijks eten ver beneden 
de aanbevolen hoeveelheid lag. De resultaten van deze studie suggereren dat met 
het verhogen van de inname van groenten een gunstiger cardiovasculair risicoprofiel 
zou kunnen worden verkregen, mogelijk dankzij een verhoging van de endogene NO-
synthese. 
De in hoofdstuk zes vastgestelde lage inname van groenten door niertransplantatie-
patiënten zou een overblijfsel kunnen zijn van het strenge dieetregime dat voor 
de meerderheid van de patiënten gold tijdens nierdialyse voorafgaand aan de 
niertransplantatie, ter voorkoming van hyperkaliëmie. Inherent aan dit strenge 
‘dialysedieet’ is echter het risico op deficiënties van verschillende nutriënten die 
ook in groenten aanwezig zijn, zoals vitamine K. Een vitamine K tekort wordt steeds 
meer erkend als een risico voor het verhoogde risico op hart- en vaatziekten in 
nierpatiënten. Een belangrijke rol voor vitamine K is weggelegd in de remming van 
vaatverkalking door carboxylering, ofwel activatie, van het beschermende ‘matrix 
glutamate protein’ (MGP). Bij een lage inname van vitamine K, wordt er minder MGP 
gecarboxyleerd waardoor sneller vaatverkalking zal optreden. Het gecombineerd 
voorkomen van een lage inname van groenten en de hoge prevalentie van verminderde 
endotheelfunctie bij niertransplantatiepatiënten zou derhalve gelegen kunnen zijn in 
een vitamine K deficiëntie als onderliggend mechanisme. In hoofdstuk zeven zagen 
we dat in de helft van de niertransplantatiepatiënten de vitamine K inname lager was 
dan de aanbevolen dagelijkse hoeveelheid. Daarbij zagen we dat er een verhoogde 
plasmaconcentratie ongecarboxyleerd MGP werd gevonden in het grootste deel van 
de niertransplantatiepatiënten. Patiënten die een tekort aan vitamine K hadden, hadden 
een grotere kans op laaggradige ontsteking, een fenomeen dat op zich ook weer een 
risico vormt voor hart- en vaatziekten na transplantatie. Of een toename van de inname 
van vitamine K daadwerkelijk zal bijdragen aan verminderde vaatverkalking, zal echter 
onderzocht moeten worden met gerandomiseerde, gecontroleerde, prospectieve 
interventiestudies. 
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De bevindingen uit de studies zoals beschreven in dit proefschrift suggereren 
dat de samenstelling van het dagelijks dieet een rol speelt in de gezondheid van 
niertransplantatiepatiënten. Desalniettemin is voorzichtigheid geboden bij het trekken 
van stevige conclusies. Het moge duidelijk zijn dat meer maar vooral prospectieve 
interventiestudies nodig zijn om te onderzoeken of de voedingsfactoren zoals deze 
aan bod zijn gekomen in dit proefschrift ook van voorspellende waarde zijn voor harde 
eindpunten zoals cardiovasculaire complicaties, transplantaatoverleving en sterfte. 
Mocht inderdaad blijken dat er winst in patiënt- dan wel transplantaatoverleving is te 
behalen door modificatie van voedingsgewoonten van niertransplantatiepatiënten, 
dan zal dit duidelijk consequenties hebben voor de invulling van de follow-up van 
deze patiëntengroep. Naast aandacht voor de medicamenteuze benadering van het 
cardiovasculaire risico van niertransplantatiepatiënten, zal ook nadruk moeten komen te 
liggen op de samenstelling van het dieet van niertransplantatiepatiënten ter bevordering 
van langetermijnoverleving. Regelmatige betrokkenheid van een voedingsdeskundige 
op de polikliniek zou hierbij van grote waarde kunnen zijn.
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Promoveren zonder bijdragen door anderen is simpelweg onmogelijk. Of dit nu bestaat 
uit de deelname aan het onderzoek, de logistieke ondersteuning ervan, de toevallige 
ontmoetingen bij de koffieautomaat op de gang of de ogenschijnlijk zo eenvoudige mail 
die je dag kan maken, alle zijn ze voor mij van onschatbare waarde geweest voor het 
vervolmaken van mijn promotietraject. Mijn onderzoeksjaren overdenkend, zo aan het 
einde van dit traject, realiseer ik me eens temeer hoeveel mensen mij hebben geholpen 
met het proefschrift in zijn huidige vorm. Aan mij nu de eervolle taak een aantal personen 
woordelijk te bedanken, voor wat ze gedaan hebben, of soms voor wie ze zijn.
In de eerste plaats zijn er de 707 niertransplantatiepatiënten wier inzet, tijd en moeite de 
basis vormen voor dit proefschrift. Geen hoofdstuk ervan had zonder hun bereidwilligheid 
geschreven kunnen worden en om die reden wil ik mijn dankbaarheid in eerste instantie 
aan hen betuigen. 
Dan mijn (co-)promotoren. Dr. S.J.L. Bakker, beste Stephan, als co-promotor was je 
nauw betrokken bij verschillende van mijn onderzoeksactiviteiten, de dalen en de om 
die reden ook bestaande pieken. Jouw vertrouwen in een goede afloop op momenten 
dat ik dat wat minder voorzag was van grote waarde. Ik prijs je om jouw positieve kijk op 
verschillende zaken en het was een genoegen om door jou begeleid te worden in mijn 
onderzoeksjaren.
Prof. dr. R.O.B. Gans, beste Rijk, het is geen onwaarheid wanneer ik schrijf dat ik zonder 
jou nooit aan een promotietraject was begonnen. Tijdens het sollicitatiegesprek voor een 
opleidingsplaats, in 2008, bood je me de mogelijkheid om de start van mijn opleiding 
tot internist met vier jaren uit te stellen en te beginnen aan wat nu geëindigd is. Ik ben 
je enorm dankbaar voor het feit dat je me toen deze kans bood. Niet alleen omdat een 
promotietraject waardevolle wetenschappelijke bagage oplevert, maar ook omdat deze 
periode me enorm veel over anderen, maar ook over mezelf, heeft geleerd.
Prof. dr. G. Navis, beste Gerjan, in de afgelopen jaren heb je me vaak doen verwonderen 
over de enorme hoeveelheid kennis die je in pacht hebt en daarbij jouw talent om de 
meest ingewikkelde materie begrijpelijk te verwoorden. Dat laatste komt ook veelvuldig 
naar voren in jouw vermogen manuscripten met enkele aanpassingen van een grote 
glans te voorzien. Dank ook voor het enthousiasme en de gedrevenheid waarmee je 
onderzoek aan de man kunt brengen. 
I would like to thank the members of the reading committee, prof. dr. Kalantar-Zadeh, 
prof. dr. Melander and prof. dr. Feskens for taking the time to read and comment upon 
my thesis.
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Prof. dr. H. van Goor, beste Harry, hoewel je officieel geen (co-)promotor van me was, 
is het niet meer dan logisch dat je de eerstvolgende bent die ik noem. Jouw rol in 
mijn onderzoeksjaren is voor mij van enorme waarde geweest. Niet in de laatste plaats 
omdat je als wetenschapper een enorme stimulans was en een drijvende kracht achter 
meerdere wetenschappelijke artikelen, maar ook omdat jij het schrijven van spitsvondige 
e-mails tot een onevenaarbare kunst hebt verheven. Dank voor alle momenten binnen 
het UMCG, maar bovenal voor die daar buiten.
Prof. dr. P.E. de Jong, beste Paul, graag wil ik je bedanken voor het feit dat ik op jouw 
afdeling mijn onderzoek heb kunnen doen. Jouw gedrevenheid en betrokkenheid bij 
onderzoek(-ers) hebben tot een respectabel aantal mooie publicaties geleid en je hebt 
daarmee de Groningse afdeling nefrologie onuitwisbaar op de wereldkaart gezet. Winie, 
gezicht van de Kidney Alley, dank voor alle ondersteuning maar vooral gezelligheid die 
je hebt geboden. Ook alle nefrologen en nio’s, die hun patiënten aan mij hebben willen 
blootstellen, dank ik voor hun medewerking, maar vooral dank ik hen voor de vaak 
opbeurende en verheffende praatjes op de gang.
Uit Wageningen wil ik graag een aantal personen expliciet noemen. Lisette, als 
projectleider had je er een flinke kluif aan om het gehele team met de neuzen dezelfde 
kant op te laten wijzen, maar je hebt een goed coherente club weten te creëren. Ik wil je 
bedanken voor de ondersteunende telefoontjes in de laatste fase van mijn onderzoek. 
Jouw gevleugelde uitspraak ‘planning keer pi’ is helaas vaak waar gebleken. Mariëlle, jij 
bent voor mij een belangrijke factor geweest, juist op het moment dat ik dat het hardst 
nodig had. Jouw hulp bij de statistiek en bij het schrijven van wetenschappelijke papers 
hebben me een flinke boost gegeven. Marianne en Marleen, dank voor jullie input bij 
alle project meetings. Collega-promovendi Janneke, Wieke en Karianna, het was me 
een genoegen met jullie samen te werken. Het ga jullie goed, in de wetenschap, maar 
vooral daar buiten.
Diederik, studiegenoot, collega, maar vooral goede vriend: al vanaf de middelbare 
school tref ik je op onverklaarbare wijze steeds na een tijdje weer op mijn levenspad, 
waarbij keer na keer blijkt dat we de zelfde weg in zijn geslagen. Ik waardeer jouw 
altijd verlichtende gezelschap en dito poststukken. Dank voor de vriendschap en veel 
succes met jouw laatste loden!
Een kleine berekening wijst uit dat voor het onderzoek zoals in dit proefschrift is 
beschreven rond de 100 liter bloed en 2000 liter urine is verwerkt. En dan heb ik het 
nog niet eens over alle bepalingen die daarin zijn verricht. Zoiets is enkel mogelijk met 
bevlogen analisten en om die reden verdienen met name Bettine en Twan, maar ook 
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Karin, Jasper, Marian, Lisette en Jan, een ereplekje op deze pagina. Dank voor al jullie 
hulp! 
Drie andere onmisbare ketens zijn de ‘nierfunctiekamerdames’ Dirkina, Marian en Roelie. 
Jullie staan inmiddels al in heel wat proefschriften vermeld, en dat is volledig terecht. 
Ook ik ben jullie dankbaar voor jullie gedrevenheid en jullie inzet voor mijn onderzoek! 
Ook Erika en Saskia, het ‘gouden duo’, zoals vele niertransplantatiepatiënten jullie 
terecht al noemden, dank ik bij dezen voor alle hulp bij de bloedafname. En in deze 
reeks hoort ook Geertien thuis, die het boegbeeld vormde van de niertransplantatiepoli 
en altijd zorgde voor een soepele verwijzing van patiënten naar mijn onderzoekskamer. 
Dan mijn zeer gewaardeerde collega’s op de Kidney Alley en in het Triade-gebouw. 
Jongens, zonder jullie was mijn tijd op kamer 4.045 nog niet half zo leuk geweest. De liters 
koffie en de kilo’s snoep die werden aangesleept, de verschillende congresbezoeken 
en de borrels in het Feithhuis hebben daar ook zeker aan bijgedragen. Arjan, 
jouw gezonde dosis zelfspot en relativeringsvermogen zijn een verademing in de 
onderzoekswereld. Ik heb genoten van jouw aanwezigheid. Tsjitske, jouw attentheid 
in een steeds individualistischer wordende wereld is een groot goed. Je bent een fijne 
aanwinst. Ineke, ik heb in jou mijn meerdere moeten erkennen voor de hoeveelheden 
snelle suikers die iemand straffeloos kan nuttigen, chapeau! Dorien, zelden heb ik een 
AIO zoveel studenten zien begeleiden. Knap werk! Nicole, waarde bureau-opvolger: 
succes met je onderzoek! Hilde en Jan, het eerste gepromoveerde nefro-koppel. Met 
jullie beiden heb ik een mooie beginperiode gehad. Ik wens jullie alle geluk samen!
Dan de collega’s op iets grotere afstand met wie ik niettemin mooie tijden heb beleefd: 
Wendy, Lieneke, Solmaz, Alaa, Hanneke, Michel, Edwin, Anne Marijn, Lucia, Laura, 
Charlotte, Willem, Janneke, Debbie, Esmée, Astrid, Pauline,, Welmoet, Kim, Anne Roos, 
Leandro, en de “oudergedienden” Maartje, Marije, Nynke, Folkert, Inge, Titia, Mieneke, 
Martin, Leendert, Rutger, Janna, Kiran, Pramod, Anna, Azadeh, Carolien, Hiddo, Merel, 
Paul, Frank, Mirjam: dank voor de fijne samenwerking en alle gezelligheid!
Dan wijd ik graag nog een aparte alinea aan wat inmiddels de skiclub is gaan heten, 
ongeacht waar we ons naar toe begeven. Steef, waarde vriend, jouw aanwezigheid 
op de kamer heeft mijn onderzoekstijd significant leuker gemaakt. Jouw gezonde 
wedijver met taalkwesties, jouw input middels af en toe best wel leuke grappen en 
jouw kracht om dingen onverbloemd te zeggen zijn grandioos. Ik ben dankbaar dat 
onze vriendschap zich heeft voortgezet buiten de muren van het UMCG. Ferdau, er zijn 
niet veel collega’s met wie ik het bed heb gedeeld, maar van dat selecte clubje ben 
jij met stip de schoonste slaper. Dank voor het gezelschap en jouw tomeloze kennis 
over allerhande, zij het niet altijd even belangrijke, zaken. Tibo, MacGyver van de 
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groep, jij maakt van een elastiekje nog een volautomatisch espresso-apparaat. Dank 
voor jouw aandeel in alle geslaagde vakanties tot nu toe! Daan, of beter DJ Crusher, in 
tegenstelling tot wat jouw artiestennaam doet vermoeden, draag je altijd constructief bij 
aan alle vakanties; veel dank daarvoor! Femke, dat onderzoek me veel zou opleveren, 
werd me door menigeen van tevoren al verzekerd, maar dat het me daarbij ook een 
‘nieuw’ familielid zou opleveren had ik nooit kunnen vermoeden. Hoe een en ander is 
verlopen mag een klein wonder heten en ik vind het bijzonder waardevol dat we zo goed 
bevriend zijn geraakt! Esther, paranimf, ik ben dankbaar dat jij, ervaringsdeskundige 
zijnde, me tijdens de verdediging zal flankeren. Jouw veelzijdigheid, binnen en buiten 
de wetenschap, in combinatie met jouw optimisme en scherpe opmerkingen waren, en 
zijn, een genot om mee te maken!
Lisette, Reinco en Petra, lieve schoonfamilie, veel dank voor de gastvrijheid waarmee 
jullie mij in jullie familie welkom hebben geheten, zo’n tien jaren geleden. Ik hoop dat er 
nog vele decennia zullen volgen!
Maaike, topzus, op menig jeugdfilm van ons is al te zien dat ik meestal in jouw nabijheid 
verkeerde, ongeacht of dit voorop de stang van jouw crossfiets was of op de slee achter 
de auto gebonden. Bij jou in de buurt, zo wist ik, kwam het altijd wel goed. Niet voor niets 
heb ik jou ook gevraagd mij te flankeren, zes maart 2013, omdat historie nou eenmaal 
leert dat er dan niet zo veel meer mis kan gaan. Ik ben er enorm trots op je zusje te zijn!
Papa en mama, een welverdiende plaats voor jullie in deze paragraaf. Niet zozeer omdat 
we aan de keukentafel alle voor- en nadelen van lineaire regressie analyse bespraken, 
maar wel omdat jullie de basis vormen van wie en wat ik ben geworden en de omgeving 
hebben gecreëerd om dat in volle vrijheid te bereiken. Jullie talent om het opvoeden van 
kinderen te combineren met jullie carrières is absoluut bewonderenswaardig!
Dennis, dat de ACLO zo’n belangrijke bijdrage zou leveren aan de invulling van mijn 
leven had ik nooit durven denken. Ik prijs me gelukkig met jou aan mijn zijde en ik kijk 
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